#### BRITISH AMERICAN TOBACCO p.l.c.

**HALF-YEAR REPORT TO 30 JUNE 2021** 



### STRONG BRANDS DRIVE NEW CATEGORY ACCELERATION

| PERFORMANCE HIGHLIGHTS   | REPOR   | TED   | ADJU  | ISTED   |
|--|---|---|---|---|
|  | Current<br>rates                                | Vs 2020                                       | Current<br>Rates                                | Vs 2020<br>(constant)                                     |
| Cigarette and THP volume share<br>Cigarette and THP value share<br>Consumers of non-combustible products <sup>1</sup>  | 16.1m   | +20 bps<br>+10 bps<br>+2.6m                   |   |   |
| Revenue (£m) Revenue from New Categories (£m) Profit from operations (£m) Operating margin (%) Diluted EPS (pence)   | £12,175m<br>£883m<br>£4,907m<br>40.3%<br>141.6p | -0.8%<br>+40.4%<br>-3.7%<br>-120 bps<br>-6.0% | £12,175m<br>£883m<br>£5,235m<br>43.0%<br>154.2p | +8.1%<br>+50.0%<br>+5.4%<br>-70 bps <sup>2</sup><br>+6.1% |
| Net cash generated from operating activities (£m)<br>Free cash flow after dividends (£m)<br>Cash conversion (%) <sup>2</sup><br>Borrowings <sup>3</sup> (£m) | £2,254m<br>45.9%<br>£45,010m                    | -35.3%<br>-22.5 ppts<br>-10.8%                | (£1,163)m<br>66.7%                              | Not meaningful<br>-13.5 ppts                              |
| Adjusted Net Debt (£m)   | ,   |   | £40,490m  | -7.6%   |

The use of non-GAAP measures, including adjusting items and constant currencies, are further discussed on pages 54 to 58, with reconciliations from the most comparable IFRS measure provided Note – 1. Internal estimate, 2. Movement in adjusted operating margin and operating cash conversion is provided at current rates. 3. Borrowings includes lease liabilities.

#### <u>Accelerating our Transformation</u>

- New Categories revenue up 50% to £942m\*
- Our highest ever non-combustible product consumer acquisition +2.6m to 16.1m in H1, with 11.8% of Group revenue delivered by non-combustible products
- Vapour revenue up 59%\*, Vuse approaching global category value share leadership
- glo revenue up 38%\*, with glo Hyper volume share gains in ENA and Japan
- Velo revenue up 63%\*, with our T5 volume share of the Modern Oral category at 39.5% up 280 bps
- Further incremental increase of £346m investment in H1, capitalising on strong momentum in all three New Categories
- Full Year New Category losses expected to reduce

#### Strong H1 Results

- Revenue up 8.1%\* led by New Category growth and a partial recovery from prior-year COVID-19 impacts
- Combustible revenue up 5.8%\* with price/mix of 4.3%, reflecting Emerging Market (EM) recovery
- Cigarette value share up 10 bps, and volume share up 10 bps reflecting strong EM performance
- Further £256m cost savings, driven by Quantum, target increased to £1.5bn (previously £1bn) by 2022
- Adjusted profit from operations up 5.4%\* includes a transactional FX impact of 2%
- Adjusted operating margin down 70 bps, driven by increased New Category investment, geographic mix and transactional FX
- Adjusted diluted EPS up 6.1%\*
- Operating cashflow conversion of 67%, reflecting phasing of excise payments in the US in 2020

#### **Jack Bowles, Chief Executive:**

"This has been an exciting period of growth in New Categories, with New Category constant currency revenue up by 50% in the first half. We added 2.6m consumers, our highest ever increase, to our non-combustible product consumer base, to reach 16.1m. This demonstrates our accelerating transformation driven by our multi-category portfolio, with continued key market share gains in all three New Categories.

We are building strong, global brands of the future with Vuse, Velo and glo. These are underpinned by industry leading multi-category consumer insights and science, with increasing digitalisation. We have invested a further incremental £346m in the first half, funded by continued value growth from combustibles and expect to reach our £1bn Quantum savings target 12 months early. We have now increased our savings target to £1.5bn by 2022.

Our rapid growth in New Categories is driving significant scale benefits and 2021 is shaping up to be a pivotal year in our journey towards A Better Tomorrow.

Our focus on New Categories growth and business sustainability puts ESG at the core of our strategy. There is great momentum across the business and we are well on track to meet our targets of £5bn of New Category revenue by 2025 and 50m non-combustible product consumers by 2030.

We are committed to reducing the health impact of our business. Our ambition remains a sustainable, high growth, multi-category, consumer products business. I am excited about the future for BAT."

#### On track for FULL YEAR 2021 guidance:

- Global tobacco industry volume now expected to be down c.-1.5% (from c.-3%), driven by strong EM recovery.
- US industry volume expected to be down c.-5.5%, given continuing macro-economic uncertainties and a strong comparator.
- Constant currency revenue growth above 5% and continued strong progress towards £5bn New Categories revenue in 2025.
- Mid-single figure constant currency adjusted EPS growth, including continued expectation of c.2% transactional FX headwind.
- Expected translational FX headwind of c.7% on full year adjusted diluted EPS growth.
- Operating cashflow conversion in excess of 90%, Adjusted Net debt/Adjusted EBITDA around three times.
- Commitment to 65% dividend pay-out ratio and growth in sterling terms.

<sup>\*</sup> at constant rates of exchange

#### CHIEF EXECUTIVE'S STATEMENT

#### TRANSFORMING OUR BUSINESS - BUILDING A BETTER TOMORROW™

We are committed to our purpose of building A Better Tomorrow<sup>TM</sup>. We will achieve this by reducing the health impact of our business through a progressive and continued portfolio transformation. As these results show, we are becoming a business that defines itself, not by the product it sells, but by the consumer needs that it meets. The addition of 2.6m consumers of non-combustible products in H1 2021, reaching 16.1m, highlights the progress we are making.

The accelerated growth of Vuse, glo and Velo positions us well to meet our New Categories revenue target of £5 billion by 2025. The progress of these brands – brands with purpose – highlights the strength of our three strategic priorities:

- Accelerating growth in New Categories, fuelled by:
  - Value growth in combustibles; and
  - Benefitting from a faster, simpler, more agile business.

Hyper has driven the growth of glo, we are growing volume share of the total modern oral market (partly due to Velo in US) and Vuse is the category value share leader in four of the top five vapour markets and market leader (by value share) in 20 US states.

Digitalisation is key to the future of our business and we continue to invest beyond our technology capabilities in manufacturing and supply chain. Our e-commerce footprint is developing quickly with consumer subscription programmes growing in priority New Category markets. Increasingly, data and analytics are playing a critical role in new capability areas such as more powerful Customer Relationship Management, pricing realisation via Revenue Growth Management and Marketing Spend Effectiveness tools.

Building A Better Tomorrow $^{\text{TM}}$  is about creating shared value for all our stakeholders. We are making good progress towards achieving our ambitions, including:

- In May, we announced that Vuse had become the world's first verified global carbon neutral vapour brand; and
- In March, we augmented our existing carbon emissions target by announcing our ambition to be carbon neutral across our entire value chain by 2050.

We are also proud of the notable recognition we have received for our ESG efforts (see page 22). So far, in 2021, this has included:

- The highest 'Gold Class' distinction in S&P Global's Sustainability Yearbook;
- Ranked as the third highest ESG-rated FTSE 100 company by Refinitiv, global provider of financial market data and a subsidiary of London Stock Exchange Group;
- Named as a Climate Leader by the Financial Times in its inaugural European ranking; and
- Named as a Global Top Employer for the fourth year running by the Top Employers Institute.

Our progress is testimony to the resilience of our staff, customers, partners and suppliers. We remain committed to supporting all our stakeholders throughout the COVID-19 pandemic.

As we enter the second half of the year, our focus on developing and delivering consumer-focused products and brands is driving accelerated momentum. We are creating multi-stakeholder value and transforming ourselves into a high-growth, consumer products business: global, consumer-centric, multi-category, with sustainability front and centre.

1-As verified by Vertis based on product Life Cycle Assessment data provided by an independent third party, taking into account the Group's purchase of carbon credits through reforestation projects.

### FINANCE & TRANSFORMATION DIRECTOR'S OUTLOOK STATEMENT

#### STRONG OPERATIONAL MOMENTUM AND CASH FLOW

Our strong momentum underpins our expectations for constant currency revenue growth of above 5% in 2021. The second half of the year will reflect the impact of geographic and portfolio mix, and a strong prior year comparator which offset the continued progress from New Categories.

Capitalising on our strong momentum, we further increased investment in New Categories by £346 million in H1 2021 and additional investment is planned for H2 2021. We continue to expect full year 2021 losses from New Categories to reduce, with a clear pathway to profitability by 2025. This investment has been funded by our continued strong growth in combustibles, and savings from Quantum, and expect to reach the £1 billion annualised savings target 12 months ahead of plan. With further savings identified, we have upgraded our Quantum target to £1.5 billion by 2022.

Full year constant currency adjusted profit from operations growth is expected to be driven by strong revenue performance and further savings from Quantum. This will be partially offset by the continued incremental New Category investment and challenges in Australia where we anticipate a one-off impact from changes in excise (£170 million) alongside a highly competitive pricing environment.

As previously communicated, we continue to expect no recovery in Global Travel Retail (GTR) until 2022, with COVID-19 continuing to negatively impact our associate income from ITC in the second half of 2021. We are also absorbing a c.2% transactional FX headwind in our constant currency guidance. Accordingly, we maintain our FY 2021 guidance of mid-single figure constant currency adjusted diluted EPS growth.

BAT is a highly cash generative business and we are on track to, once again, achieve operating cash flow conversion in excess of 90%, with year-on-year growth in H1 2021 impacted by the phasing of excise payments in 2020.

Our liquidity profile remains strong, with average debt maturity close to 10 years and maximum debt maturities in any one calendar year of around £4 billion. Our medium-term rating target remains BBB+/Baa1, with a current rating of BBB+/Baa2\*\*\*\*.

We remain committed to our 65% dividend pay-out ratio and dividend growth in sterling terms, continuing to invest in the transformation of the business and building A Better Tomorrow™, while deleveraging the balance sheet to reach around 3x adjusted net debt to adjusted EBITDA by the year end. At that point we expect increased flexibility for capital allocation.

<sup>\*\*\*\*</sup>A credit rating is not a recommendation to buy, sell or hold securities. A credit rating may be subject to withdrawal or revision at any time. Each rating should be evaluated separately of any other rating.

#### **GROUP OPERATING REVIEW**

#### **TOTAL GROUP VOLUME and REVENUE**

| For six months ended 30 June   | Volume | (unit) | Revenu  | e (£m) |        |         |            |        |        |
|--------------------------------|--------|--------|---------|--------|--------|---------|------------|--------|--------|
|                                |        |        | Reporte | ed     |        | At cons | tant rates |        |        |
|                                | 2021   | Change | 2021    | 2020   | Change | FX      | 2021 cc    | 2020   | Change |
|                                | Unit   | %      | £m      | £m     | %      | £m      | £m         | £m     | %      |
| New Categories                 |        |        | 883     | 628    | +40.4% | 59      | 942        | 628    | +50.0% |
| Vapour (10ml units / pods mn)  | 247    | +70%   | 398     | 265    | +49.9% | 25      | 423        | 265    | +59.3% |
| THP (sticks bn)                | 8.4    | +99%   | 359     | 286    | +25.3% | 35      | 394        | 286    | +37.8% |
| Modern Oral (pouches mn)       | 1,607  | +124%  | 126     | 77     | +64.2% | (1)     | 125        | 77     | +63.2% |
| Traditional Oral (stick eq bn) | 4.1    | -3.1%  | 558     | 576    | -3.3%  | 54      | 612        | 576    | +6.1%  |
| <b>Total Non-Combustibles</b>  |        |        | 1,441   | 1,204  | +19.5% | 113     | 1,554      | 1,204  | +29.0% |
| Cigarettes (sticks bn)         | 316    | +1.8%  |         |        |        |         |            |        |        |
| OTP incl RYO/MYO (stick eq bn) | 9      | -6.6%  |         |        |        |         |            |        |        |
| <b>Total Combustibles</b>      | 325    | +1.5%  | 10,527  | 10,854 | -3.0%  | 958     | 11,485     | 10,854 | +5.8%  |
| Other                          |        |        | 207     | 213    | -2.0%  | 22      | 229        | 213    | +7.9%  |
| Total                          |        |        | 12,175  | 12,271 | -0.8%  | 1,093   | 13,268     | 12,271 | +8.1%  |
| Cigarettes and THP (sticks bn) | 324    | +3.1%  |         |        |        |         |            |        |        |

Use of the term "cc" refers to the variance between the 2021 adjusted performance, at 2020 exchange rates, against the adjusted 2020 performance.

New Category consumables volume growth accelerated and was up substantially in all three categories. Combustibles volume was up 1.5%, driven by cigarette volume share gains (up 10 bps) and the recovery of emerging markets including Bangladesh, Pakistan, Vietnam, Brazil and South Africa, following the impact of COVID-19 last year. Duty paid industry cigarette volume was broadly stable in the first half of 2021.

On a reported basis, revenue was marginally lower than the prior year (down 0.8% to £12,175 million). Strong revenue growth in New Categories, up 40.4%, supported by combustible volume growth, price/mix of 4.3%, and value share gains of 10 bps, were more than offset by a translational foreign exchange headwind of 8.9%. Revenue was up 8.1% on a constant currency basis, reflecting New Category growth and a partial recovery in some EMs from the impact of COVID-19 in 2020.

Revenue from non-combustibles now represents 11.8% of Group revenue, up from 10.1% at FY 2020, reflecting strong New Category revenue growth of 40.4% (or 50.0% at constant rates of exchange).

#### PROFIT FROM OPERATIONS AND OPERATING MARGIN

| For six months ended 30 June | tara di Para d | ed PfO (£ı<br>ng Margi | •        | Adjusted PfO (£m)<br>Adjusted operating margin (%) |     |         |       |          |  |
|------------------------------|--|------------------------|----------|--|-----|---------|-------|----------|--|
|                              | 2021   | 2020                   | Change   | Adj  | FX  | 2021 cc | 2020  | Change   |  |
| Profit from Operations (PfO) | 4,907  | 5,097                  | -3.7%    | 328  | 424 | 5,659   | 5,368 | +5.4%    |  |
| Operating Margin             | 40.3%  | 41.5%                  | -120 bps |  |     | 42.6%   | 43.7% | -110 bps |  |

Use of the term "cc" refers to the variance between the 2021 adjusted performance, at 2020 exchange rates, against the adjusted 2020 performance.

Profit from operations on a reported basis was down 3.7% at £4,907 million, driven by an improvement in the Group's operating performance despite an incremental increase in investment in New Categories of £346 million (compared to the first six months of 2020) and a transactional foreign exchange headwind of 2%. This was more than offset by a translational foreign exchange headwind of 8% and £328 million in one-off charges (30 June 2020: £271 million) which included a cost of £71 million related to assets and liabilities held-for-sale, including in respect of the proposed sale of the Group's operations in Iran (as explained on page 20).

Reported operating margin was down 120 bps to 40.3%, largely due to the increased investment in New Categories, the held-for-sale impairment charges and higher costs due to transactional foreign exchange discussed earlier.

#### Adjusted profit from operations and adjusted operating margin

Adjusted profit from operations at constant rates was up 5.4%. Strong revenue growth and £256 million productivity savings driven by Quantum was partly offset by the further increase in New Category investment, up £346 million in H1 2021, geographic mix, no recovery in GTR and the absorption of a 2% transactional headwind in the period. Accordingly, adjusted operating margin was down 70 bps or down 110 bps at constant rates of exchange.

#### A STEP CHANGE IN NEW CATEGORIES

| For six months ended 30 June   | Volume       | e (unit)    | Revenue    | Revenue (£m) |             |          |               |            |             |
|--------------------------------|--------------|-------------|------------|--------------|-------------|----------|---------------|------------|-------------|
|                                |              |             | Reporte    | Reported     |             | At cor   |               |            |             |
|                                | 2021<br>Unit | Change<br>% | 2021<br>£m | 2020<br>£m   | Change<br>% | FX<br>£m | 2021 cc<br>£m | 2020<br>£m | Change<br>% |
| New Categories                 |              |             | 883        | 628          | +40.4%      | 59       | 942           | 628        | +50.0%      |
| Vapour (10ml units / pods mn)  | 247          | +70%        | 398        | 265          | +49.9%      | 25       | 423           | 265        | +59.3%      |
| THP (sticks bn)                | 8.4          | +99%        | 359        | 286          | +25.3%      | 35       | 394           | 286        | +37.8%      |
| Modern Oral (pouches mn)       | 1,607        | +124%       | 126        | 77           | +64.2%      | (1)      | 125           | 77         | +63.2%      |
| Traditional Oral (stick eq bn) | 4.1          | -3.1%       | 558        | 576          | -3.3%       | 54       | 612           | 576        | +6.1%       |
| <b>Total Non-Combustibles</b>  |              |             | 1,441      | 1,204        | +19.5%      | 113      | 1,554         | 1,204      | +29.0%      |

Use of the term "cc" refers to the variance between the 2021 adjusted performance, at 2020 exchange rates, against the adjusted 2020 performance.

#### **VUSE - VAPOUR: Approaching Global Category leadership**

- Vapour volume growth accelerating, up 70% with our highest ever consumer acquisition +0.9m to 7.5m
- Vuse value share growth of 610 bps vs FY 2020 to reach 31.6% May YTD of total vapour value share in key (T5) markets
- Vuse value share leader in four of the T5 markets, with leadership in 20 states in the US
- Vuse is the first global vapour brand to be independently verified by Vertis as carbon neutral

Vapour continued its strong momentum (driven by Vuse) with volume accelerating, up 70%, and revenue up 50%, or 59% at constant currency. We delivered strong growth and value share gains across all our T5 markets achieving our highest total vapour value share of 31.6% May YTD (up 610 bps vs FY 2020) and are approaching global value share leadership. We maintained volume share leadership of devices in all T5 markets.

In the US, Vuse consumables volume grew 97%, materially outperforming the total vapour industry which has returned to growth (with industry volume up approximately 30%). This drove revenue growth of 42%, or 56% on a constant currency basis. Vuse family value share of total vapour was 30.0% (up 510 bps on FY 2020), driven by the continued success of Vuse Alto with value share reaching 27.5% May YTD, up 720 bps vs FY 2020. We have achieved market value share leadership in 20 states and continue to approach total value share market leadership.

In our other T5 markets, we continued to extend our value share leadership position, with all T5 Vype brand migrations completed by the end of H1 2021.

- In the UK, we reached 36.3% value share of the total vapour market May YTD, up 80 bps vs. FY 2020, led by Vuse reaching value share of 19.3% YTD up 440 bps vs FY 2020.
- In France, our value share leadership of total vapour extended further to reach 43.6% May YTD, up 1,210 bps vs FY 2020 driven by both ePen3 and ePod.
- In Germany, our value share of total vapour was 59.0% Apr YTD, up 930 bps vs FY 2020, driven by ePen3 and ePod.
- In Canada, our value share of total vapour was 75.2% May YTD, up 2,900 bps vs FY 2020, driven by ePod.

We have continued the rapid expansion of our e-commerce revenue, up 77% YTD compared to the first six months of 2020, with Vuse ranked No.1 in branded web traffic in all of our T5 markets<sup>2</sup>. The number of consumers utilising our subscription programme has increased to c.20k, up 63% vs H1 2020.

This valuable subscriber base, improved trade margins and cost of sales scale efficiencies through automation and deployment of Marketing Spend Effectiveness and Revenue Growth Management tools are all contributing to our pathway to New Category profitability.

In May, the FDA posted its list of New Category 'deemed' tobacco products for which a Pre-market Tobacco Application (PMTA) had been filed, reflecting a positive step forward in the enforcement against products that are not included on the list. All our currently marketed deemed products are on the list and we remain optimistic about the impact that this will have on the addressable market for our brands going forward.

Vuse is one example of how we are driving our ESG purpose. We are very proud that Vuse has been independently certified by Vertis as the first global carbon neutral vapour brand in the period<sup>1</sup>. Together with award-winning campaigns and digital engagement we are committed to building the most trusted vaping brand worldwide with a clear consumer-led purpose.

<sup>\*</sup>T5 markets by revenue are the US, UK, France, Germany and Canada; they account for 75% of total industry vapour revenue (closed systems)

Las verified by Vertis based on product Life Cycle Assessment data provided by an independent third party, taking into account the Group's purchase of carbon credits through reforestation projects.

<sup>&</sup>lt;sup>2</sup>Source: Similar Web.

#### glo - TOBACCO HEATING PRODUCTS (THP) - Hyper continues to accelerate share growth

- Volume up 99% driven by the continued success of glo Hyper, with consumer numbers up 1.2m to 5.3m.
- glo's THP category volume share reached 16.5% May YTD, up 320 bps vs. FY 2020 in our Top 9 markets.
- ENA volume up 368%, and revenue up 241% (or 248% at constant rates of exchange), gaining volume share across all key markets.
- Japan reached 6.2% May YTD volume share of total cigarettes and THP, up 80 bps vs FY 2020.

glo total consumable volume grew 99% in H1 2021, further accelerating from H2 2020, achieving over three times the global THP industry volume growth of 31.9%. This was driven by the continued success of glo Hyper in Japan and across ENA. glo total revenue grew 25.3% or 37.8% at constant currency. Since the launch of Hyper in the first half of 2020, glo's performance on key metrics such as brand power and consumer conversion have continued to improve supporting the sustainability of our ambition for glo to be the fastest growing global THP brand.

In APME, volume grew 23.1%, driven by Hyper as we continue to invest in consumer acquisition. The increased investment together with the partial absorption of excise in Japan, due to the disproportionate impact of excise harmonisation on our products, resulted in THP revenue in the region down 11.7% or 3.5% on a constant currency basis.

In Japan, volume growth for consumables and devices was driven by Hyper, with improved consumer conversion from trial to active usage of 41%. glo's volume share of the THP category reached 19.8% May YTD up 50 bps vs FY 2020. This represents 24% of the total growth in cigarettes and THP, well ahead of our category share.

In ENA, glo volume grew 368%, more than six times faster than THP industry growth rates of 54% in the region. The region now represents around 50% of our global THP volume. Revenue growth accelerated, up 241% or 278% at constant currency.

- In Russia, glo reached 17.6% THP category volume share in May YTD, up 900 bps FY 2020 and accounting for 44% of the growth of the category.
- In the Ukraine, glo reached 19.0% THP category volume share May YTD (up 800 bps vs. FY 2020), with Kiev reaching 18.5% category volume share.
- In Italy, glo reached 10.7% THP category volume share May YTD, up 670 bps, with Hyper driving 100% of the growth.
- In Romania, we reached 22.7% category volume share May YTD, up 590 bps, and 20.1% volume share in Bucharest up 550 bps.

Hyper also continued to make good progress in Kazakhstan, Poland, Egypt, the Czech Republic and across other smaller ENA launch markets, and is now in 21 of glo's 23 markets, with further market roll-outs planned.

#### VELO - MODERN ORAL - International leadership and strong US momentum

- Accelerating global volume growth, up 124%, with consumer numbers up 0.7m to 2.2m
- Category volume share in key (T5\*) markets reached 39.5% May YTD up 280 bps on FY 2020
- US volume up 450%, with volume share of Modern Oral at 16.0% May YTD, up 840 bps vs FY 2020
- ENA volume up 77.2% driving volume share of Modern Oral to 69.1% May YTD, up 160 bps

Our Modern Oral growth accelerated in the first six months of 2021, with volume up 124% and revenue up 64.2% or 63.2% at constant currency. Volume share of the Modern Oral category in our T5 markets reached 39.5% May YTD 2021 up 280 bps vs FY 2020.

In the US, volume was up 450% to 405 million pouches (compared to 74 million pouches in the same period in 2020) significantly outpacing industry growth of around 110%, with revenue up 17.3% or 29.3% on a constant currency basis. We continue to focus on consumer acquisition with our expanded portfolio following the acquisition of the nicotine pouch products of Dryft Sciences LLC (Dryft) in October 2020.

Velo recorded the largest growth in awareness across Modern Oral brands in the US, as we continued the national roll out of our enlarged portfolio reaching over 80,000 outlets in June 2021. In a competitive market we reached 16.0% volume share of Modern Oral May YTD 2021 up 840 bps vs FY 2020, with our volume share in 6 states already over 20%.

We estimate that approximately half of Velo consumers (in the US) come from the existing Modern Oral users, with the remainder sourced evenly from combustible, snus, traditional oral and vapour consumers. Our insights suggest that a high percentage of Modern Oral users are already poly-users of other categories.

In ENA, volume grew 77.2% with revenue up 67.5% or 64.9% at constant currency, as the Modern Oral segment continues to expand rapidly, and we continue to consolidate our industry leading position\*\*. We consistently lead innovation in the category with three new formats launched and seven new flavours added in the last 12 months.

- In Sweden, where Modern Oral now represents 11.8% of the total oral category, our volume share of the Modern Oral category reached 57.8% May YTD, an increase of 410 bps vs. FY 2020\*\*.
- In Norway, where Modern Oral now represents 27.3% of the total oral category, our volume share of the Modern Oral reached 63.4% May YTD up 130 bps vs. FY 2020.
- In Denmark, Modern Oral now represents 88.8% of the total oral category and continues to be the main driver of total oral category growth. Our volume share of the Modern Oral category declined by 380 bps vs FY 2020 to 90.1% May YTD, but still drove a 460 bps increase in our Modern Oral volume share of total oral category to 80.0%.

Our pilot launches in emerging markets including Pakistan and Indonesia are now delivering valuable insights, as we continue our roll-out in key urban markets. We believe that Modern Oral is an exciting longer-term opportunity to commercialise reduced risk products by offering affordable New Category alternatives to adult nicotine consumers, with further emerging market roll-outs planned for the second half of 2021.

In Kenya sales remain suspended due to local regulatory challenges, and we continue to engage with local authorities. In Germany, sales of Modern Oral have been suspended pending engagement with the authorities regarding the classification of tobacco-free nicotine pouches.

<sup>\*</sup> Modern Oral focus markets revised to be T5 markets of US, Sweden, Norway, Denmark and Switzerland.

<sup>\*\*</sup> Sweden volume share has been rebased to include Nicotine free pouches in all periods. Accordingly, BAT's FY2020 volume share of modern oral was rebased to 53.8%.

#### **BEYOND NICOTINE**

Our corporate venturing unit, Btomorrow Ventures (BTV) made five new investments in the first six months of 2021 – four in innovative consumer and technology businesses and one fund investment. Overall, 13 BTV investments have been completed since launch in 2020, providing us with evolving capabilities for the future across both New Categories and Beyond Nicotine.

As we explore beyond nicotine, we are building an eco-system of new capabilities and insights for the future. We are leveraging the expertise of our external partners and while it is early days in this space, we see this as an exciting way to recapture lost consumer moments and drive longer term growth.

On 11 March 2021, we entered a strategic collaboration agreement with Organigram Inc., a wholly-owned subsidiary of publicly-traded Organigram Holdings Inc., focused on research and product development activities of next generation adult cannabis products, with an initial focus on cannabidiol (CBD). As described on page 20, under the terms of the transaction, a Group subsidiary acquired a 19.9% equity stake in Organigram Holdings Inc. (listed on both the Nasdaq and Toronto Stock Exchange under the symbol "OGI") to become its largest shareholder.

#### TRADITIONAL ORAL

Group volume declined 3.1% to 4.1 billion stick equivalents. Total revenue was £558 million, down 3.3% due to the impact of foreign exchange. At constant rates, revenue grew by 6.1%, driven by continued strong pricing in the US (price mix of 9.1%) which accounts for 97% of revenue from the category.

In the US, Traditional Oral volume declined 3.1% in the first half of 2021, with value share of moist up 20 bps and volume share down 20 bps. This was driven by Grizzly which continues to drive value growth through strong pricing, utilising revenue growth management techniques.

The Modified Risk Tobacco Product (MRTP) applications for Camel Snus were discussed by the Tobacco Products Scientific Advisory Committee (TPSAC) in September 2018. We continue to work with the FDA as the MRTP applications and public comments remain under review by the Agency.

#### **VALUE THROUGH COMBUSTIBLES**

- Group value share up 10 bps, driven by the US up 40 bps
- Volume up 1.5% driven by EM recovery
- Strong pricing, partially offset by negative geographic mix
- Revenue growth up 5.8% at constant rates, with Combustibles price/mix +4.3%

Group cigarette value share increased 10 bps vs FY 2020, driven by the continued performance of the strategic cigarette brands in the US (up 50 bps). This combined with higher cigarette value share in Bangladesh, Germany, Japan, Vietnam, Turkey, Mexico, Pakistan and Taiwan to more than offset lower value share in Indonesia, Saudi Arabia, South Africa and Spain. Group cigarette volume share grew 10 bps with the strategic portfolio also up 10 bps. Pricing continued to be strong, with combustibles price/mix of 4.3%.

Group cigarette volume grew by 1.8% to 316.0 billion sticks (2020: 310.5 billion sticks) driven by the recovery in emerging markets. Volume grew in:

- Bangladesh (driven by the continued strength of the local portfolio);
- Brazil (where enhanced border security and restricted population mobility due to COVID-19 led to an increase in duty paid volume);
- South Africa (as the market recovered from the COVID-19 lockdown and ban of sales in April to August 2020);
- Pakistan (where illicit trade reduced following significant excise-led growth in recent years); and
- Vietnam (with strong volume recovery post COVID-19 lockdowns in the comparator).

This was partially offset by lower volume in:

- the US where the Group's cigarette volume was down 4.4% to 34.7 billion sticks (2020: 36.2 billion sticks), broadly inline with industry volume which was down around 5%. This is more in-line with historical rates, driven by rising gas
  prices and the partial unwinding of last year's additional supply chain inventories and stronger consumption trends;
  and
- Indonesia where the Group has sought to drive increased value with pricing ahead of the industry.

Our GTR business continues to show no signs of recovery due to COVID-19 travel restrictions.

Volume of the strategic cigarette brands, collectively, grew 0.7% in the first six months of 2021:

- Dunhill's value share was down 10 bps as growth in Romania, Taiwan, Pakistan and Brazil was more than offset by
  declines in Indonesia, South Korea, Saudi Arabia, Australia, Malaysia and Netherlands. Volume was 8% lower, largely
  due to the impact of the tax increases and minimum retail price compliance in Indonesia, partially offset by
  recovering volume in Brazil and South Africa;
- Kent's value share was stable as growth in Turkey, Russia and Saudi Arabia were offset by lower value share in Japan, Romania, Brazil and Chile. Volume was down 0.5% as growth in Turkey was more than offset by lower volume in Japan and the Middle East;
- Lucky Strike's value share grew 20 bps, as growth in the US (following launch), in AMSSA (particularly Brazil, Chile and Colombia) in Japan and Russia more than offset lower value share in Indonesia, France and Spain. Volume grew 17% driven by Brazil, Russia, Argentina and the US, following the reintroduction of the brand in the final quarter of 2020. Growth was partially offset by the impact of the tax increases and minimum retail price compliance in Indonesia and lower volume in France;
- Rothmans' value share was stable as growth in Brazil, Italy, Malaysia and Czech Republic was offset by lower value share in Russia, New Zealand, Australia, South Africa, Poland, Ukraine, UK, and Pakistan. Volume was down 3.5% as growth in Brazil, Cuba and Poland was more than offset by lower volume in Russia, Ukraine, Kazakhstan and Nigeria;
- Pall Mall's value share was down by 10 bps as growth in Germany, Mexico, Australia and Chile was more than offset by lower value share in US, Saudi Arabia, Canada, Romania, New Zealand and UK. Volume was 6.1% higher, largely driven by Pakistan, Nigeria, Chile, Mexico and Saudi Arabia; and
- The Group's US domestic strategic combustibles portfolio largely performed well:
  - Newport value share increased 60 bps in the US, despite a 2.4% volume decline, as both the menthol and nonmenthol variants outperformed the market;
  - Natural American Spirit value share was marginally higher than 2020. Volume was up 1.5% against the first six months of 2020; and
  - Camel's value share declined 30 bps in the US, with volume down against the same period of 2020 by 9.7%.

Volume of other tobacco products (OTP) declined 6.6% to 9 billion sticks equivalent (being 3% of the Group's combustible portfolio).

Revenue from combustibles was down 3.0% at £10,527 million (June 2020: £10,854 million) with a translational foreign exchange headwind of 8.8% more than offsetting the impact of higher pricing across the Group. Revenue at constant rates of exchange was up 5.8% at £11,485 million (June 2020: £10,854 million) driven by good pricing notably in the US, Canada, Germany, Bangladesh and Brazil.

#### SIMPLIFYING THE BUSINESS -Transitioning to the enterprise of the future

- Quantum savings target increased (from £1bn) to £1.5bn by the end of 2022
- Quantum phase 2 drove £256m of savings in H1 2021
- The QUEST programme (Building the Enterprise of the Future) drives our transition, supported by accelerated digital transformation, technology and innovation

Building the Enterprise of the Future will give us the organisational flexibility to implement and operationalise our growth strategy – simplifying the business and speeding up decision-making. QUEST is an organisational transformation programme, built around five pillars, designed to deliver the Enterprise of the Future at enhanced speed. Underpinning QUEST is:

- Quantum, our programme designed to simplify our business;
- **U**nleashing innovation through data-driven insights and foresights, leveraging state-of-the-art technologies to ensure we are building the brands of the future;
- Empowering our organisation and attracting and retaining an increasingly diverse workforce;
- Shaping the sustainability agenda through our focus on reducing the health impact of our business and demonstrating excellence across our other ESG measures; and
- Technology and data analytics, which will drive our transformation and unlock commercial value across the entire value chain.

Phase 1 of the Quantum programme was completed last year delivering greater organisational speed and agility. We are building on this success by rolling-out Phase 2 which covers operational efficiency, route-to-market focus and supply chain productivity. We have realised further savings of £256 million in the first six months of 2021 driven by Quantum and are well on track to deliver our annualised £1 billion target by the end of 2021, being 12 months earlier than planned. As a result we have increased our expected cost savings target to annualised cost savings of £1.5 billion by the end of 2022. The savings from Quantum are enabling further increases in investment in New Categories and the building of new capabilities.

The performances of the regions are discussed below. The following discussion is based upon the Group's internal reporting structure.

#### **UNITED STATES (US):**

|                                | Volume       | (unit)      | Revenue    | Revenue (£m) |             |          |                   |            |             |
|--------------------------------|--------------|-------------|------------|--------------|-------------|----------|-------------------|------------|-------------|
|                                |              |             | Reporte    | d            |             | At cor   | At constant rates |            |             |
| For six months ended 30 June   | 2021<br>Unit | Change<br>% | 2021<br>£m | 2020<br>£m   | Change<br>% | FX<br>£m | 2021 cc<br>£m     | 2020<br>£m | Change<br>% |
| New Categories                 |              |             | 243        | 173          | +40.8%      | 24       | 267               | 173        | +55.1%      |
| Vapour (10ml units / pods mn)  | 139          | +97.3%      | 235        | 166          | +41.9%      | 24       | 259               | 166        | +56.3%      |
| THP (sticks bn)                | -            | -           | -          | -            | -           | -        | -                 | -          | -           |
| Modern Oral (pouches mn)       | 405          | +450%       | 8          | 7            | +17.3%      | -        | 8                 | 7          | +29.3%      |
| Traditional Oral (stick eq bn) | 3.6          | -3.1%       | 537        | 558          | -3.8%       | 55       | 592               | 558        | +6.0%       |
| <b>Total Non-Combustibles</b>  |              |             | 780        | 731          | +6.7%       | 79       | 859               | 731        | +17.6%      |
| Total Combustibles (sticks bn) | 35           | -4.3%       | 4,769      | 4,861        | -1.9%       | 486      | 5,255             | 4,861      | +8.1%       |
| Other                          |              |             | 14         | 27           | -49.9%      | 2        | 16                | 27         | -44.8%      |
| Total                          |              |             | 5,563      | 5,619        | -1.0%       | 567      | 6,130             | 5,619      | +9.1%       |

|                              |       | Reported PfO (£m)<br>Margin (%) |         |     | Adjusted PfO (£m)<br>Adjusted operating margin (%) |         |       |         |
|------------------------------|-------|---------------------------------|---------|-----|--|---------|-------|---------|
|                              | 2021  | 2020                            | Change  | Adj | FX   | 2021 cc | 2020  | Change  |
| Profit from Operations (PfO) | 2,570 | 2,619                           | -1.9%   | 196 | 306  | 3,072   | 2,801 | +9.7%   |
| Operating Margin             | 46.2% | 46.6%                           | -40 bps |     |  | 50.1%   | 49.8% | +30 bps |

Use of the term "cc" refers to the variance between the 2021 adjusted performance, at 2020 exchange rates, against the adjusted 2020 performance.

- Vuse revenue growth up 42% closing the gap on the market leader
- Velo volume share up strongly in a competitive market, with capacity unconstrained
- Continued strong cigarette pricing driving revenue and adjusted profit from operations growth (excluding the impact of translational foreign exchange)

#### **Regional Revenue and Profit from operations**

Reported revenue declined slightly (down 1.0%), as strong cigarette and traditional oral pricing and continued value share gains in Vuse and combustibles were offset by translational foreign exchange headwinds of 10% due to the relative strength of sterling to the US dollar. On a constant currency basis, revenue was up 9.1%.

Reported profit from operations reduced by 1.9%, as combustibles pricing, higher revenue from New Categories and savings from the Quantum programme were more than offset by the translational foreign exchange headwinds and a further increase in investment (over the same period of 2020) of £103 million to drive awareness and trial. Amortisation and impairment of brands (treated as adjusting items in line with Group policy) was in line with the first half of 2020 (30 June 2021: £137 million; 30 June 2020: £137 million).

On an adjusted, constant currency basis profit from operations was up 9.7%.

#### **New Categories**

In vapour, Vuse revenue was up 42%, being growth of 56% at constant rates of exchange. Vuse has further expanded its value share to 30.0%, up 510 bps against FY 2020, with market value share leadership in 20 US states.

The US vapour market continues to recover following the EVALI crisis in 2019 and the impacts of the flavour ban in 2020. While the Group has no presence in disposable vapour products in the US, it is notable that these products - as well as those flavoured products containing synthetic nicotine - have continued to increase market share over the period. This remains a concern given the sharp increase in consumption of disposable products noted in the 2020 National Youth Tobacco Survey.

We support efforts by the FDA to address the increasing availability of synthetic nicotine products and enhance the FDA's enforcement actions against flavoured disposable vapour products. The FDA is under increased scrutiny from Congress to act against these types of products, which we believe will likely lead to substantive action by the FDA.

#### **United States cont...**

In Modern Oral, Velo revenue increased 17% in the first six months of 2021 (to £8 million), or 29% at constant rates of exchange, as the Group invested in consumer acquisition and geographic expansion, with volume up 450%. Following the acquisition (in October 2020) of the nicotine pouch products from Dryft, the expanded range of products is now present in approximately 80,000 stores under the Velo brand and we will continue to build distribution further. Velo volume share has increased by 840 bps from FY 2020 to reach 16.0% May YTD 2021 in a competitive market.

PMTAs were submitted ahead of the 9 September 2020 deadline for four Vuse products (Alto, Solo, Ciro and Vibe) and for Velo modern oral products from both our existing portfolio and the recently acquired Dryft products. We will continue to work with the FDA as the PMTAs progress through the various stages of the review process.

#### **Traditional Oral**

Traditional Oral revenue reduced by 3.8%, being an increase of 6.0% excluding the unfavourable impact of foreign exchange. Strong price/mix of 9.1% offset a volume decline of 3.1%. Value share of moist grew 20 bps and volume share was down 20 bps, as Grizzly continues to drive value growth through strong pricing, utilising revenue growth management techniques.

The MRTP applications for Camel Snus were discussed by the TPSAC in September 2018. We continue to work with the FDA as the MRTP applications and public comments remain under review by the Agency.

#### Combustibles

Combustibles revenue was down 1.9%, driven by a volume decline of 4.3% and foreign exchange headwinds. At constant rates of exchange, revenue increased 8.1% driven by value share gains and strong price/mix from price increases at the end of 2020 and during H1 2021. Value share increased 40 bps compared to the FY 2020, driven by our premium brands Newport and Natural American Spirit and the success of our launch of Lucky Strike. We are not experiencing any acceleration in downtrading.

Volume share reduced 30 bps as we continued to focus on value generation.

On 29 April 2021, the FDA announced it is setting into motion the process for advancing two tobacco product standards regarding menthol in cigarettes and all flavours in cigars. The Group's US subsidiary, Reynolds American Inc. will evaluate any proposed regulation and will participate in any consultation and the rulemaking process by submitting robust comments grounded in science-based evidence. The published science does not support regulating menthol cigarettes differently from non-menthol. The scientific evidence neither shows a difference in health risks between menthol and non-menthol cigarettes, nor indicates that menthol cigarettes adversely affect initiation, dependence or cessation.

#### **ASIA-PACIFIC AND MIDDLE EAST (APME):**

|                                | Volume | (unit)  | Revenue | e (£m) |         |        |         |       |         |
|--------------------------------|--------|---------|---------|--------|---------|--------|---------|-------|---------|
|                                |        |         | Reporte | d      |         | At cor | es      |       |         |
| For six months ended 30 June   | 2021   | Change  | 2021    | 2020   | Change  | FX     | 2021 cc | 2020  | Change  |
|                                | Unit   | %       | £m      | £m     | %       | £m     | £m      | £m    | %       |
| New Categories                 |        |         | 228     | 250    | -9.2%   | 20     | 248     | 250   | -1.1%   |
| Vapour (10ml units/pods mn)    | 4      | +125.7% | 9       | 5      | +60.4%  | -      | 9       | 5     | +58.9%  |
| THP (sticks bn)                | 4.0    | +23.1%  | 216     | 244    | -11.7%  | 20     | 236     | 244   | -3.5%   |
| Modern Oral (pouches mn)       | 111    | +502%   | 3       | 1      | +418.2% | -      | 3       | 1     | +457.6% |
| Traditional Oral (stick eq bn) | _      | -       | -       | -      | -       | -      | -       | -     | -       |
| <b>Total Non-Combustibles</b>  |        |         | 228     | 250    | -9.2%   | 20     | 248     | 250   | -1.1%   |
| Total Combustibles (sticks bn) | 109    | +8.0%   | 1,781   | 1,838  | -3.1%   | 180    | 1,961   | 1,838 | +6.7%   |
| Other                          |        |         | 46      | 49     | -2.9%   | 5      | 51      | 49    | +5.1%   |
| Total                          |        |         | 2,055   | 2,137  | -3.8%   | 205    | 2,260   | 2,137 | +5.8%   |

|                              | Reported PfO (£m)<br>Margin (%) |       |          | Adjusted PfO (£m)<br>Adjusted operating margin (%) |    |         |       |          |
|------------------------------|---------------------------------|-------|----------|--|----|---------|-------|----------|
|                              | <b>2021</b> 2020 Change         |       |          | Adj  | FX | 2021 cc | 2020  | Change   |
| Profit from Operations (PfO) | 769                             | 865   | -11.1%   | 99   | 47 | 915     | 890   | +2.8%    |
| Operating Margin             | 37.4%                           | 40.5% | -310 bps |  |    | 40.5%   | 41.6% | -110 bps |

Use of the term "cc" refers to the variance between the 2021 adjusted performance, at 2020 exchange rates, against the adjusted 2020 performance.

- glo volume growth and share gain, driven by continued Hyper momentum, offset by the partial absorption of Japan excise increase
- Combustible volume growth, lapping the impact of COVID-19 in 2020
- Volume growth partially offset by negative geographic mix on revenue

#### **Regional Revenue and Profit from operations**

Revenue declined 3.8% largely due to the impact of foreign exchange on the reported results. At constant rates, revenue increased 5.8% driven by volume growth in combustibles, as a partial recovery from the impacts of COVID-19 were supported by volume share gains. These more than offset the negative geographic mix effect from the faster growth of lower value combustibles markets.

Reported profit from operations declined 11.1% due to the unfavourable movements in foreign exchange and impairment charges recognised in respect of the proposed sale of the Group's operations in Iran, as described on page 20.

Excluding adjusting items which mainly related to the impairment charges referred to above, adjusted profit from operations increased 2.8% at constant rates of exchange, driven by revenue growth. Adjusted operating margin reduced by 110 bps (at constant rates) as the negative mix impact of growth in lower margin, higher volume markets and the partial absorption the harmonisation of excise in Japan, offset continued savings from Project Quantum and productivity initiatives.

#### **New Categories**

In THP, consumable volume increased by 23% to 4.0 billion sticks in the first half of 2021 as glo Hyper continued to make good progress following its launch last year. THP revenue declined 11.7% or 3.5% on a constant currency basis, as strong volume growth was offset by the impact of harmonisation of excise in Japan. glo's share of the key Japanese market has continued to rise, reaching 6.2% volume share of cigarettes and THP May YTD, an increase of 80 bps relative to FY 2020.

#### **Combustibles**

Combustibles revenue declined 3.1% largely due to the impact of foreign exchange as, on a constant currency basis, revenue increased by 6.7%. This was driven by higher volume (up 8.0%), as a number of markets, notably Bangladesh, Vietnam and Pakistan, lapped lower volume in the first half of 2020 due to the impact of COVID-19 lockdowns. This was partially offset by negative price/mix largely from the faster growth of lower value markets.

Volume remains under pressure in Indonesia as the Group seeks to drive value with pricing ahead of the industry. We continued to grow volume share in combustibles, up 60 bps in the first half of 2021 led by gains in Bangladesh, Vietnam, Pakistan and Japan, while value share declined 10 bps, largely driven by Indonesia.

#### **AMERICAS AND SUB-SAHARAN AFRICA (AMSSA):**

|                                | Volum | ne (unit) | Revenue | e (£m) |        |       |         |       |        |
|--------------------------------|-------|-----------|---------|--------|--------|-------|---------|-------|--------|
|                                |       |           | Reporte | d      |        | At co | es      |       |        |
| For six months ended 30 June   | 2021  | Change    | 2021    | 2020   | Change | FX    | 2021 cc | 2020  | Change |
|                                | Unit  | %         | £m      | £m     | %      | £m    | £m      | £m    | %      |
| New Categories                 |       |           | 54      | 31     | +74.2% | -     | 54      | 31    | +74.8% |
| Vapour (10ml units / pods mn)  | 27    | +75.8%    | 54      | 30     | +77.8% | -     | 54      | 30    | +78.4% |
| THP (sticks bn)                | -     | -         | -       | -      | -      | -     | -       | -     | -      |
| Modern Oral (pouches mn)       | 0     | -100%     | 0       | 1      | -100%  | -     | 0       | 1     | -100%  |
| Traditional Oral (stick eq bn) | -     | -         |         | -      | -      | -     | -       | -     |        |
| <b>Total Non-Combustibles</b>  |       |           | 54      | 31     | +74.2% | -     | 54      | 31    | +74.8% |
| Total Combustibles (sticks bn) | 71    | +3.3%     | 1,651   | 1,646  | +0.3%  | 139   | 1,790   | 1,646 | +8.7%  |
| Other                          |       |           | 91      | 72     | +27.3% | 14    | 105     | 72    | +46.8% |
| Total                          |       |           | 1,796   | 1,749  | +2.7%  | 153   | 1,949   | 1,749 | +11.5% |

|                              | Reporte<br>Margin | ed PfO (£m<br>(%) | n)      | Adjusted PfO (£m)<br>Adjusted operating margin (%) |    |         |       |          |
|------------------------------|-------------------|-------------------|---------|--|----|---------|-------|----------|
|                              | 2021              | 2020              | Change  | Adj  | FX | 2021 cc | 2020  | Change   |
| Profit from Operations (PfO) | 694               | 669               | +3.7%   | 15   | 42 | 751     | 721   | +4.2%    |
| Operating Margin             | 38.6%             | 38.3%             | +30 bps |  |    | 38.5%   | 41.2% | -270 bps |

Use of the term "cc" refers to the variance between the 2021 adjusted performance, at 2020 exchange rates, against the adjusted 2020 performance.

- Revenue growth of over 70% in New Categories, driven by Vuse
- Vuse value share leadership in key Canadian vapour market extended further
- Combustibles volume and price/mix growth, with markets including South Africa recovering from a challenging 2020

#### **Regional Revenue and Profit from operations**

Revenue increased by 2.7%, as 11.5% growth on a constant currency basis was offset by translational foreign exchange headwinds caused by the weakness of a number of currencies relative to sterling, including the Brazilian real, Argentine peso, Nigerian naira and Kenyan shilling. Constant currency revenue growth was driven by a near doubling of vapour revenue, alongside combustible volume growth (up 3.3%) and price/mix (5.4%), in part due to the initial impact of COVID-19 in the prior period.

Reported profit from operations grew by 3.7%, driven by the growth in revenue and lower charges in respect of the restructuring programme as adjusting items reduced from £52 million in the first half of 2020 to £15 million in H1 2021. Excluding these adjusting items and on a constant currency basis, adjusted profit from operations was up 4.2%. Operating margins contracted by 270 bps owing to the negative geographic mix in combustibles and rapid growth, including increased investment, in vapour.

#### **New Categories**

In vapour, revenue grew 78%, with volume up 76% as the Group further extended its leadership position in Canada, with value share growth of 2,900 bps to 75.2% share. In South Africa, vapour revenue recovered from the suspension of sales, alongside cigarettes, as part of the country's COVID-19 response. South Africa followed the successful migration to the Vuse brand seen in other markets, including in Canada last year, with the migration from Twisp in the first half of the year.

#### **Combustibles**

Combustibles revenue was marginally higher (up 0.3%), negatively impacted by translational foreign exchange headwinds. On a constant currency basis, revenue grew 8.7%, underpinned by volume growth of 3.3% driven by the recovery in a number of markets, notably South Africa, from the initial impacts of COVID-19 in the prior period.

The Group's combustible share declined 30 bps on both a volume and value basis driven by South Africa, Brazil, and Canada. In South Africa, H1 2021 duty paid industry volume growth was strong year-on-year, following the ban on sales from April-August 2020 as part of the country's COVID-19 measures. However, the share of the illicit trade remains above pre-COVID levels and there has been some limited downtrading, negatively impacting volume and value share. Similarly in Brazil, the duty paid industry grew, in part due to the COVID-19 related travel restrictions and increased border security leading to a reduction in illicit trade, although growth in consumption at the lower end of the market has led to some volume and value share loss

#### **EUROPE AND NORTH AFRICA (ENA):**

|                                | Volume | e (unit) | Revenu | e (£m) |         |         |         |       |         |
|--------------------------------|--------|----------|--------|--------|---------|---------|---------|-------|---------|
|                                |        |          | Report | ed     |         | At cons |         |       |         |
| For six months ended 30 June   | 2021   | Change   | 2021   | 2020   | Change  | FX      | 2021 cc | 2020  | Change  |
|                                | Unit   | %        | £m     | £m     | %       | £m      | £m      | £m    | %       |
| <b>New Categories</b>          |        |          | 358    | 174    | +105.1% | 15      | 373     | 174   | +113.5% |
| Vapour (10ml units/pods mn)    | 77     | +32.8%   | 100    | 64     | +56.6%  | 1       | 101     | 64    | +57.8%  |
| THP (sticks bn)                | 4.4    | +367.8%  | 143    | 42     | +240.9% | 15      | 158     | 42    | +278.3% |
| Modern Oral (pouches mn)       | 1,091  | +77.2%   | 115    | 68     | +67.5%  | (1)     | 114     | 68    | +64.9%  |
| Traditional Oral (stick eq bn) | 0.5    | -3.2%    | 21     | 18     | +14.1%  | (1)     | 20      | 18    | +9.2%   |
| <b>Total Non-Combustibles</b>  |        |          | 379    | 192    | +96.6%  | 14      | 393     | 192   | +103.8% |
| Total Combustibles (sticks bn) | 110    | -3.4%    | 2,326  | 2,509  | -7.3%   | 153     | 2,479   | 2,509 | -1.2%   |
| Other                          |        |          | 56     | 65     | -13.8%  | 1       | 57      | 65    | -11.1%  |
| Total                          |        |          | 2,761  | 2,766  | -0.2%   | 168     | 2,929   | 2,766 | +5.9%   |

|                              |                         | Reported PfO (£m)<br>Margin (%) |          |     | Adjusted PfO (£m)<br>Adjusted operating margin (%) |         |       |          |  |
|------------------------------|-------------------------|---------------------------------|----------|-----|--|---------|-------|----------|--|
|                              | <b>2021</b> 2020 Change |                                 |          | Adj | FX   | 2021 cc | 2020  | Change   |  |
| Profit from Operations (PfO) | 874                     | 944                             | -7.4%    | 18  | 29   | 921     | 956   | -3.7%    |  |
| Operating Margin             | 31.7%                   | 34.1%                           | -240 bps |     |  | 31.4%   | 34.6% | -320 bps |  |

Use of the term "cc" refers to the variance between the 2021 adjusted performance, at 2020 exchange rates, against the adjusted 2020 performance.

- New Category revenue doubling compared to the first half of 2020
- glo Hyper expansion drives more than tripling of THP revenue
- Combustibles volume share and value share declined 10 bps

#### **Regional Revenue and Profit from operations**

Revenue was marginally lower (down 0.2%) as the doubling of New Categories revenue and combustibles pricing were more than offset by translational foreign exchange headwinds. On a constant currency basis, revenue increased 5.9%.

Profit from operations reduced by 7.4%, partly driven by the foreign exchange headwinds and investment in New Categories. Adjusted profit from operations at constant rates fell by 3.7% as higher revenue and Quantum cost savings were more than offset by the negative mix impact from New Category growth and increased investment behind the New Category brands.

#### **New Categories**

Vapour revenue increased by over 50%, ahead of the strong volume growth of 33%, driven by growth of the vapour market and value share gains by Vuse in all key European markets. The Vype brand was migrated to Vuse across the region during the first half of the year, completing the last transitions of our major markets. Vuse further extended its value share leadership position in France, Germany and the UK, although in the latter vapour revenue growth was moderated by a reduction in sales of Ten Motives and the remainder of the local portfolio.

Building on the strong momentum in 2020, THP volume quadrupled and revenue more than tripled driven by the progress of glo Hyper in a number of markets across the region. glo has grown volume share in key THP markets across ENA since the launch of glo Hyper last year. glo's May YTD 2021 share of cigarettes and THP had reached 1.8% in Russia (up 110 bps on FY 2020), 1.4% in Italy (up 110 bps on FY 2020), 2.8% in Ukraine (up 180 bps on FY 2020) and 1.6% Romania (up 70 bps on FY 2020).

In Modern Oral, revenue grew 67.5%, driven by volume growth (up 77%), with volume share gains of both the modern oral and total oral categories in more established markets such as Sweden and Norway. In Germany, sales of Modern Oral have been suspended pending engagement with the authorities regarding the classification of tobacco-free nicotine pouches.

#### Combustibles

Combustibles revenue fell 7.3% (or 1.2% at constant rates) as combustible volume declines (3.4%) more than offset price/mix growth. On a country level, revenue growth in Ukraine, UK and Romania was offset by weakness in countries including Denmark, Russia and France. Volume share declined 10 bps, as growth in Turkey and Germany was more than offset by lower volume share in Russia, France, Poland and Spain. Value share was 10 bps lower.

#### ANALYSIS OF PROFIT FROM OPERATIONS AND DILUTED EARNINGS PER SHARE BY SEGMENT

|  |          |               |          |          | 2021                        |          |                        | 2020     |
|--|----------|---------------|----------|----------|-----------------------------|----------|------------------------|----------|
| For six months ended 30 June           | Reported | Adj<br>Items¹ | Adjusted | Exchange | Adjusted at CC <sup>2</sup> | Reported | Adj Items <sup>1</sup> | Adjusted |
|  | £m       | £m            | £m       | £m       | £m                          | £m       | £m                     | £m       |
| Profit from Operations                 |          |               |          |          |                             |          |                        |          |
| US                                     | 2,570    | 196           | 2,766    | 306      | 3,072                       | 2,619    | 182                    | 2,801    |
| APME                                   | 769      | 99            | 868      | 47       | 915                         | 865      | 25                     | 890      |
| AMSSA                                  | 694      | 15            | 709      | 42       | 751                         | 669      | 52                     | 721      |
| ENA                                    | 874      | 18            | 892      | 29       | 921                         | 944      | 12                     | 956      |
| Total Region                           | 4,907    | 328           | 5,235    | 424      | 5,659                       | 5,097    | 271                    | 5,368    |
| Net finance costs                      | (756)    | 34            | (722)    | (55)     | (777)                       | (786)    | 3                      | (783)    |
| Associates and joint ventures          | 233      | (7)           | 226      | 20       | 246                         | 281      | (15)                   | 266      |
| Profit before tax                      | 4,384    | 355           | 4,739    | 389      | 5,128                       | 4,592    | 259                    | 4,851    |
| Taxation                               | (1,055)  | (64)          | (1,119)  | (76)     | (1,195)                     | (1,054)  | (93)                   | (1,147)  |
| Non-controlling interests              | (79)     | (1)           | (80)     | (8)      | (88)                        | (81)     | (4)                    | (85)     |
| Profit attributable to<br>shareholders | 3,250    | 290           | 3,540    | 305      | 3,845                       | 3,457    | 162                    | 3,619    |
| Diluted number of shares (m)           | 2,296    |               | 2,296    |          | 2,296                       | 2,294    |                        | 2,294    |
| Diluted earnings per<br>share (pence)  | 141.6    |               | 154.2    |          | 167.5                       | 150.7    |                        | 157.8    |

Notes to the analysis of profit from operations above:

(1) Adjusting items represent certain items which the Group considers distinctive based upon their size, nature or incidence.

(1) Adjusting items represent certain items which the Group considers distinctive based upon their size, nature or incidence.
(2) CC: constant currency – measures are calculated based on a re-translation, at the prior year's exchange rates, of the current year's results of the Group and, where applicable, its segments.

#### **NET FINANCE COSTS**

Net finance costs for the six months to 30 June 2021 were £756 million, compared to £786 million in the same period in 2020, with the reduction largely due to the translational foreign exchange impact due to the movement of sterling against the US dollar and euro and lower interest rates, partially offset by the impairment of investments held at fair value (£24 million) as part of the proposed sale of the Group's operations in Iran (as described on page 20).

On a constant currency basis, and after adjusting for items including the finance costs related to the Franked Investment Income Group Litigation Order (FII GLO, as described on page 45) and impairment described earlier, adjusted net finance costs were largely in line the first half of 2020, being a decrease of 1.0% to £777 million.

#### SHARE OF POST-TAX RESULTS OF ASSOCIATES AND JOINT VENTURES

The Group's share of post-tax results of associates and joint ventures decreased from £281 million to £233 million which largely relates to the performance of the Group's main associate, ITC Ltd (ITC) in India. The Group's share of ITC's post-tax results was 17.8% lower at £226 million (2020: £275 million), as the impact of COVID-19 in India continued to lead to business disruption.

Excluding adjusting items of £7 million (2020: £15 million), which largely related to the deemed gain on dilution of the Group's holding in ITC, as described on page 36, and the impact of translational foreign exchange, on an adjusted constant rate basis, the Group's share of post-tax results from associates and joint ventures decreased 7.5% to £246 million.

#### **TAXATION**

The tax rate in the income statement was 24.1% for the six months to 30 June 2021, compared to 23.0% for the six months to 30 June 2020 (31 December 2020: 24.3%). The Group's tax rate is affected by the impact of the adjusting items referred to on pages 33 to 36 and by the inclusion of the share of associates' and joint ventures' post-tax profit in the Group's pre-tax results.

Excluding these, the Group's underlying tax rate for subsidiaries reflected in the adjusted earnings per share on page 40 was 24.8% in the six months ended 30 June 2021 compared to 25.0% for the six months to 30 June 2020. For the year to 31 December 2020, it was 24.9%. A full reconciliation from taxation on ordinary activities to the underlying tax rate is provided on page 57.

The effective and underlying rate in the six months to 30 June 2021 reflects the impact of prior and current year tax reclaims in Brazil together with mix of profits.

We continue to expect the 2021 full-year underlying tax rate to be around 25%.

#### **EARNINGS PER SHARE**

Basic earnings per share were down 6.0% at 142.1p (30 June 2020: 151.2p) as the growth in operational performance was more than offset by a higher effective tax rate, lower share of associates, charges in respect of the proposed sale of the Group's operations in Iran and the translational foreign exchange headwind due to the relative strength of sterling particularly against the US dollar.

Before adjusting items and including the dilutive effect of employee share schemes, adjusted diluted earnings per share fell 2.3% to 154.2p (30 June 2020: 157.8p). Excluding the impact of translational foreign exchange, adjusted diluted earnings per share were 6.1% higher at 167.5p, at constant rates of exchange. For a full reconciliation of diluted earnings per share to adjusted diluted earnings per share, at constant rates, see page 57.

#### **CASH FLOW**

|  | For si      | x months e | For year ended<br>31 December 2020 |       |
|--|-------------|------------|------------------------------------|-------|
|  | 2021        | 2020       | Change                             | 2020  |
|  | £m          | £m         | %                                  | £m    |
| Net cash generated from operating activities | 2,254       | 3,484      | -35.3%                             | 9,786 |
| Operating cash flow conversion               | <b>67</b> % | 80%        | -13 ppts                           | 103%  |
| Free cash flow – before payment of dividends | 1,280       | 2,397      | -46.6%                             | 7,295 |
| Free cash flow – after payment of dividends  | (1,163)     | 51         | Not meaningful                     | 2,550 |

|  |        |        | As at 30 June | As at 31 December |
|--|--------|--------|---------------|-------------------|
|  | 2021   | 2020   | Change        | 2020              |
|  | £m     | £m     | %             | £m                |
| Borrowings (including lease liabilities) | 45,010 | 50,461 | -10.8%        | 43,968            |
| Adjusted net debt                        | 40,490 | 44,237 | -8.5%         | 39,451            |

In the Group's cash flow, prepared in accordance with International Financial Reporting Standards (IFRS) and presented on page 31, net cash generated from operating activities declined by 35.3% to £2,254 million (30 June 2020: £3,484 million), partly due to:

- the deferral, in the US, of excise (£795 million) and corporate tax (£438 million) payments from the first half to the second half of 2020;
- MSA-related outflows (£397 million) due to timing and one-off litigation settlements made in the first half of 2021; and
- an increase in tax paid in Canada (due to the timing of payments).

These were partly offset by an increase in dividends received from associates to £164 million (30 June 2020: £2 million) following the payment of an interim dividend by the Group's Indian associate, ITC.

Net cash generated from operating activities was also impacted by the translational foreign exchange headwind of around 8% due to the relative strength of sterling versus the Group's operating currencies (particularly US dollar).

#### Operating cash conversion and free cash flow (before and after dividends paid to shareholders)

The Group's operating cash conversion rate (based upon adjusted profit from operations and defined on page 58) was 67% (30 June 2020: 80%). The reduction was largely due to the deferral of excise in the US in the first half of 2020 (mentioned above) and higher capital expenditure in 2021 compared to the comparator period as investment was delayed to the second half of 2020 due to the COVID-19 pandemic.

The Group continues to target an operating cash flow conversion ratio of at least 90% in 2021.

Free cash flow (before the payment of dividends), as defined on page 58, declined from £2,397 million (for the six months ended 30 June 2020) to £1,280 million largely driven by the reduction in net cash generated from operations described above.

After paying dividends of £2,443 million (30 June 2020: £2,346 million), free cash flow (after dividends paid to shareholders), as defined on page 58, was an outflow of £1,163 million compared to an inflow of £51 million in the same period in 2020. For a full reconciliation of net cash generated from operating activities to free cash flow before and after dividends, see page 58.

#### **BORROWINGS AND NET DEBT**

Borrowings (including lease liabilities) were £45,010 million at 30 June 2021, compared to £50,461 million at 30 June 2020 and £43,968 million at 31 December 2020. The increase from the end of 2020 was largely due to higher short term borrowings (including commercial paper) due to short-term funding needs in the period. The movement in the Group's borrowings is described on page 38.

The Group remains confident about its ability to access the debt capital markets successfully and reviews its options on a continuing basis.

The Group defines net debt as borrowings including related derivatives, less cash and cash equivalents and current investments held at fair value. Closing net debt was £41,251 million (30 June 2020: £45,114 million; 31 December 2020: £40,241 million). A reconciliation of borrowings to net debt is provided below.

|  |          | As a     | at 30 June | As at 31 December |
|--|----------|----------|------------|-------------------|
|  | 2021     | 2020     | Change     | 2020              |
|  | £m       | £m       | %          | £m                |
| Borrowings (including lease liabilities) | (45,010) | (50,461) | -10.8%     | (43,968)          |
| Derivatives in respect of net debt       | 409      | 380      | +7.6%      | 346               |
| Cash and cash equivalents                | 3,014    | 4,784    | -37.0%     | 3,139             |
| Current investments held at fair value   | 336      | 183      | +83.6%     | 242               |
| Net debt                                 | (41,251) | (45,114) | -8.6%      | (40,241)          |
| Maturity profile of net debt:            |          |          |            |                   |
| Net debt due within one year             | (5,144)  | (2,014)  | +155.4%    | (635)             |
| Net debt due beyond one year             | (36,107) | (43,100) | -16.2%     | (39,606)          |
| Net debt                                 | (41,251) | (45,114) | -8.6%      | (40,241)          |

The movement in net debt includes the free cash outflow, after payment of dividends to shareholders, in the six months ended 30 June 2021 of £1,163 million (30 June 2020: £51 million inflow; 31 December 2020: £2,550 million inflow) as described on page 15. Also impacting the carrying value of net debt at the balance sheet date are

- other cash outflows related to share schemes and investing activities of £165 million (30 June 2020: £53 million: 31
   December 2020: £210 million);
- other non-cash movements of £45 million (mainly related to interest accruals);
- the classification of certain balances as held-for-sale related to the proposed sale of the Group's operations in Iran of £100 million; and
- foreign exchange tailwind related to the revaluation of foreign currency denominated net debt balances of £373 million (30 June 2020: £2,342 million headwind; 31 December 2020: £69 million tailwind).

In 2020, following the acquisition of a distribution company in the Middle East, the Group also recognised net debt acquired of £95 million. These movements can be summarised as follows:

|                                    | As a     | at 30 June | As at 31 December |
|------------------------------------|----------|------------|-------------------|
|                                    | 2021     | 2020       | 2020              |
|                                    | £m       | £m         | £m                |
| Opening net debt                   | (40,241) | (42,574)   | (42,574)          |
| Free cash inflow (after dividends) | (1,163)  | 51         | 2,550             |
| Other cash payments                | (165)    | (53)       | (210)             |
| Net debt acquired                  | -        | -          | 95                |
| Other non-cash movements           | 45       | (196)      | (171)             |
| Transferred to held-for-sale       | (100)    | -          | -                 |
| Foreign exchange                   | 373      | (2,342)    | 69                |
| Closing net debt                   | (41,251) | (45,114)   | (40,241)          |

# **BORROWINGS AND NET DEBT cont... Adjusted net debt**

The Group also adjusts net debt for the purchase price allocation adjustment to the debt, included within borrowings, acquired as part of the acquisition of Reynolds American Inc. This is an accounting adjustment and does not reflect the enduring repayment of the instrument. The Group Management Board believes that this additional measure, which is used internally to assess the Group's financial capacity, is useful to the users of the financial statements in helping them to see how the Group's financial capacity has changed over the year. The adjusted net debt position is provided below:

|   |          | As a     | at 30 June | As at 31 December |
|---|----------|----------|------------|-------------------|
|   | 2021     | 2020     | Change     | 2020              |
|   | £m       | £m       | %          | £m                |
| Net debt  | (41,251) | (45,114) | -8.6%      | (40,241)          |
| Purchase price allocation (PPA) adjustment to acquired debt | 761      | 877      | -13.2%     | 790               |
| Adjusted net debt   | (40,490) | (44,237) | -8.5%      | (39,451)          |
| Exchange  | (374)    |          |            |                   |
| Adjusted net debt at constant rates                         | (40,864) | (44,237) | -7.6%      |                   |

#### **DIVIDENDS**

On 17 February 2021, British American Tobacco p.l.c. (the Company) announced that the Board had declared an interim dividend of 215.6p per ordinary share of 25p for the year ended 31 December 2020, payable in four equal quarterly instalments of 53.9p per ordinary share in May 2021, August 2021, November 2021 and February 2022.

The May 2021 dividend was paid to shareholders on the UK main register and South Africa branch register on 12 May 2021 and to holders of American Depositary Shares (ADSs) on 17 May 2021. The three remaining quarterly dividends will be paid to shareholders registered on either the UK main register or the South Africa branch register, and to holders of ADSs, each on the applicable record dates set out in the table below.

| Event (2021 unless stated)      | Payment No. 2 | Payment No. 3 | Payment No. 4    |
|---------------------------------|---------------|---------------|------------------|
| Record date (JSE, LSE and NYSE) | 9 July        | 1 October     | 24 December      |
| Payment date (LSE and JSE)      | 19 August     | 11 November   | 9 February 2022  |
| ADS payment date (NYSE)         | 24 August     | 16 November   | 14 February 2022 |

#### **FOREIGN CURRENCIES**

The principal exchange rates used to convert the results of the Group's foreign operations to sterling for the purposes of inclusion and consolidation within the Group's financial statements are indicated in the table below. Where the Group has provided results "at constant rates of exchange" this refers to the translation of the results from the foreign operations at rates of exchange prevailing in the prior period - thereby eliminating the potentially distorting impact of the movement in foreign exchange on the reported results.

for the period ended

31 December

2020

1.862

6.616

1.720

1.125

95.097

137.017

92.844

21.099

1.284

The principal exchange rates used were as follows:

|                    |         | Average for t |
|--------------------|---------|---------------|
|                    |         | 30 June       |
|                    | 2021    | 2020          |
| Australian dollar  | 1.800   | 1.919         |
| Brazilian real     | 7.476   | 6.186         |
| Canadian dollar    | 1.731   | 1.720         |
| Euro               | 1.153   | 1.144         |
| Indian rupee       | 101.849 | 93.400        |
| Japanese yen       | 149.701 | 136.475       |
| Russian rouble     | 103.178 | 87.661        |
| South African rand | 20.183  | 20.956        |
| US dollar          | 1.389   | 1.261         |
|                    |         |               |

|         |         | As at       |
|---------|---------|-------------|
|         | 30 June | 31 December |
| 2021    | 2020    | 2020        |
| 1.840   | 1.795   | 1.771       |
| 6.932   | 6.784   | 7.100       |
| 1.711   | 1.683   | 1.741       |
| 1.165   | 1.100   | 1.117       |
| 102.683 | 93.292  | 99.880      |
| 153.327 | 133.303 | 141.131     |
| 100.920 | 88.042  | 101.106     |
| 19.725  | 21.469  | 20.079      |
| 1.381   | 1.236   | 1.367       |

#### **RISKS AND UNCERTAINTIES**

The Board carried out a robust assessment of the principal risks and uncertainties facing the Group for the period, including those that would threaten its business model, future performance, solvency, liquidity and viability. As part of that assessment, the Board reviewed all the risks, both individually and collectively, as they relate to the impact of COVID-19 on the performance of the Group.

The COVID-19 pandemic may have a lasting impact on operations, suppliers, customers and our people. The governments of the countries in which we operate and sell our products will adjust as they tackle the socio-economic impact of the pandemic. This could lead to increased risk of regulation, affect the ability to realise revenue growth due to consumer downtrading, excise increases or higher illicit trade, whilst also potentially impacting the supply chain, financial markets and customer credit risk. The impact of these risks is difficult to ascertain and potentially unforeseen during this period of uncertainty. As new working practices are implemented to reflect the current operating environment and associated risks are incorporated into existing Group risks (including principal risks noted below), the Group does not maintain COVID-19 as a separate principal risk.

All Group risks are managed individually and collectively by management and overseen by the Board. The principal risks remain broadly unchanged except for "market size reduction and consumer down trading" which, due to the Group's strategy to deliver long-term sustainable growth with a range of innovation and less harmful products that stimulate senses of new adult generations, is no longer considered a principal risk. The principal risks facing the Group are summarised under the headings of:

- Competition from illicit trade;
- Tobacco, New Categories and other regulation interrupts the growth strategy;
- Disputed taxes, interest and penalties;
- Inability to develop, commercialise and deliver the New Categories strategy;
- Significant increases or structural changes in tobacco, nicotine and New Categories related taxes;
- Foreign exchange rate exposures;
- Geopolitical tensions;
- Solvency and liquidity; and
- Injury, illness or death in the workplace.

A summary of the other risks for the Group which are not considered principal risks but are monitored by the Board through the Group's risk register is set out on pages 288-306 of the Group's Annual Report and Form 20-F for the year ended 31 December 2020. These and all of the Group's risks should be read in the context of the forward-looking statements on page 61 of this Half-Year Report.

#### **MANAGING THROUGH COVID-19**

The Group continues to perform well despite the operational challenges posed by the COVID-19 pandemic, whilst recognising that GTR continues to be affected by the ongoing travel restrictions in certain parts of the world. Our Board has continued to maintain close oversight of the Group's response to the impact of COVID-19 throughout this period.

Our robust contingency plans and organisational flexibility have ensured that, where operations have been affected by local lock downs, the supply chain disruption to our ongoing business has largely been mitigated. We have embraced remote working where appropriate and would like to thank our staff around the world for the resilience and agility they have demonstrated during these unprecedented times. That such progress towards building A Better Tomorrow<sup>TM</sup> has been made during such a challenging period is testimony to the resilience of our staff, customers, partners and suppliers.

We remain committed to supporting all our stakeholders throughout the COVID-19 pandemic. Our COVID-19 candidate vaccine is currently in Phase 1 trials. To enhance recruitment to the trials, we have expanded our clinical trial footprint to include study sites in the US, Canada and Germany.

#### **UPDATE ON INVESTIGATIONS INTO MISCONDUCT ALLEGATIONS**

From time-to-time, the Group investigates, and becomes aware of governmental authorities' investigations into, allegations of misconduct against Group companies. The Group co-operates with the authorities' investigations, where appropriate, including with the DOJ and OFAC in the United States, which are conducting an investigation into suspicions of breach of sanctions.

The potential for fines, penalties or other consequences cannot currently be assessed. As the investigations are ongoing, it is not possible to identify the timescale in which these matters might be resolved.

#### **UPDATE ON QUEBEC CLASS ACTION AND CCAA**

In 2015, the plaintiffs in the two certified classes in Quebec were awarded damages and interest in the amount of CAD\$15.6 billion (£9 billion), of which Imperial Tobacco Canada Ltd's (ITCAN) share is CAD\$10.4 billion (£6 billion). Also in 2015, the Quebec Court of Appeal upheld the Order for Security, of which ITCAN's share was CAD\$758 million (£436 million), which has been paid in full to the Court escrow account as required by the judgment. Following the decision of the Quebec Court of Appeal in Montreal, the Board of Directors of ITCAN reassessed the recoverability of the deposit and the Group recognised a charge against the income statement of £436 million in 2019. As a consequence, in the Group's consolidated balance sheet, the deposit has been utilised against the current estimate of the liability.

Further, on 12 March 2019, ITCAN obtained an Initial Order from the Ontario Superior Court of Justice granting it protection under the Companies' Creditors Arrangement Act (CCAA). This has the effect of staying all current tobacco litigation in Canada against ITCAN and other Group companies (the "stays"). The stays are currently in place until 30 September 2021. While the stays are in place, no steps are to be taken in connection with the Canadian tobacco litigation with respect to ITCAN, certain of its subsidiaries or any other Group company.

In addition to Quebec, across Canada, other tobacco plaintiffs and provincial governments are collectively seeking significant damages which substantially exceed ITCAN's total assets. In seeking protection under the CCAA, ITCAN will look to resolve not only the Quebec case but also all other tobacco litigation in Canada under an efficient and court supervised process, while continuing to trade in the normal course.

Under the terms of CCAA, the court appointed FTI Consulting Canada Inc. to act as a monitor. This monitor has no operational input and is not involved in the management of the business. The Group considers that ITCAN continues to meet the requirements of IFRS 10 Consolidated Financial Statements, and, until such requirements are not met, the Group will continue to consolidate the results of ITCAN. The £2.3 billion of goodwill relating to ITCAN on the Group's balance sheet at 31 December 2020 will continue to be reviewed on a regular basis. Any potential future impairment charge would result in a non-cash charge to the income statement that would be treated as an adjusting item.

Please refer to "Contingent Liabilities and Financial Commitments" below (page 43) and the Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020, note 27 Contingent Liabilities and Financial Commitments for a full discussion of the case.

#### **BANGLADESH**

In Bangladesh, on 25 July 2018, the Appellate Division of the Supreme Court of Bangladesh reversed the decision of the High Court against BAT Bangladesh in respect of the retrospective demands for VAT and Supplementary Duty amounting to approximately £153 million. On 3 February 2020, the certified Court Order was received. The Government filed a Review Petition on 25 March 2020 in the Appellate Division of the Supreme Court of Bangladesh against the judgment. The matter is yet to be taken up for hearing.

#### **CHANGES IN THE GROUP**

#### 1. ORGANIGRAM

On 11 March 2021, the Group announced a strategic collaboration agreement with Organigram Inc., a wholly-owned subsidiary of publicly-traded Organigram Holdings Inc. (collectively, Organigram). Under the terms of the transaction, a Group subsidiary acquired a 19.9% equity stake in Organigram Holdings Inc. (listed on both the Nasdaq and Toronto Stock Exchange under the symbol "OGI") to become its largest shareholder, with the ability to appoint two directors to Organigram Holdings Inc.'s board of directors and representation on its investment committee. At closing, one BAT nominee, Mr. Jeyan Heper, was added to the board and another nominee is expected to be added in the near term. The Group will account for the investment as an associate.

The investment, valued at approximately £129 million, was priced at CAD\$3.79 per share which was based on the five-day volume weighted average price of Organigram Holdings Inc.'s shares on the Toronto Stock Exchange ended 9 March 2021 and represents a discount to the closing price of CAD\$3.94 on 9 March 2021. The Group's share of the fair value of net assets acquired included £49 million of intangibles, and £30 million of goodwill, representing a strategic premium to enter the legal cannabis market in North America which was provisionally recognised as part of the acquisition.

The Group's investment provides a significant injection of capital for Organigram that will enable them to expand and accelerate their R&D and product development activities, and support business expansion.

A "Centre of Excellence" will be established to focus on developing the next generation of cannabis products with an initial focus on cannabidiol (CBD). The Centre of Excellence will be located at Organigram's indoor facility in New Brunswick, Canada, which holds the Health Canada licenses required to conduct R&D activities with cannabis products. Both BAT and Organigram will contribute scientists, researchers, and product developers to the Centre of Excellence which will be governed and supervised by a steering committee consisting of an equal number of senior members from each of BAT and Organigram. Both partners share a commitment to continue to maintain the highest regulatory and ethical standards. Furthermore, as part of the transaction, BAT and Organigram will grant each other a licence to certain intellectual property to enable the development of new and potentially disruptive, novel products. Both parties will have the ability to independently commercialise any products developed as a result of the collaboration under their own brands.

On 6 April 2021, Organigram acquired all of the issued and outstanding shares of The Edibles & Infusions Corporation (EIC) for consideration of CAD\$22 million, payable in shares, with a potential additional CAD\$13 million in shares payable upon the EIC business achieving certain earnout milestones. The impact on the Group's stake in Organigram was not material.

The transactions and results of these changes are immaterial to the Group and organic measures, excluding the results of these acquisitions, are not presented.

#### 2. B.A.T. Pars Company - IRAN

On 25 June 2021, the Group agreed to dispose of its Iranian subsidiary, B.A.T. Pars Company PJSC (BAT Pars) to DTM ME FZE LLC. Consideration is subject to the completion accounts process, with payment deferred until September 2022. It is expected that the agreement will be completed by the end of 2021. The transaction is subject to the approval by State Centre of Tobacco Planning and Supervision of the Ministry of Industry of Iran.

In accordance with IFRS, BAT Pars has been classified as held-for-sale at 30 June 2021 and presented as such on the balance sheet. An impairment charge and associated costs of £71 million has been recognised in the income statement and has been treated as a non-cash, adjusting item. On completion of the transaction, certain other items (including an estimated £270 million in respect of foreign exchange previously recognised in the Statement of Other Comprehensive Income) will be reclassified to the income statement in the period in which completion occurs. The financial impact of these items will also be treated as non-cash, adjusting items.

On a full year basis, in 2020, in respect of Iran, the Group reported 11.4 billion sticks, revenue of approximately £170 million and adjusted profit from operations of approximately £60 million (at 2020 rates of exchange).

#### **UK PENSION FUND - BUY-IN**

On 19 May 2021, the Trustee of the British American Tobacco UK Pension Fund (UK Fund) entered into an agreement with Pension Insurance Corporation plc ("PIC") to acquire a second insurance policy that matches a specific part of the UK Fund's future cash flow arising from the accrued pension liabilities of pensioners and deferred members, following the first agreement entered into in May 2019. Such an arrangement is commonly termed as a "Buy-In".

The Buy-In transaction involved the transfer of £383 million of assets held by the UK Fund to PIC and, as such, has no cash effect to the Group. On an IAS 19 basis, the fair value of the insurance policy will match the present value of the liabilities being insured and a loss of £117 million has been recognised through the statement of other comprehensive income on the revaluation of the insurance asset with no impact to the income statement.

As disclosed in the Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020, the UK Fund closed to future accrual with effect from 1 July 2020. The Trustee and the Group agreed a new Schedule of Contributions with an effective date of 5 October 2020 such that the Group would pay £12 million per annum from July 2021 until July 2023. This schedule was subsequently replaced with a new schedule with an effective date of 30 March 2021 such that the Group will effectively make no contributions in 2021, but will pay £18 million in July 2022 and £18 million in July 2023 as contributions towards de-risking of the UK Fund's assets and securing members' benefits. The funding commitment is therefore not considered onerous, and in accordance with IFRIC 14 no additional liabilities or surplus restrictions have been recognised in respect of these commitments.

#### **CHANGES TO THE MAIN BOARD**

As previously announced, Luc Jobin succeeded Richard Burrows as Chairman of British American Tobacco p.l.c. on 28 April 2021. Also as previously announced in 2021, Jerry Fowden resigned from the Board as a Non-Executive Director with effect from 1 April 2021.

#### **GOING CONCERN**

A description of the Group's business activities, its financial position, cash flows, liquidity position, facilities and borrowings position, together with the factors likely to affect its future development, performance and position, as well as risks associated with the business, are set out in the Strategic Report and in the notes to the financial statements, all of which are included in the Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020, and available on the Group's website, www.bat.com. This Half-Year Report provides updated information regarding the business activities, including cash flow, for the six months to 30 June 2021 and of the financial position and liquidity position at 30 June 2021.

The Group has, at the date of this announcement, sufficient existing financing available for its estimated requirements for at least 12 months from the date of approval of this condensed consolidated financial information. This, together with the ability to generate cash from trading activities, the performance of the Group's Strategic Portfolio, its leading market positions in a number of countries and its broad geographical spread, as well as numerous contracts with established customers and suppliers across different geographical areas and industries, provides the Directors with the confidence that the Group is well placed to manage its business risks successfully through the ongoing uncertainty and risks associated with COVID-19 and its impact on the current financial conditions and the general outlook in the global economy.

After reviewing the Group's forecast financial performance and financing arrangements, the Directors consider that the Group has adequate resources to continue operating for at least 12 months from the date of approval of this condensed consolidated financial information and that it is therefore appropriate to continue to adopt the going concern basis in preparing this Half-Year Report.

#### **EXTERNAL RECOGNITION IN RESPECT OF SUSTAINABILITY**

The Group continues to be recognised for its ESG performance, building on the numerous ESG-related awards BAT has won in the past:

| Year | Award/rating   | Environmental                         | Social   | Governance                                       |
|------|--|---------------------------------------|----------|--|
| 2021 | S&P Global's Sustainability Yearbook 2021: highest "Gold Class" distinction  | ✓                                     | ✓        | ✓  |
|      | Refinitiv: BAT ranked as the third highest ESG-rated FTSE 100 company  | ✓                                     | ✓        | ✓  |
|      | Financial Times Europe Climate Leader Ranking 2021   | ✓                                     | <b>✓</b> |  |
|      | Financial Times Diversity Leader Ranking 2021  |                                       | ✓        |  |
|      | Gartner Supply Chain 2021 Award: Top 20 ranking  |                                       | ✓        |  |
|      | Institutional Shareholder Services' (ISS) Social Disclosures Quality Score: highest rating for best-   |                                       | <b>✓</b> |  |
|      | in-class sustainability disclosure practices   |                                       |          |  |
|      | Workforce Disclosure Initiative (WDI): ranked in the top 10% of responding companies   |                                       | ✓        |  |
|      | WDI Workforce Transparency Awards: special mentions in the 'COVID-19 transparency' and 'Workforce action' categories                           |                                       | ✓        |  |
|      | Global Top Employer 2021   |                                       |          |  |
|      | Undergraduate Employability Awards: top Medium-sized Undergraduate Scheme (UK)   |                                       | · ·      |  |
|      | Corporate Equality Index 2021: our businesses in the US and Mexico were ranked among the best  |                                       |          |  |
|      | places to work for LGBTQ equality  |                                       | •        |  |
|      | dotCOMM Awards: Platinum award for our Women in Science video  |                                       | <b>*</b> |  |
| 2020 | Dow Jones Sustainability Indices (DJSI): World Index & Industry leader   | ✓                                     | ✓        | ✓  |
|      | Corporate Responsibility Reporting Awards 2020: Winner in the 'Openness and Honesty' category  | ✓                                     | ✓        | ✓  |
|      | Disability Confident Committed employer under the UK Government's accreditation scheme   |                                       | ✓        |  |
|      | MSCI: BBB rating   | ✓                                     | ✓        | ✓  |
|      | Vigeo Eiris: 47% score   | ✓                                     | <b>✓</b> | ✓  |
|      | Sustainalytics: 27.8 score   | ✓                                     | ✓        | ✓  |
|      | Corporate Reporting Awards (CRRA): Openness and Transparency   |                                       |          | ✓  |
|      | Carbon disclosure Project (CDP): Climate A and Water A-  | <b>✓</b>                              |          |  |
|      | S&P Global Sustainability Yearbook Award: highest "Gold Class" distinction   | <b>√</b>                              | ✓        | ✓  |
|      | Sustainability, Environmental Achievement and Leadership (SEAL) Awards: top 50 companies   | <b>✓</b>                              | <b>4</b> | ✓  |
|      | Global Top Employer  |                                       | <b>√</b> |  |
|      | Financial Times Diversity Leader Ranking 2020  |                                       | ✓        |  |
|      | Gartner Supply Chain Award: top 25 ranking   |                                       | <b>✓</b> |  |
|      | Corporate Equality Index: best place to work for LGBTQ equality (Reynolds American Inc. and its  |                                       |          |  |
|      | operating companies)   |                                       | ✓        |  |
|      | Undergraduate Employability Awards: top Medium-sized Undergraduate Scheme (UK)   |                                       | ✓        |  |
|      | Product of the Year: Vype ePod best e-cigarette  |                                       | 1        |  |
| 2019 | DJSI: World Index & Industry leader  | <b>✓</b>                              | <b>/</b> | <b>✓</b>   |
| -0.5 | RobecoSAM Sustainability Award: Gold Class   | <b>✓</b>                              | <b>/</b> | <b>√</b>   |
|      | MSCI: BBB rating   | <b>√</b>                              | 1        | ✓  |
|      | Vigeo Eiris: 42% score   | <b>✓</b>                              | 1        | <b>✓</b>   |
|      | CDP: Climate A and Water B   | <b>✓</b>                              |          |  |
|      | Global Child Forum benchmark: leader status  | ,                                     | <b>✓</b> |  |
|      | Global Top Employer  |                                       | 1        |  |
|      | Workforce Disclosure Initiative (WDI): industry leader   |                                       | 1        |  |
|      | International Women's Day: best practice winner  |                                       | -        |  |
|      | Product of the Year: Vype ePod best e-cigarette  |                                       | 1        |  |
| 2018 | DJSI: World Index & Industry leader  | ✓                                     | 1        | ✓  |
| -010 | RobecoSAM Sustainability Award: Gold Class   | ,                                     | -        | 7  |
|      | MSCI: A rating   | · ·                                   |          | <b>→</b>   |
|      | CDP: Climate B and Water B-  | , , , , , , , , , , , , , , , , , , , | *        | *  |
|      | Global Top Employer  | *                                     | <b>✓</b> | 1  |
|      | WDI: industry leader   |                                       | · ·      | -  |
|      | •  |                                       | <b>→</b> | <del>                                     </del> |
|      | International Women's Day: best practice winner  Fortune best workplaces: best in manufacturing and production (Reynolds American Inc. and its |                                       |          | <u> </u>   |
|      | operating companies)   |                                       | ✓        |  |
|      | dotCOMM Awards: best ebook for Science & Technology Report   |                                       |          | <b>4</b>   |

#### **DIRECTORS' RESPONSIBILITY STATEMENT**

The Directors confirm that, to the best of their knowledge, this condensed consolidated financial information has been prepared in accordance with *IAS 34 Interim Financial Reporting* as adopted for use in the UK and as issued by the International Accounting Standards Board (IASB), and that this Half-Year Report includes a fair review of the information required by both DTR 4.2.7R and DTR 4.2.8R of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

The Directors of British American Tobacco p.l.c. are as listed on pages 92 and 93 in the British American Tobacco Annual Report and Form 20-F for the year ended 31 December 2020, with the exception of Jerry Fowden who stepped down on 1 April 2021 and Richard Burrows who stepped down on 28 April 2021.

Details of all the current Directors of British American Tobacco p.l.c. are maintained on www.bat.com.

For and on behalf of the Board of Directors:

Luc Jobin Tadeu Marroco

Chairman Finance and Transformation Director

27 July 2021 27 July 2021

### **ENQUIRIES**

#### **INVESTOR RELATIONS:**

#### **PRESS OFFICE:**

Mike Nightingale +44 (0)20 7845 1180 Press Office +44 (0)20 7845 2888

Victoria Buxton +44 (0)20 7845 2012 William Houston +44 (0)20 7845 1138 John Harney +44 (0)20 7845 1263

#### Webcast and Conference Call Participant Passcode: BAT

A webcast of the results is available via <a href="www.bat.com/latestresults">www.bat.com/latestresults</a> on 28 July 2021 from 08.30 BST. If you wish to listen to the presentation via a conference call facility please use the dial in details below: Standard International Access: +44 (0) 33 0551 0200 SA (toll free): 0 800 980 512

# INDEPENDENT REVIEW REPORT TO BRITISH AMERICAN TOBACCO p.l.c.

#### Conclusion

We have been engaged by British American Tobacco p.l.c. (the Company) to review the condensed consolidated financial information in the Half-Year report for the six months ended 30 June 2021 which comprises the Group Income Statement, the Group Statement of Comprehensive Income, the Group Statement of Changes in Equity, the Group Balance Sheet, the Group Cash Flow Statement and the related explanatory notes.

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial information in the Half-Year report for the six months ended 30 June 2021 is not prepared, in all material respects, in accordance with IAS 34 *Interim Financial Reporting* as adopted for use in the UK and as issued by the International Accounting Standards Board (IASB), and the Disclosure Guidance and Transparency Rules (the DTR) of the UK's Financial Conduct Authority (the UK FCA).

#### Scope of review

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Auditing Practices Board for use in the UK. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. We read the other information contained in the Half-Year report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed consolidated financial information.

A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### **Directors' responsibilities**

The Half-Year report is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the Half-Year report in accordance with the DTR of the UK FCA.

As disclosed in the Accounting Policies and Basis of Preparation note, the latest annual financial statements of the Group were prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the IASB, and international accounting standards in conformity with the requirements of the Companies Act 2006, and in accordance with International Financial Reporting Standards adopted pursuant to Regulation (EC) No 1606/2002 as it applied in the European Union. The next annual financial statements of the Group will be prepared in accordance with IFRS as issued by the IASB and UK-adopted international accounting standards. The directors are responsible for preparing the condensed consolidated financial information included in the Half-Year report in accordance with IAS 34 Interim Financial Reporting as adopted for use in the UK and as issued by the IASB.

#### Our responsibility

Our responsibility is to express to the Company a conclusion on the condensed consolidated financial information in the Half-Year report based on our review.

#### The purpose of our review work and to whom we owe our responsibilities

This report is made solely to the Company in accordance with the terms of our engagement to assist the Company in meeting the requirements of the DTR of the UK FCA. Our review has been undertaken so that we might state to the Company those matters we are required to state to it in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company for our review work, for this report, or for the conclusions we have reached.

Philip Smart

#### for and on behalf of KPMG LLP

Chartered Accountants 15 Canada Square, London E14 5GL 27 July 2021

### **GROUP INCOME STATEMENT**

|   | Six months ended<br>30 June |         | Year ended<br>31 December |
|---|-----------------------------|---------|---------------------------|
|   | 2021                        | 2020    | 2020                      |
|   | £m                          | £m      | £m                        |
| Revenue <sup>1</sup>  | 12,175                      | 12,271  | 25,776                    |
| Raw materials and consumables used                            | (2,195)                     | (2,182) | (4,583)                   |
| Changes in inventories of finished goods and work in progress | 70                          | 183     | 445                       |
| Employee benefit costs  | (1,360)                     | (1,306) | (2,744)                   |
| Depreciation, amortisation and impairment costs               | (473)                       | (533)   | (1,450)                   |
| Other operating income  | 102                         | 42      | 188                       |
| Loss on reclassification from amortised cost to fair value    | (1)                         | (1)     | (3)                       |
| Other operating expenses                                      | (3,411)                     | (3,377) | (7,667)                   |
| Profit from operations  | 4,907                       | 5,097   | 9,962                     |
| Net finance costs   | (756)                       | (786)   | (1,745)                   |
| Finance income  | 15                          | 36      | 50                        |
| Finance costs   | (771)                       | (822)   | (1,795)                   |
| Share of post-tax results of associates and joint ventures    | 233                         | 281     | 455                       |
| Profit before taxation  | 4,384                       | 4,592   | 8,672                     |
| Taxation on ordinary activities                               | (1,055)                     | (1,054) | (2,108)                   |
| Profit for the period   | 3,329                       | 3,538   | 6,564                     |
| Attributable to:  |                             |         |                           |
| Owners of the parent  | 3,250                       | 3,457   | 6,400                     |
| Non-controlling interests                                     | 79                          | 81      | 164                       |
|   | 3,329                       | 3,538   | 6,564                     |
| Earnings per share  |                             |         |                           |
| Basic   | 142.1p                      | 151.2p  | 280.0p                    |
| Diluted   | 141.6p                      | 150.7p  | 278.9p                    |

All of the activities during both years are in respect of continuing operations.

The accompanying notes on pages 32 to 49 form an integral part of this condensed consolidated financial information.

<sup>&</sup>lt;sup>1</sup> Revenue is net of duty, excise and other taxes of £18,553 million and £18,415 million for the six months ended 30 June 2021 and 2020 respectively, and £39,172 million for the year ended 31 December 2020.

## **GROUP STATEMENT OF COMPREHENSIVE INCOME**

|   | Six months ended<br>30 June |       | Year ended<br>31 December |
|---|-----------------------------|-------|---------------------------|
|   | 2021                        | 2020  | 2020                      |
|   | £m                          | £m    | £m                        |
| Profit for the period (page 25)                                     | 3,329                       | 3,538 | 6,564                     |
| Other comprehensive income/(expense)                                |                             |       |                           |
| Items that may be reclassified subsequently to profit or loss:      | (802)                       | 4,095 | (2,997)                   |
| Differences on exchange   | (786)                       | 4,847 | (2,597)                   |
| Cash flow hedges  |                             |       |                           |
| – net fair value gains/(losses)                                     | 50                          | (267) | (257)                     |
| – reclassified and reported in profit for the period                | 4                           | 48    | 90                        |
| Investments held at fair value                                      |                             |       |                           |
| – net fair value gains  | 5                           | -     | -                         |
| Net investment hedges   |                             |       |                           |
| – net fair value gains/(losses)                                     | 111                         | (353) | (16)                      |
| – differences on exchange on borrowings                             | (121)                       | (230) | (163)                     |
| Associates – share of OCI, net of tax                               | (49)                        | -     | (98)                      |
| Tax on items that may be reclassified                               | (16)                        | 50    | 44                        |
| Items that will not be reclassified subsequently to profit or loss: | 228                         | 57    | 55                        |
| Retirement benefit schemes  |                             |       |                           |
| – net actuarial gains   | 282                         | 78    | 105                       |
| – surplus recognition   | (1)                         | (6)   | 10                        |
| Associates – share of OCI, net of tax                               | 4                           | (11)  | (34)                      |
| Tax on items that will not be reclassified                          | (57)                        | (4)   | (26)                      |
| Total other comprehensive (expense)/income for the period           | (574)                       | 4,152 | (2,942)                   |
| Total comprehensive income for the period                           | 2,755                       | 7,690 | 3,622                     |
| Attributable to:  |                             |       |                           |
| Owners of the parent  | 2,679                       | 7,596 | 3,474                     |
| Non-controlling interests   | 76                          | 94    | 148                       |
|   | 2,755                       | 7,690 | 3,622                     |

The accompanying notes on pages 32 to 49 form an integral part of this condensed consolidated financial information.

## **GROUP STATEMENT OF CHANGES IN EQUITY**

| At 30 June 2021  | Attributable to owners of the parent |   |                |                      |  |                                  |              |  |
|--|--------------------------------------|---|----------------|----------------------|--|----------------------------------|--------------|--|
|  | Share<br>capital                     | Share premium,<br>capital redemption<br>and merger reserves | Other reserves | Retained<br>earnings | Total attributable<br>to owners<br>of parent | Non-<br>controlling<br>interests | Total equity |  |
|  | £m                                   | £m  | £m             | £m                   | £m   | £m                               | £m           |  |
| Balance at 1 January 2021  | 614                                  | 26,618  | (6,600)        | 42,041               | 62,673                                       | 282                              | 62,955       |  |
| Total comprehensive (expense)/income for the period comprising: (page 26)                | -                                    | -   | (795)          | 3,474                | 2,679  | 76                               | 2,755        |  |
| Profit for the period (page 25) Other comprehensive (expense)/income for the             | -                                    | -   | -              | 3,250                | 3,250  | 79                               | 3,329        |  |
| period (page 26)   | -                                    | -   | (795)          | 224                  | (571)  | (3)                              | (574)        |  |
| Other changes in equity<br>Cash flow hedges reclassified and reported in<br>total assets | _                                    | -   | 34             | -                    | 34   | -                                | 34           |  |
| Employee share options   |                                      |   |                |                      |  |                                  |              |  |
| - value of employee services   | -                                    | -   | -              | 32                   | 32   | -                                | 32           |  |
| - treasury shares used for share option schemes  | -                                    | 4   | -              | (4)                  | -  | -                                | -            |  |
| Dividends and other appropriations   |                                      |   |                |                      |  |                                  |              |  |
| – ordinary shares  | -                                    | -   | -              | (2,443)              | (2,443)                                      | -                                | (2,443)      |  |
| - to non-controlling interests   | -                                    | -   | -              | -                    | -  | (81)                             | (81)         |  |
| Purchase of own shares   |                                      |   |                |                      |  |                                  |              |  |
| - held in employee share ownership trusts  | -                                    | -   | -              | (82)                 | (82)   | -                                | (82)         |  |
| Other movements  | -                                    | -   | -              | 4                    | 4  | -                                | 4            |  |
| Balance at 30 June 2021  | 614                                  | 26,622  | (7,361)        | 43,022               | 62,897                                       | 277                              | 63,174       |  |

| At 30 June 2020   | Attributable to owners of the parent |   |                |                      |  |                                  |              |  |
|---|--------------------------------------|---|----------------|----------------------|--|----------------------------------|--------------|--|
|   | Share<br>capital                     | Share premium, capital redemption and merger reserves | Other reserves | Retained<br>earnings | Total attributable<br>to owners<br>of parent | Non-<br>controlling<br>interests | Total equity |  |
|   | £m                                   | £m  | £m             | £m                   | £m   | £m                               | £m           |  |
| Balance at 1 January 2020   | 614                                  | 26,609  | (3,555)        | 40,234               | 63,902                                       | 258                              | 64,160       |  |
| Total comprehensive income for the period comprising: (page 26)                     | -                                    | -   | 4,071          | 3,525                | 7,596  | 94                               | 7,690        |  |
| Profit for the period (page 25) Other comprehensive income for the period (page 26) | -                                    | -   | -              | 3,457                | 3,457  | 81                               | 3,538        |  |
|   | _                                    | -   | 4,071          | 68                   | 4,139  | 13                               | 4,152        |  |
| Other changes in equity   |                                      |   |                |                      |  |                                  |              |  |
| Cash flow hedges reclassified and reported in total assets                          | -                                    | -   | (26)           | -                    | (26)   | -                                | (26)         |  |
| Employee share options  |                                      |   |                |                      |  |                                  |              |  |
| - value of employee services  | -                                    | -   | -              | 34                   | 34   | -                                | 34           |  |
| – proceeds from new shares issued   | -                                    | 1   | -              | -                    | 1  | -                                | 1            |  |
| – treasury shares used for share option schemes                                     | -                                    | 7   | -              | (7)                  | -  | -                                | -            |  |
| Dividends and other appropriations  |                                      |   |                |                      |  |                                  |              |  |
| – ordinary shares   | -                                    | -   | -              | (2,347)              | (2,347)                                      | -                                | (2,347)      |  |
| - to non-controlling interests  | -                                    | -   | -              | -                    | -  | (80)                             | (80)         |  |
| Purchase of own shares  |                                      |   |                |                      |  |                                  |              |  |
| – held in employee share ownership trusts   | -                                    | -   | -              | (17)                 | (17)   | -                                | (17)         |  |
| Other movements non-controlling interests   | -                                    | -   | -              | -                    | -  | 10                               | 10           |  |
| Balance at 30 June 2020   | 614                                  | 26,617  | 490            | 41,422               | 69,143                                       | 282                              | 69,425       |  |

 $The accompanying \ notes \ on \ pages \ 32 \ to \ 49 \ form \ an \ integral \ part \ of \ this \ condensed \ consolidated \ financial \ information.$ 

# **GROUP STATEMENT OF CHANGES IN EQUITY – cont...**

| At 31 December 2020   | Attri         | butable to ov   |                |                      |  |                                  |              |
|---|---------------|---|----------------|----------------------|--|----------------------------------|--------------|
|   | Share capital | Share premium, capital redemption and merger reserves | Other reserves | Retained<br>earnings | Total attributable<br>to owners<br>of parent | Non-<br>controlling<br>interests | Total equity |
|   | £m            | £m  | £m             | £m                   | £m   | £m                               | £m           |
| Balance at 1 January 2020   | 614           | 26,609  | (3,555)        | 40,234               | 63,902                                       | 258                              | 64,160       |
| Total comprehensive (expense)/income for the year comprising: (page 26)       | -             | -   | (3,012)        | 6,486                | 3,474  | 148                              | 3,622        |
| Profit for the year (page 25)<br>Other comprehensive (expense)/income for the | -             | -   | -              | 6,400                | 6,400  | 164                              | 6,564        |
| year (page 26)  | -             | -   | (3,012)        | 86                   | (2,926)                                      | (16)                             | (2,942)      |
| Other changes in equity   |               |   |                |                      |  |                                  |              |
| Cash flow hedges reclassified and reported in total assets                    | -             | -   | (33)           | -                    | (33)   | -                                | (33)         |
| Employee share options  |               |   |                |                      |  |                                  |              |
| - value of employee services  | -             | -   | -              | 88                   | 88   | -                                | 88           |
| – proceeds from new shares issued   | -             | 2   | -              | -                    | 2  | -                                | 2            |
| – treasury shares used for share option schemes                               | -             | 7   | -              | (7)                  | -  | -                                | -            |
| Dividends and other appropriations  |               |   |                |                      |  |                                  |              |
| – ordinary shares   | -             | -   | -              | (4,747)              | (4,747)                                      | -                                | (4,747)      |
| - to non-controlling interests  | -             | -   | -              | -                    | -  | (141)                            | (141)        |
| Purchase of own shares  |               |   |                |                      |  |                                  |              |
| – held in employee share ownership trusts                                     | -             | -   | -              | (17)                 | (17)   | -                                | (17)         |
| Other movements non-controlling interests                                     | -             | -   | -              | -                    | -  | 17                               | 17           |
| Other movements   | -             | -   | -              | 4                    | 4  | -                                | 4            |
| Balance at 31 December 2020   | 614           | 26,618  | (6,600)        | 42,041               | 62,673                                       | 282                              | 62,955       |

The accompanying notes on pages 32 to 49 form an integral part of this condensed consolidated financial information.

### **GROUP BALANCE SHEET**

|  |         | At 30 June |         |
|--|---------|------------|---------|
|  | 2021    | 2020       | 2020    |
|  | £m      | £m         | £m      |
| Assets                                       |         |            |         |
| Non-current assets                           |         |            |         |
| Intangible assets                            | 113,827 | 126,764    | 115,343 |
| Property, plant and equipment                | 4,866   | 5,444      | 5,060   |
| Investments in associates and joint ventures | 1,939   | 2,133      | 1,796   |
| Retirement benefit assets                    | 803     | 577        | 714     |
| Deferred tax assets                          | 622     | 419        | 534     |
| Trade and other receivables                  | 255     | 240        | 242     |
| Investments held at fair value               | 37      | 28         | 22      |
| Derivative financial instruments             | 295     | 504        | 367     |
| Total non-current assets                     | 122,644 | 136,109    | 124,078 |
| Current assets                               |         |            |         |
| Inventories                                  | 6,408   | 6,796      | 5,998   |
| Income tax receivable                        | 146     | 108        | 79      |
| Trade and other receivables                  | 3,934   | 4,484      | 3,721   |
| Investments held at fair value               | 336     | 183        | 242     |
| Derivative financial instruments             | 419     | 210        | 430     |
| Cash and cash equivalents                    | 3,014   | 4,784      | 3,139   |
|  | 14,257  | 16,565     | 13,609  |
| Assets classified as held-for-sale           | 94      | 3          | 3       |
| Total current assets                         | 14,351  | 16,568     | 13,612  |
| Total assets                                 | 136,995 | 152,677    | 137,690 |

The accompanying notes on pages 32 to 49 form an integral part of this condensed consolidated financial information.

## **GROUP BALANCE SHEET - cont...**

|   | At 30 June |         | At 31 December |  |
|---|------------|---------|----------------|--|
|   | 2021       | 2020    | 2020           |  |
|   | £m         | £m      | £m             |  |
| Equity – capital and reserves                                 |            |         |                |  |
| Share capital   | 614        | 614     | 614            |  |
| Share premium, capital redemption and merger reserves         | 26,622     | 26,617  | 26,618         |  |
| Other reserves  | (7,361)    | 490     | (6,600)        |  |
| Retained earnings   | 43,022     | 41,422  | 42,041         |  |
| Owners of the parent  | 62,897     | 69,143  | 62,673         |  |
| Non-controlling interests                                     | 277        | 282     | 282            |  |
| Total equity  | 63,174     | 69,425  | 62,955         |  |
| Liabilities   |            |         |                |  |
| Non-current liabilities                                       |            |         |                |  |
| Borrowings  | 36,361     | 43,395  | 39,927         |  |
| Retirement benefit liabilities                                | 1,279      | 1,574   | 1,524          |  |
| Deferred tax liabilities                                      | 16,245     | 18,104  | 16,314         |  |
| Other provisions for liabilities                              | 411        | 399     | 387            |  |
| Trade and other payables                                      | 1,058      | 1,034   | 1,064          |  |
| Derivative financial instruments                              | 49         | 212     | 41             |  |
| Total non-current liabilities                                 | 55,403     | 64,718  | 59,257         |  |
| Current liabilities   |            |         |                |  |
| Borrowings  | 8,649      | 7,066   | 4,041          |  |
| Income tax payable  | 776        | 1,295   | 868            |  |
| Other provisions for liabilities                              | 372        | 365     | 598            |  |
| Trade and other payables                                      | 8,504      | 9,535   | 9,693          |  |
| Derivative financial instruments                              | 97         | 273     | 278            |  |
| Liabilities associated with asset classified as held-for-sale | 20         | -       | -              |  |
| Total current liabilities                                     | 18,418     | 18,534  | 15,478         |  |
| Total equity and liabilities                                  | 136,995    | 152,677 | 137,690        |  |

The accompanying notes on pages 32 to 49 form an integral part of this condensed consolidated financial information.

### **GROUP CASH FLOW STATEMENT**

|  | Six months ended<br>30 June |         | Year ended<br>31 December |  |
|--|-----------------------------|---------|---------------------------|--|
|  | 2021                        | 2020    | 2020                      |  |
|  | £m                          | £m      | £m                        |  |
| Cash flows from operating activities   |                             |         |                           |  |
| Cash generated from operating activities (page 37)                                   | 3,317                       | 4,034   | 11,567                    |  |
| Dividends received from associates   | 164                         | 2       | 351                       |  |
| Tax paid   | (1,227)                     | (552)   | (2,132)                   |  |
| Net cash generated from operating activities   | 2,254                       | 3,484   | 9,786                     |  |
| Cash flows from investing activities   |                             |         |                           |  |
| Interest received  | 14                          | 27      | 48                        |  |
| Purchases of property, plant and equipment   | (129)                       | (106)   | (511)                     |  |
| Proceeds on disposal of property, plant and equipment                                | 19                          | 13      | 44                        |  |
| Purchases of intangibles   | (46)                        | (62)    | (244)                     |  |
| Purchases of investments   | (220)                       | (183)   | (343)                     |  |
| Proceeds on disposals of investments   | 101                         | 97      | 184                       |  |
| Investment in associates and acquisitions of other subsidiaries net of cash acquired | (130)                       | (3)     | 39                        |  |
| Net cash used in investing activities  | (391)                       | (217)   | (783)                     |  |
| Cash flows from financing activities   |                             |         |                           |  |
| Interest paid  | (753)                       | (841)   | (1,737)                   |  |
| Interest element of lease liabilities  | (11)                        | (14)    | (26)                      |  |
| Capital element of lease liabilities   | (72)                        | (76)    | (164)                     |  |
| Proceeds from increases in and new borrowings  | 2,986                       | 5,204   | 9,826                     |  |
| Outflows relating to derivative financial instruments                                | (171)                       | (2)     | (283)                     |  |
| Purchases of own shares held in employee share ownership trusts                      | (82)                        | (17)    | (18)                      |  |
| Reductions in and repayments of borrowings   | (1,153)                     | (2,811) | (10,633)                  |  |
| Dividends paid to owners of the parent   | (2,443)                     | (2,346) | (4,745)                   |  |
| Capital injection from non-controlling interests                                     | -                           | 10      | 17                        |  |
| Dividends paid to non-controlling interests  | (81)                        | (70)    | (136)                     |  |
| Other  | -                           | 1       | 2                         |  |
| Net cash used in financing activities  | (1,780)                     | (962)   | (7,897)                   |  |
| Net cash flows from operating, investing and financing activities                    | 83                          | 2,305   | 1,106                     |  |
| Transferred to held-for-sale   | (100)                       | -       | -                         |  |
| Differences on exchange  | (173)                       | 9       | (253)                     |  |
| (Decrease)/increase in net cash and cash equivalents in the period                   | (190)                       | 2,314   | 853                       |  |
| Net cash and cash equivalents at 1 January   | 2,888                       | 2,035   | 2,035                     |  |
| Net cash and cash equivalents at period end  | 2,698                       | 4,349   | 2,888                     |  |
| Cash and cash equivalents per balance sheet  | 3,014                       | 4,784   | 3,139                     |  |
| Overdrafts and accrued interest  | (316)                       | (435)   | (251)                     |  |
| Net cash and cash equivalents at period end  | 2,698                       | 4,349   | 2,888                     |  |
|  |                             |         |                           |  |

The accompanying notes on pages 32 to 49 form an integral part of this condensed consolidated financial information. The net cash outflows relating to the adjusting items within profit from operations on pages 33 and 34, included in the above, are £322 million (30 June 2020: £411 million; 31 December 2020: £732 million).

#### **ACCOUNTING POLICIES AND BASIS OF PREPARATION**

The condensed consolidated financial information comprises the unaudited interim financial information for the six months to 30 June 2021. This condensed consolidated financial information has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted for use in the UK and as issued by the International Accounting Standards Board (IASB), and the Disclosure Guidance and Transparency Rules issued by the Financial Conduct Authority. The interim condensed consolidated financial information is unaudited but has been reviewed by the auditor and its review report is set out on page 24.

This condensed consolidated financial information does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006 and should be read in conjunction with the Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020, including the audited financial statements for the year ended 31 December 2020, which were prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), and international accounting standards in conformity with the requirements of the Companies Act 2006, and in accordance with International Financial Reporting Standards adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the European Union (EU) ('IFRS as adopted by the EU'). The Group's Annual Report and Form 20-F for the year ending 31 December 2021 will be prepared in accordance with IFRS as issued by the IASB and UK-adopted international accounting standards.

IFRS as adopted by the UK, IFRS as adopted by the EU and international accounting standards in conformity with the requirements of the Companies Act 2006 differ in certain respects from IFRS as issued by the IASB. The differences have no impact on the Group's consolidated financial statements for the periods presented. The Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020 represent the statutory accounts for that year and have been filed with the Registrar of Companies. The auditor's report on those statements was unmodified and did not contain an emphasis of matter paragraph and did not contain any statement under Section 498 (2) or (3) of the Companies Act 2006.

These condensed consolidated financial statements have been prepared under the historical cost convention, except in respect of certain financial instruments. They are prepared on a basis consistent with the IFRS accounting policies as set out in the Group's Annual Report and Form 20-F for the year ended 31 December 2020. In addition, the investments in associates and joint ventures shown in the Group balance sheet include biological assets held by Organigram Holdings Inc., which was acquired by the Group on 11 March 2021. In accordance with IAS 41 Agriculture, the Group measures biological assets at fair value less costs to sell up to the point of harvest, at which point this becomes the basis for the cost of finished goods inventories after harvest with subsequent expenditures incurred on these being capitalised, where applicable, in accordance with IAS 2 Inventories. Unrealised fair value gains and losses arising during the growth of biological assets are recognised immediately in the income statement.

The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities at the date of these condensed consolidated financial statements. Such estimates and assumptions are based on historical experience and various other factors that are believed to be reasonable in the circumstances and constitute management's best judgement at the date of the condensed consolidated financial statements. The key estimates and assumptions were the same as those that applied to the consolidated financial information for the year ended 31 December 2020, apart from updating the assumptions used to determine the carrying value of liabilities for retirement benefit schemes. As described on page 35, the Group has reviewed the carrying value of the significant investments of goodwill and intangibles (due in part to the announcements in the US regarding potential menthol regulation, the impact of COVID-19 across the Group and ongoing challenging trading conditions in certain markets) and determined that no impairment is required. In the future, actual experience may deviate from these estimates and assumptions, which could affect these condensed consolidated financial statements as the original estimates and assumptions are modified, as appropriate, in the period in which the circumstances change.

As discussed on page 21, after reviewing the Group's forecast financial performance and financing arrangements, the Directors consider that the Group has adequate resources to continue operating for at least 12 months from the date of approval of this condensed consolidated financial information and that it is therefore appropriate to continue to adopt the going concern basis in preparing this Half-Year Report.

#### **ADJUSTING ITEMS**

Adjusting items are significant items of income or expense in profit from operations, net finance costs, taxation and the Group's share of the post-tax results of associates and joint ventures which individually or, if of a similar type, in aggregate, are relevant to an understanding of the Group's underlying financial performance because of their size, nature or incidence. In identifying and quantifying adjusting items, the Group consistently applies a policy that defines criteria that are required to be met for an item to be classified as adjusting. These items are separately disclosed in the segmental analyses or in the notes to the accounts as appropriate.

The Group believes that these items are useful to users of the Group financial statements in helping them to understand the underlying business performance and are used to derive the Group's principal non-GAAP measures of adjusted profit from operations, adjusted diluted earnings per share, and operating cash flow conversion ratio, all of which are before the impact of adjusting items and which are reconciled from profit from operations, diluted earnings per share, cash conversion ratio and net cash generated from operating activities.

#### ANALYSIS OF REVENUE AND PROFIT FROM OPERATIONS BY SEGMENT

| Six months ended          |                |               |          |                | 2021                           |                |                           | 2020     |
|---------------------------|----------------|---------------|----------|----------------|--------------------------------|----------------|---------------------------|----------|
| 30 June Revenue           | Reported<br>£m |               |          | Exchange<br>£m | At CC <sup>2</sup><br>£m       | Reported<br>£m |                           |          |
| US                        | 5,563          |               |          | 567            | 6,130                          | 5,619          |                           |          |
| АРМЕ                      | 2,055          |               |          | 205            | 2,260                          | 2,137          |                           |          |
| AMSSA                     | 1,796          |               |          | 153            | 1,949                          | 1,749          |                           |          |
| ENA                       | 2,761          |               |          | 168            | 2,929                          | 2,766          |                           |          |
| Total Region              | 12,175         |               |          | 1,093          | 13,268                         | 12,271         |                           |          |
| Six months ended          |                |               |          |                | 2021                           |                |                           | 2020     |
| 30 June                   | Reported       | Adj<br>Items¹ | Adjusted | Exchange       | Adjusted<br>at CC <sup>2</sup> | Reported       | Adj<br>Items <sup>1</sup> | Adjusted |
| Profit from<br>Operations | £m             | £m            | £m       | £m             | £m                             | £m             | £m                        | £m       |
| US                        | 2,570          | 196           | 2,766    | 306            | 3,072                          | 2,619          | 182                       | 2,801    |
| АРМЕ                      | 769            | 99            | 868      | 47             | 915                            | 865            | 25                        | 890      |
| AMSSA                     | 694            | 15            | 709      | 42             | 751                            | 669            | 52                        | 721      |
| ENA                       | 874            | 18            | 892      | 29             | 921                            | 944            | 12                        | 956      |
| Total Region              | 4,907          | 328           | 5,235    | 424            | 5,659                          | 5,097          | 271                       | 5,368    |

Notes to the analysis of revenue and profit from operations above:
(1) Adjusting items represent certain items which the Group considers distinctive based upon their size, nature or incidence.

CC: constant currency - measures are calculated based on a re-translation, at the prior year's exchange rates, of the current year's results of the Group and, where applicable, its

#### ADJUSTING ITEMS INCLUDED IN PROFIT FROM OPERATIONS

Adjusting items are significant items in the profit from operations that individually or, if of a similar type, in aggregate, are relevant to an understanding of the Group's underlying financial performance.

In summary, in the six months ended 30 June 2021, the Group incurred £328 million (30 June 2020: £271 million; 31 December 2020: £1,403 million) of adjusting items within profit from operations:

|  | Six months ended 30 June |      | Year ended 31 December |
|--|--------------------------|------|------------------------|
|  | 2021                     | 2020 | 2020                   |
|  | £m                       | £m   | £m                     |
| Restructuring and integration costs  | 83                       | 69   | 408                    |
| Amortisation and impairment of trademarks and similar intangibles              | 151                      | 171  | 339                    |
| Impairment of goodwill   | -                        | 11   | 209                    |
| Impairment and associated costs in respect of assets/liabilities held-for-sale | 71                       | -    | -                      |
| Credit in respect of an excise dispute in Russia                               | -                        | (15) | (40)                   |
| Charge in respect of MSA liabilities related to brands sold to a third party   | -                        | -    | 400                    |
| Other adjusting items (largely other litigation including<br>Engle)            | 23                       | 35   | 87                     |
| Total adjusting items included in profit from operations                       | 328                      | 271  | 1,403                  |

#### Adjusting items included in profit from operations cont...

#### (a) Restructuring and integration costs

Restructuring costs reflect the costs incurred as a result of initiatives to improve the effectiveness and the efficiency of the Group as a globally integrated enterprise. These costs represent additional expenses incurred that are not related to the normal business and day-to-day activities. These initiatives include a review of the Group's manufacturing operations, and the costs associated with Quantum. Quantum is the review of the Group's organisational structure announced in 2019 to simplify the business and create a more efficient, agile and focused company. Quantum was expected to deliver at least £1 billion of annualised savings over a three-year period (to 2022). However, with further savings identified, we have upgraded our Quantum target to £1.5 billion by 2022. The charges include the cost of packages in respect of permanent headcount reductions and permanent employee benefit reductions in the Group. The costs of the Group's initiatives are included in profit from operations under the following headings:

|   | Six months er    | nded 30 June | Year ended 31 December |
|---|------------------|--------------|------------------------|
|   | <b>2021</b> 2020 |              | 2020                   |
|   | £m               | £m           | £m                     |
| Employee benefit costs                          | 68               | 34           | 91                     |
| Depreciation, amortisation and impairment costs | (4)              | 3            | 151                    |
| Other operating expenses                        | 19               | 32           | 166                    |
| Total   | 83               | 69           | 408                    |

The restructuring costs in the six months ended 30 June 2021 include the cost of employee packages in respect of Quantum and the ongoing costs associated with initiatives to improve the effectiveness and efficiency of the Group as a globally integrated organisation. The credit recognised in depreciation and impairment costs is due to a partial impairment reversal following the revision of factory rationalisation initiatives.

The restructuring costs in the six months ended 30 June 2020 include the costs of packages paid to employees in respect of Quantum and the ongoing costs of the previously announced factory rationalisation activities in Russia and APME. In the twelve months ended 31 December 2020, in addition to the activities described in relation to the first half of 2020, the Group incurred restructuring costs in relation to factory rationalisation activities in the Netherlands, Hungary and Indonesia.

#### (b) Amortisation and impairment of trademarks and similar intangibles

Acquisitions in previous years have resulted in the capitalisation of trademarks and similar intangibles including those which are amortised over their expected useful lives, which do not exceed 20 years. The amortisation and impairment charge of £151 million (30 June 2020: £171 million; 31 December 2020: £339 million) is included in depreciation, amortisation and impairment costs in the income statement for the six months ended 30 June 2021.

#### (c) Other

In the six months ended 30 June 2021, the Group incurred £94 million (30 June 2020: £31 million; 31 December 2020: £656 million) of other adjusting items. In the first half of 2021, the Group has recognised a charge of £71 million, largely in relation to the impairment arising from the proposed sale of the Group's operations in Iran, as described on page 20, as the assets and liabilities have been classified as held-for-sale at 30 June 2021.

The charge in 2020 included impairment of goodwill related to the Group's acquisition of Twisp in South Africa (£11 million) and in the second half of 2020 a further £198 million of impairment of goodwill was recognised largely relating to Malaysia due to the ongoing challenging operating environment, including the continued level of illicit trade. These costs were partially offset by a credit of £40 million (of which £15 million was recognised in the first half of 2020) recognised in relation to the excise dispute in Russia for which a charge of £202 million was recognised, and disclosed, in 2019.

The charge for the first six months of 2021 also includes £23 million (30 June 2020: £35 million; 31 December 2020: £87 million) predominantly related to other litigation costs including Engle progeny.

In the second half of 2020, the Group recognised charges in respect of developments in cases regarding payment obligations under the state settlement agreements with Florida, Texas, Minnesota and Mississippi for brands previously sold to a third party. A total of £400 million was recognised following a decision in the Florida court (with respect to which the Group will continue to pursue indemnification remedies in a Delaware court) and following settlement discussions with other manufacturers and the states of Texas, Minnesota and Mississippi.

#### Adjusting items included in profit from operations cont...

#### (d) Ongoing impairment review of assets

The Group reviews and monitors the performance of its non-financial assets (including goodwill) in line with the requirements of IAS 36 *Impairment of Assets*. COVID-19 continues to impact the ability of a certain number of our cash generating units to return to normal operations and, where applicable, this was considered to be a trigger to review the carrying value of those assets. Specifically, in preparing the half year report for the six months ended 30 June 2021, the Group has assessed the Group's operations in GTR due to the ongoing difficult trading conditions. In line with the assessment undertaken as part of the year-end 2020 exercise, management has applied a reasonable range of sensitivities and continues to assess that, despite a delayed return to normal operations, there was no indication of impairment. For GTR's headroom to be reduced to nil, the forecast cash flows will have to reduce by 66% in each forecast year which is not considered to be a reasonably possible scenario as we continue to believe that the duty-free business will recover.

On 29 April 2021, in the US, the FDA reconfirmed its intention to issue a proposed product standard to ban menthol as a characterising flavour in cigarettes. Management notes that the FDA announcement does not itself constitute a ban on menthol in cigarettes, and any proposed regulation of menthol in cigarettes would need to be introduced through the established US comprehensive rule-making process, the timetable and outcome for which was, and remains, uncertain. Management continues to believe that any ban, given the mechanisms and processes required to be followed in the US, is unlikely to be implemented within the next five years.

However, it is recognised that the April 2021 announcement constituted a trigger for management to undertake a more detailed impairment indicator review of goodwill related to Reynolds American and the value of the Newport and Camel trademarks.

As previously described in the Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020, the value-in-use calculations have been prepared on a five-year cash flow forecast which assumes long-term volume decline of cigarettes, offset by pricing. After this forecast, a growth rate into perpetuity has been applied. Pre-tax discount rates were used in the impairment testing, based upon the Group's weighted average cost of capital, taking into account the cost of capital and borrowings, to which specific market-related premium adjustments were made. These adjustments are derived from external sources and are based on the spread between bonds (or credit default swaps, or similar indicators) issued by the US or comparable governments and by local government, adjusted for the Group's own credit market risk. For ease of use and consistency of application, these results are periodically calibrated into bands based on internationally recognised credit ratings. The long-term growth rates and discount rates have been applied to forecast cash flows, determined by local management based upon experience, specific market and brand trends as well as pricing and cost expectations. A further adjustment of approximately 70 bps to the pre-tax discount rate was applied to the US cash generating unit to reflect ongoing risk related to potential future regulation, not otherwise reflected in the forecast cash flows. The below table illustrates the carrying values, the key assumptions used in the assessment and the variance in that assumption required before an impairment is required:

|                            | Carrying Value          | Pi      | e-tax discount rate            | Per     | petuity growth rate            |
|----------------------------|-------------------------|---------|--------------------------------|---------|--------------------------------|
|                            | At 30 June 2021<br>(£m) | Assumed | Required to reach nil headroom | Assumed | Required to reach nil headroom |
| Reynolds American Goodwill | 32,375                  | 7.6%    | 8.3%                           | 1.00%   | 0.4%                           |
|                            |                         |         | +70 bps                        |         | -60bps                         |
| Newport                    | 28,941                  | 9.1%    | 9.7%                           | 0.75%   | -1.5%                          |
|                            |                         |         | +60 bps                        |         | -225 bps                       |
| Camel                      | 12,241                  | 8.7%    | 11.8%                          | 0.85%   | -4.7%                          |
|                            |                         |         | +310 bps                       |         | -555 bps                       |

In management's view, the required movement to the discount rate and perpetuity growth rates required to trigger a material impairment were not deemed to be likely. Further, in making the assessment, management also considered a number of scenarios related to the potential impact to volume in the event of a ban. There was no scenario that management considered likely that would, at this time, result in a reduction to the value-in-use that would trigger an impairment.

Accordingly, after carefully analysing both the qualitative and quantitative considerations, management concluded that no impairment was required for either the Newport and Camel brands or the overall Reynolds American goodwill balance. As part of the standard year-end impairment process another detailed impairment review will be undertaken for all the cash generating units in line with IAS 36. This will include the entire Reynolds American portfolio (including Newport and Camel) to ensure the book values remain supportable.

#### ADJUSTING ITEMS INCLUDED IN NET FINANCE COSTS

In the six months ended 30 June 2021, the Group incurred adjusting items within net finance costs of £34 million (30 June 2020: £3 million; 31 December 2020: £153 million).

This includes, in the first half of 2021, the impairment of investments held at fair value (£24 million) as part of the proposed sale of the Group's operations in Iran (as described on page 20). Also included is interest on adjusting tax payables of £10 million (30 June 2020: £3 million; 31 December 2020: £11 million), including interest of £10 million (30 June 2020: £12 million) in relation to the FII GLO, as described on page 45. In addition, in 2020, the Group recognised a net credit of £10 million in respect of an excise dispute and in respect of withholding tax in Russia.

In the second half of 2020, the Group also incurred net finance costs of £142 million (being interest costs of £157 million partly offset by fair value gains of £15 million) in relation to the early redemption and repurchase of bonds. This was in respect of a tender offer in October 2020 of £2,653 million, followed by a "make-whole" redemption of £462 million in November 2020, in respect of certain bonds and was treated as an adjusting item.

All of the adjustments noted above have been included in the adjusted earnings per share calculation on page 40.

# ADJUSTING ITEMS INCLUDED IN SHARE OF POST-TAX RESULTS OF ASSOCIATES AND JOINT VENTURES

The Group's interest in ITC decreased from 29.42% to 29.41% as a result of ITC issuing ordinary shares under the company's Employees Share Option Scheme. The issue of these shares and change in the Group's share of ITC resulted in a gain of £8 million (30 June 2020: £19 million; 31 December 2020: £17 million), which is treated as a deemed partial disposal and included in the income statement. Also, in the six months to 30 June 2021, the Group incurred a £1 million charge in relation to the amortisation of acquired intangibles associated with the acquisition of Organigram in March 2021, as described on page 20.

In 2020, ITC recognised a charge in respect of the cost of leaf tobacco stocks destroyed in a third-party warehouse fire, the Group's share of which was £4 million.

The share of post-tax results of associates and joint ventures is after the adjusting items noted above, which are excluded from the calculation of adjusted earnings per share as set out on page 40.

#### ADJUSTING ITEMS INCLUDED IN TAXATION

The Group's tax rate is affected by the adjusting items referred to below and by the inclusion of the share of associates' and joint ventures' post-tax profit in the Group's pre-tax results.

In the six months to 30 June 2021, adjusting tax items included a net credit of £4 million (30 June 2020: £26 million; 31 December 2020: £35 million) relating to the impact of tax rate changes on deferred tax balances.

Adjusting tax items also includes £60 million for the six months to 30 June 2021 (30 June 2020: £67 million; 31 December 2020: £287 million) in respect of the taxation on adjusting items, which are described on pages 33 to 36.

As the above items are not reflective of the ongoing business, they have been recognised as adjusting items within taxation. Refer to page 45 for the FII GLO update. All of the adjustments noted above have been included in the adjusted earnings per share calculation on page 40.

#### **CASH FLOW**

# Net cash generated from operating activities

Net cash generated from operating activities in the IFRS cash flows on page 31 includes the following items:

|  | Six n   | nonths ended<br>30 June | Year ended<br>31 December |
|--|---------|-------------------------|---------------------------|
|  | 2021    | 2020                    | 2020                      |
|  | £m      | £m                      | £m                        |
|  |         |                         |                           |
| Profit from operations                             | 4,907   | 5,097                   | 9,962                     |
| Depreciation, amortisation and impairment          | 473     | 533                     | 1,450                     |
| Increase in inventories                            | (600)   | (574)                   | (144)                     |
| (Increase)/decrease in trade and other receivables | (325)   | (368)                   | 300                       |
| (Decrease)/increase in provision for MSA           | (670)   | (386)                   | 369                       |
| Decrease in trade and other payables               | (314)   | (4)                     | (320)                     |
| Decrease in net retirement benefit liabilities     | (41)    | (26)                    | (96)                      |
| Decrease in other provisions                       | (193)   | (245)                   | -                         |
| Other non-cash items                               | 80      | 7                       | 46                        |
| Cash generated from operating activities           | 3,317   | 4,034                   | 11,567                    |
| Dividends received from associates                 | 164     | 2                       | 351                       |
| Tax paid   | (1,227) | (552)                   | (2,132)                   |
| Net cash generated from operating activities       | 2,254   | 3,484                   | 9,786                     |
|  |         |                         |                           |

Net cash generated from operating activities declined by 35.3% to £2,254 million (30 June 2020: £3,484 million), partly due to

- the deferral of excise and corporate tax payments from the first half to the second half of 2020 in the US (£1,233 million):
- MSA-related outflows (£397 million) due to timing and one-off litigation settlements made in the first half of 2021; and
- an increase in tax paid in Canada (due to the timing of payments).

These were partly offset by an increase in dividends received from associates to £164 million (30 June 2020: £2 million) following the payment of an interim dividend by the Group's Indian associate, ITC. Net cash generated from operating activities was also impacted by the translational foreign exchange headwind of around 8% due to the relative strength of sterling versus the Group's operating currencies (particularly US dollar).

Expenditure on research and development was approximately £142 million in the six months ended 30 June 2021 (30 June 2020: £137 million) with a focus on products that could potentially reduce the risk associated with smoking conventional cigarettes.

## Net cash used in investing activities

Net cash used in investing activities in the six months ended 30 June 2021 was higher than the same period in 2020 at £391 million (30 June 2020: £217 million) largely due to the investment in OGI (as described on page 20) and a net outflow from short-term investment products, including treasury bills. Purchases of property, plant, equipment and intangibles totalled £175 million in the six months ended 30 June 2021 (30 June 2020: £168 million), which includes the investment in the Group's global operational infrastructure (including, but not limited to, the manufacturing network, trade marketing and IT systems).

# Net cash used in financing activities

Net cash used in financing activities was an outflow of £1,780 million in the first six months of 2021 (30 June 2020: £962 million outflow). The 2021 outflow was mainly due to the payment of the dividend £2,443 million (30 June 2020: £2,346 million), an increase on prior year due to the higher dividend per share. The higher cash outflow from financing activities in the period, compared to the same period in 2020, was largely due to the prior period including the net inflow from new borrowings in the period in response to the COVID-19 pandemic. In the six months ended 30 June 2021 the net inflow from borrowings was £1,833 million compared to £2,393 million in the same period of 2020.

#### LIQUIDITY

The Treasury function is responsible for raising finance for the Group, managing the Group's cash resources and the financial risks arising from underlying operations. All these activities are carried out under defined policies, procedures and limits, reviewed and approved by the Board, delegating oversight to the Finance and Transformation Director and Treasury function. The Group has targeted an average centrally managed bond maturity of at least five years with no more than 20% of centrally managed debt maturing in a single rolling 12-month period. As at 30 June 2021, the average centrally managed debt maturity of bonds was 9.7 years (30 June 2020: 8.9 years; 31 December 2020: 9.9 years) and the highest proportion of centrally managed debt maturing in a single rolling 12-month period was 16.8% (30 June 2020: 17.4%: 31 December 2020: 16.4%).

The Group continues to maintain investment-grade credit ratings, with ratings from Moody's/S&P at Baa2 (stable outlook)/BBB+ (stable outlook), respectively, with a medium-term target of Baa1/BBB+. The strength of the ratings has underpinned debt issuance and the Group is confident of its ability to continue to successfully access the debt capital markets. A credit rating is not a recommendation to buy, sell or hold securities. A credit rating may be subject to withdrawal or revision at any time. Each rating should be evaluated separately of any other rating. In order to manage its interest rate risk, the Group maintains both floating rate and fixed rate debt. The Group sets targets (within overall guidelines) for the desired ratio of floating to fixed rate debt on a net basis (at least 50% fixed on a net basis in the short to medium term). At 30 June 2021, the relevant ratios of floating\* to fixed rate borrowings were 15:85 (30 June 2020: 12:88, 31 December 2020: 7:93) on a net basis.

#### **Available facilities**

It is Group policy that short-term sources of funds (including drawings under both the US\$4 billion US commercial paper programme and £3 billion euro commercial paper programme) are backed by undrawn committed lines of credit and cash. As at 30 June 2021, there was £1,653 million of commercial paper outstanding (30 June 2020: £224 million drawn; 31 December 2020: undrawn).

In February 2021, the Group exercised the one-year extension options on both tranches of the £6.0 billion revolving credit facility. The £3.0 billion 364-day tranche was reduced to £2.85 billion and extended to March 2022. The £3.0 billion five-year tranche remains available until March 2025 after which it will reduce to £2.85 billion until March 2026. This facility was undrawn at 30 June 2021.

In March 2021, the Group extended short term bilateral facilities totalling £2.5 billion for one year. As at 30 June 2021, £900 million was drawn on a short-term basis.

#### Issuance and repayment of bonds in the period

- In February 2021, the Group repaid a €650 million bond at maturity; and
- In June 2021, the Group repaid £500 million of the £1,929 million term loan that has a maturity date in January 2022.

Subsequent to the balance sheet date, in July 2021, the Group repaid a £500 million bond at maturity.

\* In relation to the Group's floating rate borrowings and hedge instruments, there is exposure to uncertainty associated with the LIBOR Reform. The Group believes that its contracts with interest rates based on LIBOR benchmarks adequately provide for alternate rates and calculations of interest in the event that the relevant LIBOR rate is unavailable. The Group believes that hedge relationships on derivatives will continue with the resulting ineffectiveness likely to be immaterial. Furthermore, the Group signed up to the ISDA 2020 IBOR Fallback Protocol as published by the International Swaps and Derivative Association Inc., ensuring that appropriate fallback rates can apply in relation to derivatives that are impacted by LIBOR cessation.

#### FAIR VALUE MEASUREMENTS AND VALUATION PROCESSES

The Group held certain financial instruments at fair value at 30 June 2021. The definitions and valuation techniques employed for these as at 30 June 2021 are consistent with those used at 31 December 2020 and disclosed in Note 22 on pages 212 to 217 of the Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020:

- Level 1 financial instruments are traded in an active market and fair value is based on quoted prices at the period end.
- Level 2 financial instruments are not traded in an active market, but the fair values are based on quoted market prices, broker/dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The Group's level 2 financial instruments include OTC derivatives.
- The fair values of level 3 financial instruments have been determined using a valuation technique where at least one input (which could have a significant effect on the instrument's valuation) is not based on observable market data. The Group's level 3 financial instruments primarily consist of an equity investment in an unquoted entity, interest free loans and other treasury products which are valued using the discounted cash flows of estimated future cash flows.

While the carrying values of assets and liabilities at fair value have changed since 31 December 2020, the Group does not consider the movements in value to be significant, and the categorisation of these assets and liabilities in accordance with the disclosure requirements of IFRS 7 has not materially changed. The values of level 1 assets and level 3 assets are not material to the Group and were £299 million and £74 million, respectively, at 30 June 2021 (30 June 2020: £56 million and £155 million respectively and 31 December 2020: £171 million and £93 million, respectively).

Level 2 assets and liabilities are shown below.

|                                      |      | At 30 June | At 31 December |
|--------------------------------------|------|------------|----------------|
|                                      | 2021 | 2020       | 2020           |
|                                      | £m   | £m         | £m             |
| Assets at fair value                 |      |            |                |
| Derivatives relating to              |      |            |                |
| – interest rate swaps                | 50   | 65         | 65             |
| – cross-currency swaps               | 326  | 466        | 444            |
| – forward foreign currency contracts | 338  | 183        | 288            |
| Assets at fair value                 | 714  | 714        | 797            |
| Liabilities at fair value            |      |            |                |
| Derivatives relating to              |      |            |                |
| – interest rate swaps                | 34   | 52         | 53             |
| - cross-currency swaps               | 9    | 156        | -              |
| – forward foreign currency contracts | 103  | 277        | 266            |
| Liabilities at fair value            | 146  | 485        | 319            |
|                                      |      |            |                |

Borrowings are carried at amortised cost. The fair value of borrowings is estimated to be £46,607 million (30 June 2020: £52,544 million; 31 December 2020: £47,029 million). The value of other assets and liabilities held at amortised cost are not materially different from their fair values.

# **RELATED PARTY DISCLOSURES**

The Group's related party transactions and relationships for 2020 were disclosed on pages 222 and 223 of the Group's Annual Report and Form 20-F for the year ended 31 December 2020. Apart from the investment in and collaboration with Organigram, explained on page 20, there were no material changes in related parties or related party transactions in the six months ended 30 June 2021.

#### **EARNINGS PER SHARE**

Basic earnings per share were down 6.0% at 142.1p (30 June 2020: 151.2p) as the growth in operational performance was more than offset by a higher effective tax rate, lower share of associates, charges in respect of the proposed sale of the Group's operations in Iran and the translational foreign exchange headwind due to the relative strength of sterling particularly against the US dollar.

Before adjusting items and including the dilutive effect of employee share schemes, adjusted diluted earnings per share fell 2.3% to 154.2p (30 June 2020: 157.8p). Excluding the impact of translational foreign exchange, adjusted diluted earnings per share were 6.1% higher at 167.5p, at constant rates of exchange. For a full reconciliation of diluted earnings per share to adjusted diluted earnings per share, at constant rates, see page 57.

|                             | Six m | onths ended | Year ended  |  |
|-----------------------------|-------|-------------|-------------|--|
|                             |       | 30 June     | 31 December |  |
|                             | 2021  | 2020        | 2020        |  |
|                             | pence | pence       | pence       |  |
| Earnings per share          |       |             |             |  |
| - basic                     | 142.1 | 151.2       | 280.0       |  |
| - diluted                   | 141.6 | 150.7       | 278.9       |  |
| Adjusted earnings per share |       |             |             |  |
| - basic                     | 154.8 | 158.3       | 333.0       |  |
| - diluted                   | 154.2 | 157.8       | 331.7       |  |
| Headline earnings per share |       |             |             |  |
| - basic                     | 144.7 | 151.9       | 295.5       |  |
| - diluted                   | 144.2 | 151.4       | 294.4       |  |

Basic earnings per share are based on the profit for the year attributable to ordinary shareholders and the weighted average number of ordinary shares in issue during the period (excluding treasury shares). For the calculation of the diluted earnings per share, the weighted average number of shares reflects the potential dilutive effect of employee share schemes.

**Adjusted diluted earnings per share** are calculated by taking the following adjustments into account (see pages 33 to 36):

|   | Six months ended<br>30 June |       | Year ended<br>31 December |
|---|-----------------------------|-------|---------------------------|
|   | 2021                        | 2020  | 2020                      |
|   | pence                       | pence | pence                     |
| Diluted earnings per share  | 141.6                       | 150.7 | 278.9                     |
| Effect of restructuring and integration costs   | 3.1                         | 2.1   | 14.9                      |
| Effect of amortisation and impairment of goodwill, trademarks and similar intangibles | 4.8                         | 6.4   | 20.5                      |
| Effect of the Russian excise dispute  | -                           | -     | (1.1)                     |
| Effect of retrospective guidance on overseas withholding tax                          | -                           | -     | (1.8)                     |
| Effect of other adjusting items   | 3.5                         | (0.7) | 16.7                      |
| Effect of associates' adjusting items   | (0.3)                       | (0.7) | (0.6)                     |
| Effect of other adjusting items in net finance costs                                  | 1.4                         | -     | 5.1                       |
| Effect of adjusting items in respect of deferred taxation                             | 0.1                         | -     | (0.9)                     |
| Adjusted diluted earnings per share   | 154.2                       | 157.8 | 331.7                     |

# **Earnings per share cont...**

The presentation of headline earnings per share, as an alternative measure of earnings per share, is mandated under the JSE Listing Requirements. It is calculated in accordance with Circular 1/2021 'Headline Earnings' as issued by the South African Institute of Chartered Accountants.

Diluted headline earnings per share are calculated by taking the following adjustments into account:

|   | Six months ended<br>30 June |       | Year ended<br>31 December |
|---|-----------------------------|-------|---------------------------|
|   | 2021                        | 2020  | 2020                      |
|   | pence                       | pence | pence                     |
| Diluted earnings per share  | 141.6                       | 150.7 | 278.9                     |
| Effect of impairment of intangibles and property, plant and equipment and held-for-sale assets (net of tax)   | 3.2                         | 1.7   | 17.0                      |
| Effect of losses on disposal of property, plant and equipment, held-for-sale assets, partial/full implementation of IFRS 16 <i>Leases</i> and sale and leaseback (net of tax) | (0.3)                       | (0.2) | (0.8)                     |
| Issue of shares and changes in shareholding of associates   | (0.3)                       | (0.8) | (0.7)                     |
| Diluted headline earnings per share   | 144.2                       | 151.4 | 294.4                     |

The following is a reconciliation of earnings to headline earnings, in accordance with the JSE Listing Requirements:

|   | Six months ended<br>30 June |       | Year ended<br>31 December |
|---|-----------------------------|-------|---------------------------|
|   | 2021                        | 2020  | 2020                      |
|   | £m                          | £m    | £m                        |
| Earnings  | 3,250                       | 3,457 | 6,400                     |
| Effect of impairment of intangibles and property, plant and equipment and held-for-sale assets (net of tax)   | 75                          | 41    | 391                       |
| Effect of losses on disposal of property, plant and equipment, held-for-sale assets, partial/full implementation of IFRS 16 <i>Leases</i> and sale and leaseback (net of tax) | (7)                         | (6)   | (18)                      |
| Issue of shares and changes in shareholding of associates   | (8)                         | (19)  | (17)                      |
| Headline earnings   | 3,310                       | 3,473 | 6,756                     |

The earnings per share are based on:

|                             |          |        | Six months end | ed 30 June | Year ended 31 | December |
|-----------------------------|----------|--------|----------------|------------|---------------|----------|
|                             |          | 2021   |                | 2020       |               | 2020     |
|                             | Earnings | Shares | Earnings       | Shares     | Earnings      | Shares   |
|                             | £m       | m      | £m             | m          | £m            | m        |
| Earnings per share          |          |        |                |            |               |          |
| - basic                     | 3,250    | 2,287  | 3,457          | 2,286      | 6,400         | 2,286    |
| - diluted                   | 3,250    | 2,296  | 3,457          | 2,294      | 6,400         | 2,295    |
| Adjusted earnings per share |          |        |                |            |               |          |
| - basic                     | 3,540    | 2,287  | 3,619          | 2,286      | 7,613         | 2,286    |
| - diluted                   | 3,540    | 2,296  | 3,619          | 2,294      | 7,613         | 2,295    |
| Headline earnings per share |          |        |                |            |               |          |
| - basic                     | 3,310    | 2,287  | 3,473          | 2,286      | 6,756         | 2,286    |
| - diluted                   | 3,310    | 2,296  | 3,473          | 2,294      | 6,756         | 2,295    |

#### CONTINGENT LIABILITIES AND FINANCIAL COMMITMENTS

The Group has contingent liabilities in respect of litigation, taxes and guarantees in various countries. These are described below and further described in Note 27 to the Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020, pages 224 to 248. The Group is subject to contingencies pursuant to requirements that it complies with relevant laws, regulations and standards. Failure to comply could result in restrictions in operations, damages, fines, increased tax, increased cost of compliance, interest charges, reputational damage or other sanctions. These matters are inherently difficult to quantify.

In cases where the Group has an obligation as a result of a past event existing at the balance sheet date, it is probable that an outflow of economic resources will be required to settle the obligation and the amount of the obligation can be reliably estimated, a provision will be recognised based on best estimates and management judgement. There are, however, contingent liabilities in respect of litigation, taxes in some countries and guarantees for which no provisions have been made. While the amounts that may be payable or receivable could be material to the results or cash flows of the Group in the period in which they are recognised, the Board does not expect these amounts to have a material effect on the Group's financial condition.

#### **Taxes**

The Group has exposures in respect of the payment or recovery of a number of taxes. The Group is and has been subject to a number of tax audits covering, among others, excise tax, value-added taxes, sales taxes, corporate taxes, overseas withholding taxes and payroll taxes. The estimated costs of known tax obligations have been provided in these accounts in accordance with the Group's accounting policies. In some countries, tax law requires that full or part payment of disputed tax assessments be made pending resolution of the dispute. To the extent that such payments exceed the estimated obligation, they would not be recognised as an expense.

There are disputes that are in or may proceed to litigation in a number of countries including Brazil and the Netherlands.

In Turkey, British American Tobacco Tutun Mamulleri Sanayi ve Ticaret Anonim Sirketi (BAT Tutun) has been subject to tax audits on inventory movements for the years 2015, 2016 and 2019. In November 2020, BAT Tutun received a tax assessment amounting to £84 million for the years 2015 and 2016. The Group has not, at the date of this report, received a tax assessment in relation to 2019. Management is engaging with the tax authorities comprising principal, penalty and interest for the years on the matter but believes that the tax claims are unfounded.

In Bangladesh, on 25 July 2018, the Appellate Division of the Supreme Court of Bangladesh reversed the decision of the High Court against BAT Bangladesh in respect of the retrospective demands for VAT and Supplementary Duty amounting to approximately £153 million. On 3 February 2020, the certified Court Order was received. The Government filed a Review Petition on 25 March 2020 in the Appellate Division of the Supreme Court of Bangladesh against the judgment. The matter is yet to be taken up for hearing.

British American Tobacco Egypt LLC is subject to two ongoing civil cases concerning the imposition of sales tax on low-price category brands brought by the Egyptian tax authority for £121 million. Management believes that the tax claims are unfounded and has appealed the tax claims. These cases are under review by the Council of State. During hearings in August 2020, the courts decided, in both cases, to transfer the files to court appointed experts. One case has been referred to a court-appointed expert with no hearing date set yet and in the other case, the expert has concluded his report and filed it with the court. In May 2021, a judgment was issued. However the court has not yet recorded the judgment in the official records. The Group is following up with the court on the judgment.

The Group is also appealing the ruling in respect of central and local excise taxes and penalties in South Korea.

# Contingent liabilities and financial commitments cont...

#### **Group litigation**

Group companies, as well as other leading cigarette manufacturers, are defendants in a number of product liability cases. In a number of these cases, the amounts of compensatory and punitive damages sought are significant.

While it is impossible to be certain of the outcome of any particular case or of the amount of any possible adverse verdict, the Group believes that the defences of the Group's companies to all these various claims are meritorious on both the law and the facts, and a vigorous defence is being made everywhere. If an adverse judgment is entered against any of the Group's companies in any case, avenues of appeal will be pursued as necessary. Such appeals could require the appellants to post appeal bonds or substitute security in amounts that could in some cases equal or exceed the amount of the judgment. At least in the aggregate, and despite the quality of defences available to the Group, it is not impossible that the Group's results of operations or cash flows in a particular period could be materially affected by this and by the final outcome of any particular litigation.

#### Canada

In Canada, following the implementation of legislation enabling provincial governments to recover healthcare costs directly from tobacco manufacturers, ten actions for recovery of healthcare costs arising from the treatment of smoking and health-related diseases were commenced in ten provinces. Damages sought have not yet been quantified by all ten provinces; however, in respect of five provinces, the damages quantified in each of the provinces range between CAD\$10 billion (approximately £5.8 billion) and CAD\$118 billion (approximately £69 billion), and the province of Ontario delivered an expert report quantifying its damages in the range of CAD\$280 billion (approximately £163 billion) and CAD\$630 billion (approximately £368 billion) in 2016/2017 dollars. Ontario has amended its Statement of Claim to claim damages of CAD\$330 billion (approximately £193 billion). On 31 January 2019, the Province delivered a further expert report claiming an additional CAD\$9.4 - CAD\$10.9 billion in damages (approximately £5.5 billion - £6.4 billion) in respect of environmental tobacco smoke. No trial date has been set. In respect of New Brunswick, on 7 March 2019, the New Brunswick Court of Queen's Bench released a decision requiring the Province to produce a substantial amount of additional documentation and data to the defendants. As a result, the original trial date of 4 November 2019 would have been delayed. No new trial date has been set.

In addition to the actions commenced by the provincial governments, there are numerous class actions outstanding against Group companies. As set out below, all of these actions are currently subject to stays of proceedings. On 1 March 2019, the Quebec Court of Appeal handed down a judgment which largely upheld and endorsed the lower court's previous decision in the Quebec class actions. ITCAN's share of the judgment is approximately CAD\$ 9.2 billion. As a result of this judgment, the then immediate attempts by the Quebec plaintiffs to obtain payment out of the CAD\$758 million on deposit with the court, the fact that JTI-MacDonald Corp (a co-defendant in the cases) filed for protection under the CCAA on 8 March 2019 and obtained a court ordered stay of all tobacco litigation in Canada as against all defendants (including the RJR Group Companies) until 4 April 2019, and the need for a process to resolve all of the outstanding litigation across the country, on 12 March 2019, ITCAN filed for protection under the CCAA. In its application, ITCAN asked the Ontario Superior Court to stay all pending or contemplated litigation against ITCAN, certain of its subsidiaries and all other Group companies that were defendants in the Canadian tobacco litigation (the "stays"). The stays are currently in place until 30 September 2021. While the stays are in place, no steps are to be taken in connection with the Canadian tobacco litigation with respect to any of the defendants.

#### US - Engle

As at 30 June 2021, the Group's subsidiaries, R. J. Reynolds Tobacco Company (RJRT), Lorillard Tobacco Company (Lorillard) and Brown & Williamson Holdings, Inc., had collectively been served in 1,274 pending Engle progeny cases filed on behalf of approximately 1,573 individual plaintiffs. Many of these are in active discovery or nearing trial.

In the first half of 2021, RJRT or Lorillard paid judgments in three Engle progeny cases. Those payments totalled US\$0.8 million (approximately £0.6 million) in compensatory or punitive damages. Additional costs were paid in respect of attorneys' fees and statutory interest. In addition, since 1 January 2019 through to 30 June 2021, outstanding jury verdicts in favour of the Engle progeny plaintiffs had been entered against RJRT or Lorillard for US\$51.6 million (approximately £37 million) in compensatory damages and US\$152 million (approximately £110 million) in punitive damages. A significant majority of these verdicts are in various stages in the appellate process and have been bonded as required by Florida law under the US\$200 million (approximately £144 million) bond cap passed by the Florida legislature in 2009. Although the Group cannot currently predict when or how much it may be required to bond and pay, the Group companies will likely be required to bond and pay additional judgments as the litigation proceeds.

# Contingent liabilities and financial commitments cont...

#### Fox Diver

In January 2017, NCR and Appvion entered into a Consent Decree with the US Government to resolve how the remaining clean-up will be funded and to resolve further outstanding claims between them. The Consent Decree was approved by the District Court of Wisconsin in August 2017. The US Government enforcement action against NCR was terminated as a result of that order and contribution claims from the Potentially Responsible Parties ("PRPs") against NCR were dismissed. On 4 January 2019, the US Government, P. H. Glatfelter and Georgia-Pacific (the remaining Fox River PRPs) sought approval for a separate Consent Decree settling the allocation of costs on the Fox River. This Consent Decree was approved by the District Court in the Eastern District of Wisconsin on 14 March 2019, and concludes all existing litigation on the Fox River clean-up. Considering these developments, the provision has been reviewed. No adjustment has been proposed, other than as related to the payments in the period of £2 million, with the provision standing at £68 million at 30 June 2021 (30 June 2020: £70 million; 31 December 2020: £70 million) after disbursements.

In July 2016, the High Court ruled in favour of a Group subsidiary, BTI 2014 LLC (BTI), stating that a dividend of €135 million (approximately £123 million) paid by Windward to Sequana in May 2009 was a transaction made with the intention of putting assets beyond the reach of BTI and of negatively impacting its interests. On 10 February 2017, further to a hearing in January 2017 to determine the relief due, the Court found in BTI's favour, ordering that Sequana must pay an amount up to the full value of the dividend plus interest which equates to around US\$185 million (approximately £134 million), related to past and future clean-up costs. The Court granted all parties leave to appeal and Sequana a stay in respect of the above payments. The appeal was heard in June 2018. Judgment was given on 6 February 2019 and the Court of Appeal upheld the High Court's findings against Sequana. The Court of Appeal refused applications made by both parties for a further appeal to the U.K. Supreme Court. Both parties applied directly to the U.K. Supreme Court for permission to appeal in March 2019. On 31 July 2019, BTI was granted permission to appeal to the Supreme Court. On the same day, the Supreme Court refused Sequana permission to appeal. The hearing of BTI's appeal was listed to take place on 25 and 26 March 2020 but was adjourned because of the COVID-19 pandemic. The hearing of BTI's appeal took place before the Supreme Court on 4 and 5 May 2021 and the judgment is awaited. In February 2017, Sequana entered into a process in France seeking court protection (the "Sauvegarde"), exiting the Sauvegarde in June 2017. No payments have been received.

#### **Investigations**

From time-to-time, the Group investigates, and becomes aware of governmental authorities' investigations into, allegations of misconduct against Group companies. The Group co-operates with the authorities' investigations, where appropriate, including with the DOJ and OFAC in the United States, which are conducting an investigation into suspicions of breach of sanctions.

The potential for fines, penalties or other consequences cannot currently be assessed. As the investigations are ongoing, it is not possible to identify the timescale in which these matters might be resolved.

#### **Summary**

With regard to all these matters, with the exception of Fox River, Quebec and certain Engle progeny cases, the Group does not consider it appropriate to make any provision or charge in respect of any pending litigation. The Group does not believe that the ultimate outcome of this litigation will significantly impair the Group's financial condition. If the facts and circumstances change, then there could be a material impact on the financial statements of the Group.

Full details of the litigation against Group companies and tax disputes as at 31 December 2021 will be included in the Group's Annual Report and Form 20-F for the year ending 31 December 2021. Whilst there has been some movement on new and existing cases against Group companies, there have been, except as otherwise stated, no material developments in 2021 that would impact the financial position of the Group.

#### FRANKED INVESTMENT INCOME GROUP LITIGATION ORDER

The Group is the principal test claimant in an action in the United Kingdom against HM Revenue and Customs ("HMRC") in the FII GLO. There are 23 corporate groups in the FII GLO. The case concerns the treatment for UK corporate tax purposes of profits earned overseas and distributed to the UK. The Supreme Court heard appeals in two separate trials during 2020. The judgment in the first hearing was handed down in November 2020 and concerned the time limit for bringing claims. The Supreme Court remitted that matter to the High Court to determine whether the claim is within time on the facts. The judgment from the second hearing was handed down in July 2021 and concerned the appropriate methodology to compute the claim. Applying that judgment reduces the value of the FII claim to approximately £0.3 billion, mainly as the result of the application of simple interest, which is subject to the determination of the timing issue by the High Court and any subsequent appeal.

During 2015, HMRC paid to the Group a gross amount of £1.2 billion in two separate payments, less a deduction (withheld by HMRC) of £0.3 billion. The payments made by HMRC have been made without any admission of liability and are subject to refund, were HMRC to succeed on appeal. Due to the uncertainty of the amounts and eventual outcome the Group has not recognised any impact in the Income Statement in the current or prior period in respect of the receipt (being net £0.9 billion) and is held as deferred income. Any future recognition as income will be treated as an adjusting item, due to the size of the order, with interest of £10 million for the six months ended 30 June 2021 (30 June 2020: £12 million; 31 December 2020: £21 million) accruing on the balance, which was also treated as an adjusting item. Further information on FII GLO is described in Note 6 to the Group's Annual Report and Accounts and Form 20-F for the year ended 31 December 2020, page 174.

#### SUMMARISED FINANCIAL INFORMATION

The following summarised financial information is required by the rules of the Securities and Exchange Commission and has been prepared in accordance with Section 3-10 of Regulation S-X in respect of the guarantees of:

The financial information relates to the guarantees of:

- US\$12.35 billion of outstanding bonds issued by B.A.T Capital Corporation (BATCAP) in connection with the
  acquisition of Reynolds, including registered bonds issued in exchange for the initially issued bonds (the
  2017 Bonds);
- US\$10.65 billion of outstanding bonds issued by BATCAP pursuant to the Shelf Registration Statement on Form F-3 filed on July 17, 2019, pursuant to which BATCAP or BATIF may issue an indefinite amount of debt securities; and
- US\$1.50 billion of outstanding bonds issued by BATIF pursuant to the Shelf Registration Statement on Form F-3 filed on July 17, 2019, pursuant to which BATCAP or BATIF may issue an indefinite amount of debt securities.

As of July 28, 2020, all relevant Group entities suspended their reporting obligations with respect to the US\$7.7 billion (30 June 2020: US\$8.9 billion; 31 December 2020: US\$7.7 billion) of RAI unsecured notes and US\$40.9 million (30 June 2020 and 31 December 2020: US\$40.9 million) of Lorillard unsecured notes. As such, no summarised financial information is provided with respect to these securities.

As described below, Reynolds American Inc. (Reynolds American/RAI) is a subsidiary guarantor of all outstanding series of BATCAP and BATIF bonds. Under the terms of the indentures governing such notes, any subsidiary guarantor (including Reynolds American) other than BATCAP or BATIF, as applicable, BATNF and BATHTN, will automatically and unconditionally be released from all obligations under its guarantee, and such guarantee shall thereupon terminate and be discharged and of no further force or effect, in the event that (1) its guarantee of all then outstanding notes issued under the Group's EMTN Programme is released or (2) at substantially the same time its guarantee of the debt securities is terminated, such subsidiary guarantor is released from all obligations in respect of indebtedness for borrowed money for which such subsidiary guarantor is an obligor (as a guarantor or borrower). Under the EMTN Programme, Reynolds American's guarantee is released if at any time the aggregate amount of indebtedness for borrowed money, subject to certain exceptions, for which Reynolds American is an obligor, does not exceed 10% of the outstanding long-term debt of BAT as reflected in the balance sheet included in BAT's most recent publicly released interim or annual consolidated financial statements.

Reynolds American's guarantee may be released notwithstanding Reynolds American guaranteeing other indebtedness, provided Reynolds American's guarantee of outstanding notes issued under the EMTN Programme is released. If Reynolds American's guarantee is released, BAT is not required to replace such guarantee, and the debt securities will have the benefit of fewer subsidiary guarantees for the remaining maturity of the debt securities.

Note: The following summarised financial information reports the unconsolidated contribution of each applicable company to the Group's consolidated results and not the separate financial statements for each applicable company as local financial statements are prepared in accordance with local legislative requirements and may differ from the financial information provided below. In particular, in respect of the United States region, all financial statements and financial information provided by or with respect to the US business or RAI (and/ or RAI and its subsidiaries (collectively, the Reynolds Group)) are prepared on the basis of US GAAP and constitute the primary financial statements or financial information of the US business or RAI (and/or the Reynolds Group). Solely for the purpose of consolidation within the results of BAT p.l.c. and the BAT Group, this financial information is then converted to IFRS. To the extent any such financial information provided in these financial statements relates to the US business or RAI (and/or the Reynolds Group), it is provided as an explanation of the US business's or RAI's (and/or the Reynolds Group) primary US GAAP-based financial statements and information.

#### **Summarised Financial Information cont...**

The subsidiaries disclosed below are wholly-owned and the guarantees provided are full and unconditional, and joint and several:

- a. British American Tobacco p.l.c. (as the parent guarantor), referred to as 'BAT p.l.c.' in the financials below;
- b. B.A.T Capital Corporation (as an issuer or a subsidiary guarantor, as the case may be), referred to as 'BATCAP' in the financials below;
- c. B.A.T. International Finance p.l.c. (as an issuer or a subsidiary guarantor, as the case may be), referred to as 'BATIF' in the financials below;
- d. B.A.T. Netherlands Finance B.V. (as a subsidiary guarantor), referred to as 'BATNF' in the financials below;
- e. Reynolds American Inc. (as a subsidiary guarantor), referred to as 'RAI' in the financials below; and
- f. British American Tobacco Holdings (The Netherlands) B.V. (as a subsidiary guarantor of the 2017 Bonds only), referred to as 'BATHTN' in the financials below.

In accordance with Section 13-01 of Regulation S-X, information in respect of investments in subsidiaries that are not issuers or guarantors has been excluded from non-current assets as shown in the balance sheet table below. The "BATHTN" column in the summarised financial information is only applicable in the context of the 2017 Bonds. British American Tobacco Holdings (The Netherlands) B.V. ('BATHTN') is not an issuer nor a guarantor of any of the other securities referenced in this note. None of the issuers or other guarantors has material balances with or an investment in BATHTN. Investments in subsidiaries represent share capital acquired in relation to or issued by subsidiary undertakings.

# **Summarised Financial Information cont...**

| Six months ended 30 June 2021   | BAT p.l.c. | ВАТСАР | BATIF | BATNF | RAI   | BATHTN |
|---|------------|--------|-------|-------|-------|--------|
|   | £m         | £m     | £m    | £m    | £m    | £m     |
| Income Statement  |            |        |       |       |       |        |
| Revenue   | -          | -      | -     | -     | -     | -      |
| (Loss)/profit from operations   | (10)       | (1)    | (1)   | -     | 4     | -      |
| Dividend income   | -          | -      | -     | -     | 2,255 | -      |
| Net finance income/(costs)  | 83         | (16)   | 133   | -     | (208) | -      |
| Profit/(loss) before taxation   | 73         | (17)   | 132   | -     | 2,051 | -      |
| Taxation on ordinary activities   | -          | 13     | (1)   | -     | 43    | -      |
| Profit/(loss) for the period  | 73         | (4)    | 131   | -     | 2,094 | -      |
| Intercompany transactions – Income<br>Statement<br>Transactions with non-issuer/non-guarantor | (10)       | (1)    | (1)   |       | 17    | _      |
| subsidiaries (expense)/income   |            |        |       |       |       |        |
| Transactions with non-issuer/non-guarantor<br>subsidiaries net finance income                 | -          | 356    | 281   | -     | 14    | -      |
| Dividend income from non-issuer/non-<br>guarantor subsidiaries                                | -          | -      | -     | -     | 2,255 | -      |

| Six months ended 30 June 2020   | BAT p.l.c. | BATCAP | BATIF | BATNF | RAI   | BATHTN |
|---|------------|--------|-------|-------|-------|--------|
|   | £m         | £m     | £m    | £m    | £m    | £m     |
| Income Statement  |            |        |       |       |       |        |
| Revenue   | -          | -      | -     | -     | -     | -      |
| (Loss)/profit from operations   | (19)       | 3      | (1)   | -     | (3)   | -      |
| Dividend income   | -          | -      | -     | -     | 2,310 | -      |
| Net finance income/(costs)  | 49         | 425    | 96    | -     | (456) | -      |
| Profit/(loss) before taxation   | 30         | 428    | 95    | -     | 1,851 | -      |
| Taxation on ordinary activities   | -          | (98)   | -     | -     | 109   | -      |
| Profit/(loss) for the period  | 30         | 330    | 95    | -     | 1,960 | -      |
| Intercompany transactions – Income<br>Statement                                   |            |        |       |       |       |        |
| Transactions with non-issuer/non-guarantor subsidiaries (expense)/income          | (19)       | 3      | (1)   | -     | 8     | -      |
| Transactions with non-issuer/non-guarantor subsidiaries net finance income/(cost) | 5          | 573    | 419   | -     | 16    | -      |
| Dividend income from non-issuer/non-<br>guarantor subsidiaries                    | -          | -      | -     | -     | 2,310 | -      |

# **Summarised Financial Information cont...**

| As at 30 June 2021   | BAT p.l.c.                          | ВАТСАР   | BATIF   | BATNF                              | RAI   | BATHTN                       |
|--|-------------------------------------|--|---|------------------------------------|---|------------------------------|
|  | £m                                  | £m   | £m  | £m                                 | £m  | £m                           |
| Balance Sheet  |                                     |  |   |                                    |   |                              |
| Non-current assets   | 236                                 | 18,795   | 9,655   | 1,448                              | 362   | 70                           |
| Current assets   | 4,707                               | 2,419  | 30,953  | 18                                 | 997   | 20                           |
| Non-current liabilities  | 9                                   | 17,688   | 12,070  | 1,448                              | 8,788   | 18                           |
| Non-current borrowings   | -                                   | 17,677   | 11,975  | 1,448                              | 8,724   | -                            |
| Other non-current liabilities  | 9                                   | 11   | 95  | -                                  | 64  | 18                           |
| Current liabilities  | 1,621                               | 3,419  | 26,835  | 18                                 | 722   | 7                            |
| Current borrowings   | 1,579                               | 3,389  | 26,454  | 18                                 | 199   | 3                            |
| Other current liabilities  | 42                                  | 30   | 381   | -                                  | 523   | 4                            |
| Intercompany transactions – Balance Sheet  |                                     |  |   |                                    |   |                              |
| Amounts due from non-issuer/non-<br>guarantor subsidiaries   | 4,671                               | 15,570   | 38,172  | -                                  | 1,322   | 20                           |
| Amounts due to non-issuer/non-guarantor subsidiaries   | -                                   | 2,228  | 18,376  | -                                  | 55  | 2                            |
| Investment in subsidiaries (that are not issuers or guarantors)  | 27,234                              | -  | 718   | -                                  | 23,189  | 1,516                        |
|  |                                     |  |   |                                    |   |                              |
| As at 31 December 2020   | BAT p.l.c.                          | BATCAP   | BATIF   | BATNE                              | PΔI   | BATHTN                       |
| As at 31 December 2020   | BAT p.l.c.                          | BATCAP   | BATIF   | BATNF                              | RAI   | BATHTN                       |
|  | BAT p.l.c.                          | BATCAP<br>£m   | BATIF<br>£m   | BATNF<br>£m                        | RAI<br>£m   | BATHTN<br>£m                 |
| Balance Sheet  | £m                                  | £m   | £m  | £m                                 | £m  | £m                           |
| Balance Sheet Non-current assets   | <b>£m</b>                           | <b>£m</b><br>18,991  | <b>£m</b>   | <b>£m</b>                          | <b>£m</b> 402   | <b>£m</b>                    |
| Balance Sheet Non-current assets Current assets  | £m 236 7,070                        | <b>£m</b><br>18,991<br>3,404                               | <b>£m</b> 10,332 30,601   | <b>£m</b> 1,509 22                 | <b>£m</b> 402 268                                       | <b>£m</b> 26                 |
| Balance Sheet Non-current assets Current assets Non-current liabilities  | 236<br>7,070<br>1,580               | 18,991<br>3,404<br>17,867                                  | 10,332<br>30,601<br>15,326  | 1,509<br>22<br>1,509               | <b>£m</b> 402 268 8,885                                 | <b>£m</b> 26 15              |
| Balance Sheet Non-current assets Current assets Non-current liabilities Non-current borrowings   | 236<br>7,070<br>1,580               | <b>£m</b><br>18,991<br>3,404                               | 10,332<br>30,601<br>15,326<br>15,243                                  | <b>£m</b> 1,509 22                 | 402<br>268<br>8,885<br>8,823                            | <b>£m</b> 26 15 6            |
| Balance Sheet  Non-current assets  Current assets  Non-current liabilities  Non-current borrowings  Other non-current liabilities  | 236<br>7,070<br>1,580<br>1,571      | 18,991<br>3,404<br>17,867<br>17,867                        | 10,332<br>30,601<br>15,326<br>15,243<br>83                            | 1,509<br>22<br>1,509<br>1,509      | 402<br>268<br>8,885<br>8,823<br>62                      | 26<br>15<br>6                |
| Balance Sheet Non-current assets Current assets Non-current liabilities Non-current borrowings Other non-current liabilities Current liabilities   | 236<br>7,070<br>1,580<br>1,571<br>9 | 18,991<br>3,404<br>17,867<br>17,867                        | 10,332<br>30,601<br>15,326<br>15,243<br>83<br>24,038                  | 1,509<br>22<br>1,509<br>1,509<br>- | 402<br>268<br>8,885<br>8,823<br>62<br>972               | 26<br>15<br>6                |
| Balance Sheet Non-current assets Current assets Non-current liabilities Non-current borrowings Other non-current liabilities Current liabilities Current borrowings  | 236 7,070 1,580  1,571 9  52        | 18,991<br>3,404<br>17,867<br>17,867<br>-<br>4,444<br>4,329 | 10,332<br>30,601<br>15,326<br>15,243<br>83<br>24,038<br>23,478        | 1,509<br>22<br>1,509<br>1,509      | 402<br>268<br>8,885<br>8,823<br>62<br>972<br>200        | 26<br>15<br>6<br>-<br>6<br>2 |
| Balance Sheet Non-current assets Current assets Non-current liabilities Non-current borrowings Other non-current liabilities Current liabilities   | 236<br>7,070<br>1,580<br>1,571<br>9 | 18,991<br>3,404<br>17,867<br>17,867                        | 10,332<br>30,601<br>15,326<br>15,243<br>83<br>24,038                  | 1,509<br>22<br>1,509<br>1,509<br>- | 402<br>268<br>8,885<br>8,823<br>62<br>972               | 26<br>15<br>6                |
| Balance Sheet Non-current assets Current assets Non-current liabilities Non-current borrowings Other non-current liabilities Current liabilities Current borrowings  | 236 7,070 1,580  1,571 9  52        | 18,991<br>3,404<br>17,867<br>17,867<br>-<br>4,444<br>4,329 | 10,332<br>30,601<br>15,326<br>15,243<br>83<br>24,038<br>23,478        | 1,509<br>22<br>1,509<br>1,509<br>- | 402<br>268<br>8,885<br>8,823<br>62<br>972<br>200        | 26<br>15<br>6<br>-<br>6<br>2 |
| Balance Sheet  Non-current assets  Current assets  Non-current liabilities  Non-current borrowings  Other non-current liabilities  Current liabilities  Current borrowings  Other current liabilities  | 236 7,070 1,580  1,571 9  52        | 18,991<br>3,404<br>17,867<br>17,867<br>-<br>4,444<br>4,329 | 10,332<br>30,601<br>15,326<br>15,243<br>83<br>24,038<br>23,478        | 1,509<br>22<br>1,509<br>1,509<br>- | 402<br>268<br>8,885<br>8,823<br>62<br>972<br>200        | 26<br>15<br>6<br>-<br>6<br>2 |
| Balance Sheet  Non-current assets  Current assets  Non-current liabilities  Non-current borrowings  Other non-current liabilities  Current liabilities  Current borrowings  Other current liabilities  Intercompany transactions – Balance Sheet  Amounts due from non-issuer/non- | 236 7,070 1,580 1,571 9 52 9 43     | 18,991<br>3,404<br>17,867<br>17,867<br>-<br>4,444<br>4,329 | 10,332<br>30,601<br>15,326<br>15,243<br>83<br>24,038<br>23,478<br>560 | 1,509<br>22<br>1,509<br>1,509<br>- | 402<br>268<br>8,885<br>8,823<br>62<br>972<br>200<br>772 | 26<br>15<br>6<br>-<br>6<br>2 |

#### **DIVIDENDS**

On 17 February 2021, the Company announced that the Board had declared an interim dividend of 215.6p per ordinary share of 25p, payable in four equal quarterly instalments of 53.9p per ordinary share in May 2021, August 2021, November 2021 and February 2022.

The May 2021 dividend was paid to shareholders on the UK main register and South Africa branch register on 12 May 2021 and to holders of American Depositary Shares (ADSs) on 17 May 2021. The three remaining quarterly dividends will be paid to shareholders registered on either the UK main register or the South Africa branch register, and to holders of ADSs, each on the applicable record dates set out under the heading 'Key Dates' below.

#### **General dividend information**

Under IFRS, the interim dividend is recognised in the period that it is paid. Therefore, the results for the six months ended 30 June 2021 reflect the fourth quarterly dividend from the declaration made on 27 February 2020 of 52.6p per ordinary share and the first quarterly dividend from the declaration made on 16 February 2021, of 53.9p per ordinary share as these were paid in February 2021 and May 2021, respectively.

|   | For the six months e | nded 30 June 2021 |
|---|----------------------|-------------------|
|   | Pence per share      | US\$ per ADS      |
| Quarterly payment paid in February 2021 | 52.60                | 0.717832          |
| Quarterly payment paid in May 2021      | 53.90                | 0.757618          |
|   | 106.50               | 1.475450          |

#### **Holders of ADSs**

For holders of ADSs listed on the New York Stock Exchange (NYSE), the record dates and payment dates are set out below. The equivalent quarterly dividends receivable by holders of ADSs in US dollars will be calculated based on the exchange rate on the applicable payment date. A fee of US\$0.005 per ADS will be charged by Citibank, N.A. in its capacity as depositary bank for the BAT American Depositary Receipt (ADR) programme in respect of each quarterly dividend payment.

#### **South Africa Branch Register**

In accordance with the JSE Limited (JSE) listing requirements, the finalisation information relating to shareholders registered on the South Africa branch register (comprising the amount of the dividend in South African rand, the exchange rate and the associated conversion date) will be published on the dates stated below, together with South Africa dividends tax information.

The quarterly dividends are regarded as 'foreign dividends' for the purposes of the South Africa Dividends Tax. For the purposes of South Africa Dividends Tax reporting, the source of income for the payment of the quarterly dividends is the United Kingdom.

# Dividends cont...

#### **Key dates**

In compliance with the requirements of the London Stock Exchange (LSE), the NYSE and Strate, the electronic settlement and custody system used by the JSE, the following salient dates for the quarterly dividends payments are applicable. All dates are 2021, unless otherwise stated.

| Event  | Payment No. 2      | Payment No. 3               | Payment No. 4               |
|--|--------------------|-----------------------------|-----------------------------|
| Preliminary announcement<br>(includes declaration data<br>required for JSE purposes)         | F.                 | 17 February                 |                             |
| Publication of finalisation information (JSE)  | 29 June*           | 20 September                | 13 December                 |
| No removal requests permitted<br>between the UK main register<br>and the South Africa branch | 29 June–<br>9 July | 20 September–<br>1 October  | 13 December-<br>24 December |
| register   | (inclusive)        | (inclusive)                 | (inclusive)                 |
| Last Day to Trade (LDT) cum<br>dividend (JSE)  | 6 July             | 28 September                | 21 December                 |
| Shares commence trading exdividend (JSE)   | 7 July             | 29 September                | 22 December                 |
| No transfers permitted between the UK main register and the                                  | 7 July–<br>9 July  | 29 September –<br>1 October | 22 December–<br>24 December |
| South Africa branch register   | (inclusive)        | (inclusive)                 | (inclusive)                 |
| No shares may be dematerialised or rematerialised on the South                               | 7 July–<br>9 July  | 29 September–<br>1 October  | 22 December–<br>24 December |
| Africa branch register   | (inclusive)        | (inclusive)                 | (inclusive)                 |
| Shares commence trading exdividend (LSE and NYSE)  | 8 July             | 30 September                | 23 December                 |
| Record date<br>(JSE, LSE and NYSE)   | 9 July             | 1 October                   | 24 December                 |
| Last date for receipt of Dividend<br>Reinvestment Plan (DRIP)<br>elections (LSE)             | 29 July            | 21 October                  | 19 January 2022             |
| Payment date (LSE and JSE)   | 19 August          | 11 November                 | 9 February 2022             |
| ADS payment date (NYSE)  | 24 August          | 16 November                 | 14 February 2022            |

# Note:

<sup>(1)</sup> The dates set out above may be subject to any changes to public holidays arising and changes or revisions to the LSE, JSE and NYSE timetables. Any confirmed changes to the dates will be announced.

<sup>(2) \*</sup>JSE finalisation information published on 29 June 2021 can be found on the British American Tobacco website www.bat.com.

#### **NON-FINANCIAL KPIS**

#### Volume

Volume is defined as the number of units sold. Units may vary between categories. This can be summarised for the principal metrics as follows:

- Factory made cigarettes (FMC) sticks, regardless of weight or dimensions;
- Roll-Your-Own / Make-Your-Own kilos, converted to a stick equivalent based upon 0.8 grams (per stick equivalent) for Roll-Your-Own and between 0.5 and 0.7 grams (per stick equivalent) for Make-Your-Own;
- Traditional oral pouches (being 1:1 conversion to stick equivalent) and kilos, converted to a stick equivalent based upon 2.8 grams (per stick equivalent) for Moist Snuff, 2.0 grams (per stick equivalent) for Dry Snuff and 7.1 grams (per stick equivalent) for other oral;
- Modern Oral pouches, being 1:1 conversion to stick equivalent;
- Tobacco Heat sticks sticks, being 1:1 conversion to stick equivalent; and
- Vapour pods and 10 millilitre bottles. There is no conversion to a stick equivalent.

Volume is recognised in line with IFRS 15 Revenue from Contracts with Customers, based upon transfer of control. It is assumed that there is no material difference, in line with the Group's recognition of revenue, between the transfer of control and shipment date.

Volume is used by management and investors to assess the relative performance of the Group and its brands within categories, given volume is a principal determinant of revenue.

#### Volume share

Volume share is the number of units bought by consumers of a specific brand or combination of brands, as a proportion of the total units bought by consumers in the industry, category or other sub-categorisation. Subcategories include, but are not limited to, the total nicotine category, modern oral, vapour, traditional oral, total oral or cigarette. Except when referencing particular markets, volume share is based on our key markets (representing over 80% of the Group's cigarette volume).

Where possible, the Group utilises data provided by third-party organisations, including AC Nielsen, based upon retail audit of sales to consumers. In certain markets, where such data is not available, other measures are employed which assess volume share based upon other movements within the supply chain, such as sales to retailers. This may depend on the provision of data to the industry by the customers including distributors / wholesalers.

Volume share is used by management to assess the relative performance of the Group and its brands against the performance of its competitors in the categories and geographies in which the Group operates. The Group's management believes that this measure is useful to investors to understand the relative performance of the Group and its brands against the performance of its competitors in the categories and geographies in which the Group operates. This measure is also useful to understand the Group's performance when seeking to grow scale within a market or category from which future financial returns can be realised. Volume share provides an indicator of the Group's relative performance in unit terms versus competitors.

Volume share in each period compares the average volume share in the period with the average volume share in the prior year. This is a more robust measure of performance, removing short-term volatility that may arise at a point in time.

However, in certain circumstances, related to periods of introduction to a market, in order to illustrate the latest performance, data may be provided as at the end of the period rather than the average in that period. In these instances, the Group states these at a specific date (for instance, June 2021).

#### Value share

Value share is the retail value of units bought by consumers of a particular brand or combination of brands, as a proportion of the total retail value of units bought by consumers in the industry, category or other subcategorisation in discussion.

#### Non-Financial KPIs cont....

Where possible, the Group utilises data provided by third-party organisations, including AC Nielsen, based upon retail audit of sales to consumers. In certain markets, where such data is not available, other measures are employed which assess value share based upon other movements within the supply chain, such as sales to retailers. This may depend on the provision of data to the industry by the customers (including distributors and wholesalers).

Value share is used by management to assess the relative performance of the Group and its brands against the performance of its competitors in the categories and geographies in which the Group operates, specifically indicating the Group's ability to realise value relative to the market. The measure is particularly useful when the Group's products and/or the relevant category in the market in which they are sold has developed or achieved scale from which value can be realised. The Group's management believes that this measure is useful to investors to comprehend the relative performance of the Group and its brands against the performance of its competitors in the categories and geographies in which the Group operates, specifically indicating the Group's ability to realise value relative to the market.

Value share in each period compares the average value share in the period with the average value share in the prior year. This is a more robust measure of performance, removing short-term volatility that may arise at a point of time.

However, in certain circumstances, related to periods of introduction to a market, in order to illustrate the latest performance, data may be provided as at the end of the period rather than the average in that period. In these instances, the Group states these at a specific date (for instance, June 2021).

#### **Price mix**

Price mix is a term used by management and investors to explain the movement in revenue between periods. Revenue is affected by the volume (how many units are sold) and the value (how much is each unit sold for). Price mix is used to explain the value component of the sales as the Group sells each unit for a value (price) but may also achieve a movement in revenue due to the relative proportions of higher value volume sold compared to lower value volume sold (mix).

This term is used to explain the Group's relative performance between periods only. It is calculated as the difference between the movement in revenue (between periods) and volume (between periods). For instance, the growth in combustibles revenue (excluding translational foreign exchange movements) of 5.8% in the six months ended 30 June 2021, with an increase in combustibles volume of 1.5% in the six months ended 30 June 2021, leads to a price mix of 4.3% in the period. No assumptions underlie this metric as it utilises the Group's own data

# **Consumers of Non-Combustible products**

The number of consumers of Non-Combustible products is defined as the estimated number of Legal Age (minimum 18 years) consumers of the Group's Non-Combustible products. In markets where regular consumer tracking is in place, this estimate is obtained from adult consumer tracking studies conducted by third parties (including Kantar). In markets where regular consumer tracking is not in place, the number of consumers of Non-Combustible products is derived from volume sales of consumables and devices in such markets, using consumption patterns obtained from other similar markets with adult consumer tracking (utilising studies conducted by third parties including Kantar). The number of consumers is adjusted for those identified (as part of the consumer tracking studies undertaken) as using more than one BAT Brand – referred to as "poly users".

The number of consumers of Non-Combustible products is used by management to assess the number of consumers using the Group's New Categories products as the increase in Non-Combustible products is a key pillar of the Group's ESG ambition and is integral to the sustainability of our business.

The Group's management believes that this measure is useful to investors given the Group's ESG ambition and alignment to the sustainability of the business with respect to the Non-Combustibles portfolio.

#### **NON-GAAP MEASURES**

To supplement the presentation of the Group's results of operations and financial condition in accordance with IFRS, the Group also presents several non-GAAP measures used by management to monitor the Group's performance. The Group's management regularly reviews the measures used to assess and present the financial performance of the Group and, as relevant, its geographic segments.

Although the Group does not believe that these measures are a substitute for IFRS measures, the Group does believe such results excluding the impact of adjusting items provide additional useful information to investors regarding the underlying performance of the business on a comparable basis.

The principal non-GAAP measures which the Group uses are adjusted profit from operations, adjusted diluted earnings per share, operating cash flow conversion ratio, free cash flow (before dividends paid to shareholders) and free cash flow (after dividends paid to shareholders) which are before the impact of adjusting items and are reconciled from profit from operations, diluted earnings per share, cash conversion ratio and net cash generated from operating activities. Adjusting items, as identified in accordance with the Group's accounting policies, represent certain items of income and expense which the Group considers distinctive based on their size, nature or incidence. These include significant items in profit from operations, net finance costs, taxation and the Group's share of the post-tax results of associates and joint ventures which individually or, if of a similar type, in aggregate, are relevant to an understanding of the Group's underlying financial performance. The adjusting items are used to calculate the non-GAAP measures of adjusted profit from operations, adjusted operating margin, adjusted net finance costs, adjusted taxation, adjusted share of post-tax results of associates and joint ventures, underlying tax rate and adjusted diluted earnings per share. In addition to the operating cash flow conversion ratio, free cash flow (before dividends paid to shareholders) and free cash flow (after dividends paid to shareholders), the Group also provides other non-GAAP measures of net debt, adjusted net debt and adjusted net debt to adjusted earnings before interest, tax, depreciation, amortisation and post-tax income from associates and joint-ventures (adjusted EBITDA), which the Group uses to monitor its financial position. The Group also supplements its presentation of revenue in accordance with IFRS by presenting the non-GAAP component breakdowns of revenues by product category (including revenue generated from Vapour, Tobacco Heating Products, Modern Oral, New Categories as a whole, Combustibles and Traditional Oral), including by geographic segment (including revenue generated in the United States, Europe and North Africa, Americas and Sub-Saharan Africa and Asia-Pacific and Middle East). The Group's Management Board believes these measures, which are used internally, are useful to the users of the financial statements in helping them understand the underlying business performance of individual Group product categories, including by geographic segments.

The Management Board, as the chief operating decision maker, reviews a number of our IFRS and non-GAAP measures for the Group and its product categories and geographic segments at constant rates of exchange. This allows comparison of the Group's results, had they been translated at the previous year's average rates of exchange. The Group does not adjust for the normal transactional gains and losses in profit from operations that are generated by exchange movements. Although the Group does not believe that these measures are a substitute for IFRS measures, the Group does believe that such results excluding the impact of currency fluctuations year-on-year provide additional useful information to investors regarding the operating performance on a local currency basis.

The Group also supplements its presentation of cash flows in accordance with IFRS by presenting the non-GAAP measures of free cash flow (before dividends paid to shareholders), free cash flow (after dividends paid to shareholders) and operating cash flow conversion ratio. The Group's Management Board believes these measures, which are used internally, are useful to the users of the financial statements in helping them understand the underlying business performance and can provide insights into the cash flow available to, among other things, reduce debt and pay dividends. Free cash flow (before dividends paid to shareholders), free cash flow (after dividends paid to shareholders) and operating cash flow conversion ratio have limitations as analytical tools. They are not presentations made in accordance with IFRS and should not be considered as an alternative to net cash generated from operating activities determined in accordance with IFRS. Free cash flow (before dividends paid to shareholders), free cash flow (after dividends paid to shareholders) and operating cash flow conversion ratio are not necessarily comparable to similarly titled measures used by other companies. As a result, readers should not consider these measures in isolation from, or as a substitute analysis for, the Group's results of operations or cash flows as determined in accordance with IFRS.

#### Non-GAAP measures cont...

The Group also presents net debt and adjusted net debt, non-GAAP measures, on page 1 and pages 16 and 17. The Group uses net debt and adjusted net debt to assess its financial capacity. The Management Board believes that these additional measures, which are used internally, are useful to the users of the financial statements in helping them to see how business financing has changed over the year. Net debt and adjusted net debt have limitations as analytical tools. They are not presentations made in accordance with IFRS and should not be considered as an alternatives to borrowings or total liabilities determined in accordance with IFRS. Net debt and adjusted net debt are not necessarily comparable to similarly titled measures used by other companies. As a result, readers should not consider these measures in isolation from, or as a substitute analysis for the Group's measures of financial position as determined in accordance with IFRS.

Due to the secondary listing of the ordinary shares of British American Tobacco p.l.c. on the main board of the JSE Limited (JSE) in South Africa, the Group is required to present headline earnings per share and diluted headline earnings per share, as alternative measures of earnings per share, calculated in accordance with Circular 1/2021 'Headline Earnings' issued by the South African Institute of Chartered Accountants. These are shown on page 41.

The Group also presents the underlying tax rate, a non-GAAP measure, on page 14. The Group uses the underlying tax rate to assess the tax rate applicable to the Group's underlying operations, excluding the Group's share of post-tax results of associates and joint ventures in BAT's pre-tax results and adjusting items. The Management Board believes that this additional measure, which is used internally, is useful to the users of the financial statements because it excludes the contribution from the Group's associates, recognised after tax but within the Group's pre-tax profits, and adjusting items, thereby enhancing users' understanding of underlying business performance. Underlying tax rate has limitations as an analytical tool. It is not a presentation made in accordance with IFRS and should not be considered as an alternative to the Group's headline effective tax rate as determined in accordance with IFRS. Underlying tax rate is not necessarily comparable to similarly titled measures used by other companies. As a result, this measure should not be considered in isolation from, or as a substitute analysis for, the Group's underlying tax rate as determined in accordance with IFRS.

#### Revenue at constant rates of exchange

Definition: Revenue before the impact of foreign exchange.

| Six months ended 30 June                         | 2021   | 2020   |
|--|--------|--------|
|  | £m     | £m     |
| Revenue  | 12,175 | 12,271 |
| Impact of translational foreign exchange         | 1,093  |        |
| Revenue re-translated at constant exchange rates | 13,268 |        |

#### Revenue by Product Category, including New Categories, at constant rates of exchange

Definition: Revenue derived from each of the main product categories, including New Categories, before the impact of foreign exchange. This measure enables users of the financial statements to better compare the Group's business performance across periods and with reference to the Group's investment activity.

| Six months ended 30 June | 2021   | Impact of exchange | 2021 at 2020<br>CC | 2020   |
|--------------------------|--------|--------------------|--------------------|--------|
|                          | £m     | £m                 | £m                 | £m     |
| New Categories           | 883    | 59                 | 942                | 628    |
| Vapour                   | 398    | 25                 | 423                | 265    |
| THP                      | 359    | 35                 | 394                | 286    |
| Modern Oral              | 126    | (1)                | 125                | 77     |
| Traditional Oral         | 558    | 54                 | 612                | 576    |
| Non Combustibles         | 1,441  | 113                | 1,554              | 1,204  |
| Combustibles             | 10,527 | 958                | 11,485             | 10,854 |
| Other                    | 207    | 22                 | 229                | 213    |
| Total Revenue            | 12,175 | 1,093              | 13,268             | 12,271 |

# Non-GAAP measures cont...

# Adjusted profit from operations and adjusted operating margin

Definition: Profit from operations before the impact of adjusting items (described on pages 33 to 34) and adjusted profit from operations as a percentage of revenue.

| Six months ended 30 June  | 2021  | 2020  |
|---|-------|-------|
|   | £m    | £m    |
| Profit from operations  | 4,907 | 5,097 |
| Restructuring and integration costs   | 83    | 69    |
| Amortisation and impairment of trademarks and similar intangibles             | 151   | 171   |
| Impairment of goodwill  | -     | 11    |
| Credit in respect of an excise dispute in Russia                              | -     | (15)  |
| Impairment in respect of assets/liabilities held-for-sale                     | 71    | -     |
| Other adjusting items (including Engle)                                       | 23    | 35    |
| Adjusted profit from operations   | 5,235 | 5,368 |
| Impact of translational foreign exchange                                      | 424   |       |
| Adjusted profit from operations re-translated at constant exchange rates      | 5,659 |       |
| Operating margin (Profit from operations as % of revenue)                     | 40.3% | 41.5% |
| Adjusted operating margin (Adjusted profit from operations as a % of revenue) | 43.0% | 43.7% |

# Adjusted net finance costs

Definition: Net finance costs before the impact of adjusting items (described on page 36).

| Six months ended 30 June                                   | 2021  | 2020  |
|--|-------|-------|
|  | £m    | £m    |
| Finance costs  | (771) | (822) |
| Finance income   | 15    | 36    |
| Net finance costs  | (756) | (786) |
| Less: Adjusting items in net finance costs                 | 34    | 3     |
| Net adjusted finance costs                                 | (722) | (783) |
| Comprising:  |       |       |
| Interest payable   | (747) | (832) |
| Interest and dividend income                               | 15    | 29    |
| Fair value changes – derivatives                           | (210) | 527   |
| Exchange differences                                       | 220   | (507) |
| Net adjusted finance costs                                 | (722) | (783) |
| Impact of translational foreign exchange                   | (55)  |       |
| Net adjusted finance costs (at constant rates of exchange) | (777) |       |

# **Adjusted taxation**

Definition: Taxation before the impact of adjusting items (described on page 36).

| £m    |
|-------|
|       |
| 45    |
| 5     |
|       |
| 1,083 |
| 15    |
| 1,148 |
| (94)  |
| 1,054 |
| 93    |
| 1,147 |
|       |

# Non-GAAP measures cont...

# **Underlying tax rate**

Definition: Tax rate incurred before the impact of adjusting items (described on page 33 to 36) and to adjust for the inclusion of the Group's share of post-tax results of associates and joint ventures within the Group's pre-tax results.

| Six months ended 30 June  | 2021  | 2020  |
|---|-------|-------|
|   | £m    | £m    |
| Profit before taxation (PBT)  | 4,384 | 4,592 |
| Less: Share of post-tax results of associates and joint ventures          | (233) | (281) |
| Adjusting items within profit from operations                             | 328   | 271   |
| Adjusting items within finance costs                                      | 34    | 3     |
| Adjusted PBT, excluding associates and joint ventures                     | 4,513 | 4,585 |
| Impact of translational foreign exchange                                  | 369   |       |
| Adjusted PBT, excluding associates and joint ventures (at constant rates) | 4,882 |       |
| Taxation on ordinary activities   | 1,055 | 1,054 |
| Adjusting items within taxation and taxation on adjusting items           | 64    | 93    |
| Adjusted taxation   | 1,119 | 1,147 |
| Impact of translational foreign exchange on adjusted taxation             | 76    |       |
| Adjusted taxation (at constant rates)                                     | 1,195 |       |
| Underlying tax rate   | 24.8% | 25.0% |
| Underlying tax rate (constant rates)                                      | 24.5% | 24.9% |
| Effective tax rate  | 24.1% | 23.0% |

# Adjusted diluted earnings per share, at constant rates of exchange

Definition: Diluted earnings per share before the impact of adjusting items, presented in the prior year's rate of exchange.

| Six months ended 30 June  | 2021  | 2020  |
|---|-------|-------|
|   | pence | pence |
| Diluted earnings per share  | 141.6 | 150.7 |
| Effect of restructuring and integration costs   | 3.1   | 2.1   |
| Effect of amortisation and impairment of goodwill, trademarks and similar intangibles | 4.8   | 6.4   |
| Effect of other adjusting items   | 3.5   | (O.7) |
| Effect of associates' adjusting items   | (0.3) | (O.7) |
| Effect of other adjusting items in net finance costs                                  | 1.4   | -     |
| Effect of adjusting items in respect of deferred taxation                             | 0.1   | -     |
| Adjusted diluted earnings per share   | 154.2 | 157.8 |
| Impact of translational foreign exchange  | 13.3  |       |
| Adjusted diluted earnings per share, at constant exchange rates                       | 167.5 |       |

#### Non-GAAP measures cont...

# Operating cash flow conversion ratio

Definition: Net cash generated from operating activities before the impact of adjusting items and dividends from associates and excluding trading loans to third-parties, pension short-fall funding, taxes paid and after net capital expenditure, as a proportion of adjusted profit from operations.

| Six months ended 30 June   | 2021  | 2020  |
|--|-------|-------|
|  | £m    | £m    |
| Net cash generated from operating activities                                       | 2,254 | 3,484 |
| Cash related to adjusting items  | 322   | 411   |
| Dividends from associates  | (164) | (2)   |
| Tax paid   | 1,227 | 552   |
| Net capital expenditure  | (149) | (141) |
| Other  | 1     | -     |
| Operating cash flow  | 3,491 | 4,304 |
| Adjusted profit from operations  | 5,235 | 5,368 |
| Operating cash flow conversion ratio   | 67%   | 80%   |
| Cash conversion ratio  | 46%   | 68%   |
| Cash conversion is not cash generated from operating activities as a proportion of |       |       |

Cash conversion is net cash generated from operating activities as a proportion of profit from operations

# Free cash flow (before and after dividends paid to shareholders)

Definition: Net cash generated from operating activities before the impact of trading loans provided to a third-party and after dividends paid to non-controlling interests, net interest paid and net capital expenditure. This measure is presented before and after dividends paid to shareholders.

| Six months ended 30 June                               | 2021    | 2020    |
|--|---------|---------|
|  | £m      | £m      |
| Net cash generated from operating activities           | 2,254   | 3,484   |
| Dividends paid to non-controlling interests            | (81)    | (70)    |
| Net interest paid                                      | (744)   | (876)   |
| Net capital expenditure                                | (149)   | (141)   |
| Other  | -       | -       |
| Free cash flow (before dividends paid to shareholders) | 1,280   | 2,397   |
| Dividends paid to shareholders                         | (2,443) | (2,346) |
| Free cash flow (after dividends paid to shareholders)  | (1,163) | 51      |

# Adjusted net debt

Definition: Total borrowings, including related derivatives, less cash and cash equivalents and current investments held at fair value, excluding the impact of the revaluation of RAI acquired debt arising as part of the PPA process.

| As at 30 June  | 2021             | 2020     |
|--|------------------|----------|
|  | £m               | £m       |
| Borrowings (excluding lease liabilities)                       | (44,571)         | (49,921) |
| Lease liabilities  | (439)            | (540)    |
| Total borrowings (including lease liabilities)                 | (45,010)         | (50,461) |
| Derivatives in respect of net debt                             | 409              | 380      |
| Cash and cash equivalents                                      | 3,014            | 4,784    |
| Current assets held at fair value                              | 336              | 183      |
| Total net debt   | <b>(41,251</b> ) | (45,114) |
| Purchase price adjustment (PPA) to Reynolds American Inc. debt | 761              | 877      |
| Adjusted net debt  | (40,490)         | (44,237) |
| Impact of translational foreign exchange on adjusted net debt  | (374)            |          |
| Adjusted net debt, at constant rates of exchange               | (40,864)         |          |

#### **ADDITIONAL INFORMATION**

British American Tobacco is one of the world's leading consumer products businesses, with brands sold in more than 200 markets. We have strategic combustible and THP brands – Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Neo, Newport, Camel (in the US) and Natural American Spirit (in the US) – and over 200 brands in our portfolio, including a growing portfolio of potentially reduced-risk, New Category products. We hold robust market positions in each of our regions and have leadership positions in more than 55 markets.

References in this document to information on websites, including the web address of BAT, have been included as inactive textual references only. These websites and the information contained therein or connected thereto are not intended to be incorporated into or to form part of this report.

#### **PUBLICATION OF HALF-YEAR REPORT**

This Half-Year Report is released or otherwise made available or notified to the London Stock Exchange, the JSE Limited and the New York Stock Exchange and filed in accordance with applicable regulations. It may be viewed and downloaded from our website <a href="https://www.bat.com">www.bat.com</a>.

Copies of the announcement may also be obtained by contacting: (1) the Company's registered office; (2) the Company's representative office in South Africa; (3) British American Tobacco Publications; or (4) Citibank Shareholder Services. Contact details are set out on page 62.

# **ANNUAL REPORT: Statutory Accounts**

The information for the year ended 31 December 2020 does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. A copy of the statutory accounts for the year 2020 has been delivered to the Registrar of Companies. The auditor's report on the 2020 accounts was unmodified, did not draw attention to any matters by way of emphasis and did not contain statements under Section 498(2) or (3) of the Companies Act 2006.

# SHAREHOLDER INFORMATION FINANCIAL CALENDAR

December 2021 Friday 11 February 2022 Pre-close Trading Update Preliminary Statement 2021

# PROPOSED DATES FOR QUARTERLY DIVIDEND PAYMENTS FOR THE YEAR ENDING 31 DECEMBER 2021

| Event                              | Payment No. 1 | Payment No. 2  | Payment No. 3     | Payment No. 4    |
|------------------------------------|---------------|----------------|-------------------|------------------|
| Last day to trade (JSE)            | 22 March 2022 | 5 July 2022    | 27 September 2022 | 20 December 2022 |
| Ex-dividend date (JSE)             | 23 March 2022 | 6 July 2022    | 28 September 2022 | 21 December 2022 |
| Ex-dividend date (LSE and NYSE)    | 24 March 2022 | 7 July 2022    | 29 September 2022 | 22 December 2022 |
| Record date<br>(JSE, LSE and NYSE) | 25 March 2022 | 8 July 2022    | 30 September 2022 | 23 December 2022 |
| Payment date<br>(LSE and JSE)      | 4 May 2022    | 17 August 2022 | 10 November 2022  | 2 February 2023  |
| ADS payment date (NYSE)            | 9 May 2022    | 22 August 2022 | 15 November 2022  | 6 February 2023  |

#### Notes

(1) A complete timetable for the quarterly dividend payments for the year ending 31 December 2021 and the declared amount will be included in the Preliminary Results Announcement in February 2022.

(2) The dates set out above may be subject to any changes to public holidays arising and changes or revisions to the LSE, JSE and NYSE timetables. Any confirmed changes to the dates will be announced.

#### **OTHER PRODUCTS**

The Group reports volume as additional information. This is done, where appropriate, with cigarette sticks as the basis, with usage levels applied to other products to calculate the equivalent number of cigarette units.

The conversion rates that are applied:

|                               | <u>Unit</u>                  |
|-------------------------------|------------------------------|
| Factory Made Cigarettes (FMC) | 1 stick                      |
| Cigars                        | 1 cigar (regardless of size) |
| Pipe tobacco                  | 0.8 grams                    |
| Roll-your-own                 | 0.8 grams                    |
| Make-your-own                 |                              |
| - Expanded tobacco            | 0.5 grams                    |
| - Optimised tobacco           | 0.7 grams                    |
| Tobacco Heat sticks           | 1 heat stick                 |
| Modern Oral                   | 1 pouch                      |
| Traditional Oral              |                              |
| - Pouch                       | 1 pouch                      |
| - Moist Snuff                 | 2.8 grams                    |
| - Dry Snuff                   | 2.0 grams                    |
| - Loose leaf, plug, twist     | 7.1 grams                    |

# Roll-your-own (RYO)

Loose tobacco designed for hand rolling, normally a finer cut with higher moisture, compared to cigarette tobacco.

# Make-your-own (MYO)

MYO expanded tobacco; also known as volume tobacco.

Loose cigarette tobacco with enhanced filling properties – to allow higher yields of cigarettes/kg - designed for use with cigarette tubes and filled via a tobacco tubing machine.

MYO non-expanded tobacco; also known as optimised tobacco.

 $Loose\ cigarette\ tobacco\ designed\ for\ use\ with\ cigarette\ tubes\ and\ filled\ via\ a\ tobacco\ tubing\ machine.$ 

#### FORWARD-LOOKING STATEMENTS AND OTHER MATTERS

This announcement contains certain forward-looking statements, including "forward-looking" statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.

In particular, these forward-looking statements include, among other statements, statements regarding the Group's future financial performance, planned product launches and future regulatory developments, as well as: (i) certain statements in the Strong Brands Drive New Category Acceleration section and in the Chief Executive commentary (pages 1 to 2); (ii) certain statements in the Finance and Transformation Director's Statement (page 2); (iii) certain statements in the Category Performance Review (pages 4 to 8); (iv) certain statements in the Regional Review section (pages 9 to 13); (v) certain statements in the Other Financial Information section (pages 14 to 17); (vi) certain statements in the Other Information section (pages 18 to 23); (vii) certain statements in the Notes to the Unaudited Interim Financial Statements section (pages 32 to 49), including the Liquidity and Contingent Liabilities and Financial Commitments sections; and (viii) certain statements in the Other Information section (pages 50 to 62), including the Non-GAAP Measures sections and under the heading "Dividends".

These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "expect," "estimate," "project," "positioned," "strategy," "outlook", "target" and similar expressions. These include statements regarding our intentions, beliefs or current expectations concerning, amongst other things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the economic and business circumstances occurring from time to time in the countries and markets in which the British American Tobacco Group (the "Group") operates, including the projected future financial and operating impacts of the COVID-19 pandemic.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this announcement are reasonable, but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are uncertainties related to the following: the impact of competition from illicit trade; the impact of adverse domestic or international legislation and regulation; the inability to develop, commercialise and deliver the Group's New Categories strategy; adverse litigation and dispute outcomes and the effect of such outcomes on the Group's financial condition; the impact of significant increases or structural changes in tobacco, nicotine and New Categories related taxes; translational and transactional foreign exchange rate exposure; changes or differences in domestic or international economic or political conditions; the ability to maintain credit ratings and to fund the business under the current capital structure; the impact of serious injury, illness or death in the workplace; adverse decisions by domestic or international regulatory bodies; and changes in the market position, businesses, financial condition, results of operations or prospects of the Group.

A review of the reasons why actual results and developments may differ materially from the expectations disclosed or implied within forward-looking statements can be found by referring to the information contained under the headings "Cautionary statement", "Group Principal Risks" and "Group Risk Factors" in the 2020 Annual Report and Form 20-F of British American Tobacco p.l.c. (BAT). Additional information concerning these and other factors can be found in BAT's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, <a href="http://www.sec.gov">http://www.sec.gov</a> and BAT's Annual Reports, which may be obtained free of charge from the British American Tobacco website <a href="https://www.bat.com">www.bat.com</a>.

No statement in this announcement is intended to be a profit forecast and no statement in this communication should be interpreted to mean that earnings per share of BAT for the current or future financial years would necessarily match or exceed the historical published earnings per share of BAT. Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and information available at the date of preparation of this announcement and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

All financial statements and financial information provided by or with respect to the U.S. or Reynolds American Inc. (Reynolds American) are initially prepared on the basis of U.S. GAAP and constitute the primary financial statements or financial records of the U.S. / Reynolds American. This financial information is then converted to International Financial Reporting Standards as issued by the IASB and as adopted for use in the UK ("IFRS") for the purpose of consolidation within the results of the Group. To the extent any such financial information provided in this announcement relates to the U.S. or Reynolds American it is provided as an explanation of, or supplement to, Reynolds American's primary U.S. GAAP based financial statements and information.

Our vapour product Vuse (including Alto, Solo, Ciro and Vibe), and certain products including Velo, Grizzly, Kodiak, Camel Snus and Granit, which are sold in the U.S., are subject to FDA regulation and no reduced-risk claims will be made as to these products without Agency clearance.

#### **Paul McCrory**

Secretary 27 July 2021

#### SHAREHOLDER INFORMATION

#### **CORPORATE INFORMATION**

British American Tobacco p.l.c. is a public limited company which is listed on the London Stock Exchange, New York Stock Exchange and the JSE Limited in South Africa. British American Tobacco p.l.c. is incorporated in England and Wales (No. 3407696) and domiciled in the UK.

# **Premium listing**

London Stock Exchange (Share Code: BATS; ISIN: GB0002875804)

Computershare Investor Services PLC

The Pavilions, Bridgwater Road, Bristol BS99 6ZZ, UK

tel: 0800 408 0094; +44 370 889 3159 Share dealing tel: 0370 703 0084 (UK only)

Your account: www.computershare.com/uk/investor/bri Share dealing: www.computershare.com/dealing/uk Web-based enquiries: www.investorcentre.co.uk/contactus

#### **Secondary listing**

JSE (Share Code: BTI)

Shares are traded in electronic form only and transactions settled electronically through Strate.

Computershare Investor Services Proprietary Limited

Private Bag X9000. Saxonwold 2132. South Africa

Rosebank Towers, 15 Biermann Avenue, Rosebank, South Africa

tel: 0861 100 634; +27 11 870 8216

email enquiries: web.queries@computershare.co.za

Sponsor for the purpose of the JSE - UBS South Africa (Pty) Ltd

# **American Depositary Receipts (ADRs)**

NYSE (Symbol: BTI; CUSIP Number: 110448107)

BAT's shares are listed on the NYSE in the form of American Depositary Shares (ADSs) and these are evidenced by American Depositary Receipts (ADRs), each one of which represents one ordinary share of British American Tobacco p.l.c. Citibank, N.A. is the depositary bank for the sponsored ADR programme.

Citibank Shareholder Services

PO Box 43077, Providence, Rhode Island 02940-3077, USA

tel: +1 888 985 2055 (toll-free) or +1 781 575 4555

email enquiries: citibank@shareholders-online.com; website: www.citi.com/dr

#### **Publications**

British American Tobacco Publications

Unit 80, London Industrial Park, Roding Road, London E6 6LS, UK

tel: +44 20 7511 7797; e-mail enquiries: bat@team365.co.uk or the Company's Representative office in South Africa using the contact details below.

#### British American Tobacco p.l.c. - Registered office

Globe House, 4 Temple Place, London, WC2R 2PG, UK tel: +44 20 7845 1000; facsimile: +44 20 7240 0555

# British American Tobacco p.l.c. - Representative office in South Africa

Waterway House South

No 3 Dock Road, V&A Waterfront, Cape Town 8000 South Africa

PO Box 631, Cape Town 8000, South Africa

tel: +27 21 003 6712

# **GLOSSARY and DEFINITIONS**

The following is a summary of the key terms used within this report:

| Term   | Definition   |
|--|--|
| AMSSA  | Americas (excluding US) and Sub-Saharan Africa. The key markets are:<br>Argentina, Brazil, Canada, Chile, Colombia, Mexico, Nigeria, South Africa.   |
| АРМЕ   | Asia Pacific and Middle East. The key markets are:<br>Australia, Bangladesh, Gulf Cooperation Council, Indonesia, Iran, Iraq, Japan, Malaysia, New Zealand, Pakistan,<br>South Korea, Taiwan, Vietnam.   |
| British American<br>Tobacco, BAT, Group, we,<br>us and our | When the reference denotes an opinion, this refers to British American Tobacco p.l.c. and when the reference denotes business activity, this refers to British American Tobacco Group operating companies, either collectively or individually, as the case may be.  |
| Cigarette  | Factory made cigarettes (FMC) and products that have similar characteristics and are manufactured in the same manner, but due to specific features may not be recognised as cigarettes for regulatory, duty or similar reasons.  |
| Combustibles   | Cigarettes and OTP.  |
| Constant Currency /<br>Constant rates                      | Presentation of results in the prior year's exchange rate, removing the potentially distorting effect of translational foreign exchange on the Group's results. The Group does not adjust for normal transactional gains or losses in profit from operations which are generated by exchange rate movements.   |
| Developed Markets  | As defined by the World Economic Outlook as Advanced Economies and those within the European Union.  |
| Emerging Markets   | Those markets not defined as Developed Markets.  |
| ENA  | Europe and North Africa. The key markets are:<br>Algeria, Belgium, Czech Republic, Egypt, Denmark, France, Germany, Italy, Kazakhstan, Morocco, the<br>Netherlands, Poland, Romania, Russia, Spain, Switzerland, Turkey, United Kingdom, Ukraine.  |
| GTR  | Global Travel Retail.  |
| Key markets  | The key markets are: Argentina, Brazil, Canada, Chile, Colombia, Mexico, Nigeria, South Africa, Australia, Bangladesh, Gulf Cooperation Council, Indonesia, Iran, Iraq, Japan, Malaysia, New Zealand, Pakistan, South Korea, Taiwan, Vietnam, Algeria, Belgium, Czech Republic, Denmark, Egypt, France, Germany, Italy, Kazakhstan, Morocco, the Netherlands, Poland, Romania, Russia, Spain, Switzerland, Turkey, United Kingdom, Ukraine and the United States.                |
| Modern Oral  | Includes EPOK, Lyft, Velo and other modern white snus.   |
| New Categories   | Includes Vapour, THP and Modern Oral.  |
| Non-Combustibles   | New Categories plus Traditional Oral.  |
| OTP  | Other Tobacco Products, including make-your-own, roll-your-own, Pipe and Cigarillos.   |
| Project Quantum  | Review of the Group's operating model to drive increased agility and efficiency.   |
| Reduced risk*  | Based on the available science, products within "New Categories" and "Traditional Oral" have been shown to be reduced-risk; are likely to be reduced-risk; or may have the potential to be reduced-risk, in each case if switched to exclusively as compared to continuing to smoke cigarettes.  |
| Strategic combustible and THP brands                       | Includes Kent, Dunhill, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit (US), Camel (US), glo<br>and Neo.  |
| Strategic Portfolio  | Comprises strategic combustibles, strategic traditional oral and New Categories – and includes Kent, Dunhill, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit (US), Camel (US), Vype, Vuse, glo, Neo, Ten Motives, Velo, EPOK, Lyft, Granit, Mocca, Grizzly, Camel Snus, Kodiak.   |
| Top 5 / T5 vapour<br>markets                               | Being the top 5 markets for industry vapour sales by revenue – US, Canada, UK, France and Germany. These markets represent an estimated 75% of Global industry vapour revenue (closed systems).  |
| Top 5 / T5 modern oral<br>markets                          | Being the top 5 markets for industry modern oral sales by revenue – US, Sweden, Norway, Denmark and Switzerland. These markets represent an estimated 90-95% of Global industry modern oral revenue. Germany has been removed from the priority market given the suspension in sales in 2021.  |
| Top 9 / T9 THP markets                                     | Being the top 9 markets for industry THP sales by revenue – Japan, South Korea, Russia, Italy, Romania, Germany, Ukraine, Poland and Czech Republic. These markets represent an estimated 90-95% of Global industry THP revenue.   |
| THP  | Tobacco heating products (i.e., the devices, which include glo and our hybrid products) or Tobacco heated products (i.e., the consumables used by Tobacco heating product devices).  |
| Traditional Oral   | Moist Snuff (Granit, Mocca, Grizzly, Kodiak) and other traditional snus products (including Camel Snus and Lundgrens).   |
| US   | United States of America (a key market).   |
| Value share  | Value share is the retail value of units bought by consumers of a particular brand or combination of brands, as proportion of the total retail value of units bought by consumers in the industry, category or other subcategorisation in discussion.  |
| Volume share   | Offtake volume share, as independently measured by retail audit agencies (including Nielsen and Marlin) and scanner sales to consumers, where possible or based on movements within the supply chain (such as sales to retailers) to generate an estimate of shipment share, based upon latest available data. Except when referencing particular markets, volume share is based on our key markets. The Group's key markets represent over 80% of the Group's cigarette volume. |
| Vapour   | Rechargeable, battery-powered devices that heat liquid formulations – e-liquids – to create a vapour which is inhaled. Vapour products include Vype, Vuse, ViP and Ten Motives.  |
| Juryanaur product Vuca (incl                               | Inding Alto and Vibe), and oral products (including Grizzly, Camel Spus, Kodiak and Velo), which are only sold in the US, are  |

\*Our vapour product Vuse (including Alto and Vibe), and oral products (including Grizzly, Camel Snus, Kodiak and Velo), which are only sold in the US, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

# Additional Information on Volume / Revenue by Category and by Region

| Volume (unit)                 |      |          |       |          |       |          |       |          |       |          |
|-------------------------------|------|----------|-------|----------|-------|----------|-------|----------|-------|----------|
| Six months ended 30 June      | US   |          | APME  |          | AMSSA |          | ENA   |          | Group |          |
|                               | 2021 | % change | 2021  | % change | 2021  | % change | 2021  | % change | 2021  | % change |
| New Categories                |      |          |       |          |       |          |       |          |       |          |
| Vapour                        | 139  | +97.3%   | 4     | +125.7%  | 27    | +75.8%   | 77    | +32.8%   | 247   | +69.5%   |
| THP                           | -    | -        | 4.0   | +23.1%   | -     | -        | 4.4   | +367.8%  | 8.4   | +99.3%   |
| Modern Oral                   | 405  | +450.4%  | 111   | +502.5%  | 0     | -100%    | 1,091 | +77.2%   | 1,607 | +124.1%  |
| Traditional Oral              | 3.6  | -3.1%    | -     | -        | -     | -        | 0.5   | -3.2%    | 4.1   | -3.1%    |
| <b>Total Non-Combustibles</b> |      |          |       |          |       |          |       |          |       |          |
| Cigarettes                    | 34.7 | -4.4%    | 107.9 | +8.2%    | 70.5  | +3.5%    | 102.9 | -3.2%    | 316.0 | +1.8%    |
| OTP                           | 0.0  | -3.1%    | 0.9   | -8.6%    | 0.9   | -7.0%    | 7.4   | -6.4%    | 9.2   | -6.6%    |
| <b>Total Combustibles</b>     | 34.7 | -4.3%    | 108.8 | +8.0%    | 71.4  | +3.3%    | 110.3 | -3.4%    | 325.2 | +1.5%    |
| Memo: Cigarettes and THP      | 34.7 | -4.4%    | 111.9 | +8.6%    | 70.5  | +3.5%    | 107.3 | +0.0%    | 324.4 | +3.1%    |

| Revenue- at current rates (£m) |       |          |       |          |       |          |       |          |        |          |
|--------------------------------|-------|----------|-------|----------|-------|----------|-------|----------|--------|----------|
| Six months ended 30 June       | US    |          | APME  |          | AMSSA |          | ENA   |          | Group  |          |
|                                | 2021  | % change | 2021   | % change |
| New Categories                 | 243   | +40.8%   | 228   | -9.2%    | 54    | +74.2%   | 358   | +105.1%  | 883    | +40.4%   |
| Vapour                         | 235   | +41.9%   | 9     | +60.4%   | 54    | +77.8%   | 100   | +56.6%   | 398    | +49.9%   |
| THP                            | -     | -        | 216   | -11.7%   | -     | -        | 143   | +240.9%  | 359    | +25.3%   |
| Modern Oral                    | 8     | +17.3%   | 3     | +418.2%  | 0     | -100%    | 115   | +67.5%   | 126    | +64.2%   |
| Traditional Oral               | 537   | -3.8%    | -     | -        | -     | -        | 21    | +14.1%   | 558    | -3.3%    |
| <b>Total Non-Combustibles</b>  | 780   | +6.7%    | 228   | -9.2%    | 54    | +74.2%   | 379   | +96.6%   | 1,441  | +19.5%   |
| <b>Total Combustibles</b>      | 4,769 | -1.9%    | 1,781 | -3.1%    | 1,651 | +0.3%    | 2,326 | -7.3%    | 10,527 | -3.0%    |
| Other                          | 14    | -49.9%   | 46    | -2.9%    | 91    | +27.3%   | 56    | -13.8%   | 207    | -2.0%    |
| Total                          | 5,563 | -1.0%    | 2,055 | -3.8%    | 1,796 | +2.7%    | 2,761 | -0.2%    | 12,175 | -0.8%    |
| Of which:                      |       |          |       |          |       |          |       |          |        |          |
| Strategic                      | 5,267 | -0.4%    | 1,030 | -8.4%    | 1,025 | +9.8%    | 2,056 | +3.1%    | 9,378  | +0.4%    |
| Non-strategic                  | 296   | -10.6%   | 1,025 | +1.3%    | 771   | -5.4%    | 705   | -8.6%    | 2,797  | -4.5%    |
|                                | 5,563 | -1.0%    | 2,055 | -3.8%    | 1,796 | +2.7%    | 2,761 | -0.2%    | 12,175 | -0.8%    |

| Revenue- at constant ra       | ites (£m) |          |       |          |       |          |       |          |        |          |
|-------------------------------|-----------|----------|-------|----------|-------|----------|-------|----------|--------|----------|
| Six months ended 30 June      | US        |          | APME  |          | AMSSA |          | ENA   |          | Group  |          |
|                               | 2021      | % change | 2021  | % change | 2021  | % change | 2021  | % change | 2021   | % change |
| New Categories                | 267       | +55.1%   | 248   | -1.1%    | 54    | +74.8%   | 373   | +113.5%  | 942    | +50.0%   |
| Vapour                        | 259       | +56.3%   | 9     | +58.9%   | 54    | +78.4%   | 101   | +57.8%   | 423    | +59.3%   |
| THP                           | -         | -        | 236   | -3.5%    | -     | -        | 158   | +278.3%  | 394    | +37.8%   |
| Modern Oral                   | 8         | +29.3%   | 3     | +457.6%  | 0     | -100%    | 114   | +64.9%   | 125    | +63.2%   |
| Traditional Oral              | 592       | +6.0%    | -     | -        | -     | -        | 20    | +9.2%    | 612    | +6.1%    |
| <b>Total Non-Combustibles</b> | 859       | +17.6%   | 248   | -1.1%    | 54    | +74.8%   | 393   | +103.8%  | 1,554  | +29.0%   |
| <b>Total Combustibles</b>     | 5,255     | +8.1%    | 1,961 | +6.7%    | 1,790 | +8.7%    | 2,479 | -1.2%    | 11,485 | +5.8%    |
| Other                         | 16        | -44.8%   | 51    | +5.1%    | 105   | +46.8%   | 57    | -11.1%   | 229    | +7.9%    |
| Total                         | 6,130     | +9.1%    | 2,260 | +5.8%    | 1,949 | +11.5%   | 2,929 | +5.9%    | 13,268 | +8.1%    |
| Of which:                     |           |          |       |          |       |          |       |          |        |          |
| Strategic                     | 5,804     | +9.8%    | 1,140 | +1.4%    | 1,126 | +20.5%   | 2,180 | +9.3%    | 10,250 | +9.7%    |
| Non-strategic                 | 326       | -1.5%    | 1,120 | +10.6%   | 823   | +1.1%    | 749   | -2.9%    | 3,018  | +3.0%    |
|                               | 6,130     | +9.1%    | 2,260 | +5.8%    | 1,949 | +11.5%   | 2,929 | +5.9%    | 13,268 | +8.1%    |

Note – n/m – not meaningful